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The influenza virus is a negative-stranded ssRNA virus of the Orthomyxoviridae family. Influenza 
viruses are able to infect numerous species, which include humans, birds, pigs, dogs and horses. 
In humans, influenza viruses infects via the respiratory tract.  Symptoms of influenza infection 
include coughing, rhinitis, headache, fever, chills, muscle pain and fatigue. Severe cases of 
influenza infections may lead to primary viral pneumonia, secondary bacterial pneumonia and 
sinus infections, which are potentially lethal. Influenza epidemics occur annually in the northern 
(October through May) and southern (May through October) hemispheres. Estimations of the World 
Health Organization (WHO) indicate that annually, around 3 to 5 million influenza cases lead to 
severe illness and 0.5 million cases lead to influenza-associated death. Furthermore, each influenza 
season has considerable financial consequences, from hospitalization and treatment costs, to 
costs involved with sick personnel. Thus, for both health and economic reasons, it is essential that 
influenza infections are prevented.
Influenza vaccination
Vaccination is the only way to prevent influenza infections. Today, influenza vaccines are adapted 
each season to match circulating strains as predicted by worldwide epidemiological monitoring. 
These vaccines elicit antibodies specific to the main surface proteins of influenza, hemagglutinin 
and neuraminidase (Figure 1). However, these proteins are highly variable due to random genetic 
mutations (antigen drift) or genetic reassortment (antigenic shift). Antigenic drift is a continuous 
process that leads to small antigenic changes within an influenza subtype. However, antigenic 
shift is a complete genetic reassortment of the influenza subtypes, and vaccine-elicited immune 
responses are generally unable to prevent infection of influenza viruses that do not match with 
the vaccine strain. The greatest concern currently is the emergence of a pandemic influenza strain, 
which is created by recombination of influenza strains hosted by different species. Since current 
influenza vaccines lack cross reactivity, a pandemic can only be managed by antiviral drugs. While 
these antivirals are effective, increasing numbers of resistant influenza virus strains, including 
prepandemic H1N1, have been reported since 2007, casting serious doubt on the effectiveness 
of these antivirals during future influenza outbreaks. Increasing the cross reactivity of influenza 
vaccines is therefore an important goal in influenza vaccine development.
T cell-based influenza vaccines
To address the lack of cross reactivity of current influenza vaccines, several novel vaccine approaches 
are currently being pursued. One of these approaches is the induction of influenza-specific T cells 
that recognize conserved epitopes located on internal proteins. Such T cells have the potential to 
recognize any influenza virus, regardless of antigenic shift or drift. Peptide antigens derived from 
influenza proteins can be used to induce such T cells. However, peptides are poorly immunogenic. 
Multiple factors contribute to this poor immunogenicity: peptides are easily degraded, they are not 
adequately recognized and taken up by antigen presenting cells (APCs), and lack immunostimulatory 
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signals to activate APCs. Additional formulation of peptide antigens is thus needed to increase the 
immunogenicity of the peptides and to make an effective T cell-based influenza vaccine. In this 
thesis, several formulation strategies for peptide-based influenza vaccines were investigated.
NeuraminidaseHemagglutinin
Matrix proteins Viral RNA
A B
Figure 1. Schematic drawing of an influenza virus particle (A), and a cryogenic transmission electron microscopic 
image of inactivated influenza virus particles (B).
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CHAPTER 1
The main objective of this thesis is to investigate and develop novel formulations for peptide-based 
influenza vaccines that ultimately could be used as universal influenza vaccines. Several formulation 
approaches are evaluated in this thesis. Furthermore, the current landscape of influenza vaccine 
research in general is assessed and the feasibility of T cell-based influenza vaccines in particular is 
reviewed.
In Chapter 2 the status of current and future influenza vaccines is reviewed. The limitations of 
current seasonal vaccines and possible solutions to these limitations are addressed. Immunological 
and formulation aspects play important roles in these solutions, and are highlighted in this review. 
Finally, the production of current influenza vaccines and the production feasibility of future influenza 
vaccines are discussed.
In Chapter 3 the development of peptide-loaded virosomes, a T cell-based influenza vaccine, is 
described. Peptide-loaded virosomes were produced from whole inactivated influenza virus (WIV) 
and synthetic T cell peptides. Physicochemical characteristics such as peptide loading efficiency, 
protein content of virosomes and membrane fusion capacity of the peptide-loaded virosomes were 
studied. The immunogenicity and protection against virus challenge of peptide-loaded virosomes 
with or without adjuvant was evaluated in HLA-A2.1 transgenic mice. In addition, the ability of 
virosomes to deliver peptides was assessed in a human dendritic cell (DC) model and in mice.
Chapter 4 presents the use of WIV as an adjuvant for influenza T cell peptides. The adjuvant effect 
of WIV in combination with a T cell peptide was investigated in HLA-A2.1 transgenic mice in a proof-
of-principle study. Subsequently, a dose response study was carried out by varying both WIV and 
peptide doses. A DoE approach was used to identify potential synergistic effects between WIV and 
peptide doses. Moreover, the effect of WIV and peptide co-localization and membrane fusogenicity 
of WIV on the immunogenicity was investigated in the same transgenic mice. Finally, WIV was used 
as an adjuvant for mixtures of either three wild type influenza peptides or three chemically modified 
influenza peptides.
A novel method to develop optimized liposomal formulations for peptide antigens is described in 
Chapter 5. Using a DoE approach, the influence of liposomal lipid composition on liposomal size, 
surface charge and liposome-induced DC maturation was investigated. Four different lipids were 
varied during the formulation of liposomes. The liposomes were tested in a human DC maturation 
model and the influence of the liposomal lipid composition on the expression of DC maturation 
factors was modeled. Finally, the accuracy of the generated prediction model was evaluated.
In Chapter 6, the latest developments in T cell-based influenza vaccine research are reviewed. The 
immunological steps of T cell activation are presented and an overview of T cell-based vaccines in 
both preclinical and clinical development is given. Furthermore, the need for cellular correlates of 
theSiS SCoPe and outline
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protection for influenza vaccines and the risks and limitations associated with T cell-based influenza 
vaccines are discussed.
An  alternative delivery system for influenza vaccines, the Bioneedle, is presented in Chapter 7. 
Bioneedles were filled with either subunit, split, virosomal or WIV influenza antigens, stabilized 
with trehalose. Antigen-filled Bioneedles were implanted in C57BL/6 mice and influenza-specific 
humoral and cellular responses were evaluated and compared to those induced by intramuscular 
or subcutaneous administered influenza vaccines. In addition, the thermostability of vaccine-filled 
Bioneedles and conventional liquid vaccines were assessed at temperatures up to 60°C.
Chapter 8 summarizes the findings and conclusions of this thesis. The prospect of T cell-based 
influenza vaccines and alternative delivery systems for influenza vaccines are discussed.
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Vaccination is the most effective method to prevent influenza infection. However, current influenza 
vaccines have several limitations. Relatively long production times, limited vaccine capacity, 
moderate efficacy in certain populations and lack of cross-reactivity are important issues that 
need to be addressed. We give an overview of the current status and novel developments in the 
landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel 
vaccine concepts not only depends on immunological or clinical outcomes, but also depends 
on biotechnological aspects, such as formulation and production methods, which are frequently 
overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully 
will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies 
ahead in the influenza vaccine field.
abStraCt
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Influenza viruses are negative stranded RNA viruses of the Orthomyxoviridae family. Three types of 
influenza viruses, influenza A, B and C, are capable of infecting humans, of which influenza A and B 
are the most common circulating types. Individuals infected with influenza virus generally display 
symptoms such as chills, fever, headache, muscle pain, fatigue, rhinitis and coughing. Progressed 
influenza infections can lead to severe complications including bronchitis, pneumonia, secondary 
bacterial infections, acute respiratory distress and cardiovascular complications, which all can lead to 
death if left untreated. Individuals with a weakened immune system, such as immunocompromised 
patients, elderly and young children [1-3], are particularly vulnerable to influenza infections and are 
thus classified as high-risk populations. 
Global influenza epidemics emerge seasonally and typically occur during the winter seasons of 
the northern and southern hemispheres. The WHO estimates that there are 3-5 million cases of 
severe influenza infections annually, with 250.000-500.000 deaths globally. The reemergence of a 
pandemic H1N1 strain in 2009 [4], and the emergence of highly pathogenic avian H5N1 and H7N9 
influenza viruses [5, 6], has reaffirmed that influenza remains a global threat to this day.
Vaccination against influenza is the most cost-effective method to prevent influenza infections. 
Fast availability of influenza vaccines to the world population is one of the key factors for effective 
coverage against seasonal and pandemic influenza. Despite the fact that influenza vaccines are on 
the market since the 1930s, several limitations still exist involving both their availability and their 
effectiveness, which are listed in Table 1.
Current influenza vaccines are predominantly produced by egg-based production methods. Being 
dependent on the supply of vaccine-quality eggs, vaccine manufacturers cannot be flexible in 
the amount of doses produced. This can lead to vaccine shortages, especially during pandemic 
situations. Alternative production platforms, such as cell culture-based vaccine production, 
plant-based vaccine production or synthetic vaccines, could increase the flexibility of manufacturers. 
It is often thought that these novel production methods decrease the time needed to develop and 
release an influenza vaccine. However, the availability of strain-specific reagents for vaccine potency 
and release tests such as the single radial immunodiffusion (SRID) assay and subsequent clinical 
trials are the main factors that delay the commercial release of influenza vaccines.
Directly tied to the commercial release of influenza vaccines are the regulatory approval procedures. 
To speed up these procedures, mock-up vaccines are developed to generate a registration dossier, 
which can subsequently be used for the licensing of an actual seasonal or pandemic influenza 
vaccine.
Limited vaccine availability is not only caused due to the inflexibility of the vaccine production 




to developing countries increases the worldwide vaccine production capacity. Increasing the 
(heat) stability and shelf life of influenza vaccines negates the need of a cold chain, which is imperfect 
in developing countries. This prevents unnecessary vaccine loss. Furthermore, decreasing antigen 
dose by the addition of adjuvants can also increase the number of influenza vaccines. Development 
of stabile vaccine formulations and effective adjuvants is thus important.
In several population groups, such as unprimed young children, the elderly and immunocompromised 
individuals, influenza vaccines have limited efficacy. Unprimed individuals have a reduced response 
to influenza vaccines, whereas elderly, due to immunosenescence, and immunocompromised 
individuals generally suffer from a declined immune function. Increasing the immunogenicity and 
breadth of the immune response elicited by influenza vaccines might improve vaccine efficacy in 
these vulnerable groups.
Current influenza vaccines induce neutralizing antibodies against the viral membrane surface 
proteins hemagglutinin (HA) and neuraminidase (NA). Due to antigenic shift and drift of HA and 
NA genes, neutralizing antibodies elicited by influenza vaccines lack cross-reactivity against 
non-matching influenza strains. While seasonal adjustments to the vaccine strains are made to 
cope with this problem, it is not as convenient and fast as a potential cross-protective influenza 
vaccine.  Thus, the identification of alternative correlates of protection (CoPs) against influenza is an 
important step towards the development of cross-reactive influenza vaccines.
Limitations Potential solution(s)
Dependence on egg-based production
- Cell culture-based production of virus
- Recombinant antigens
- Synthetic vaccines
Regulatory approval procedures - Mock-up vaccines to generate regulatory dossier
Limited worldwide vaccine availability
- Technology transfer of vaccine production 
methods
- Dose sparing by the addition of adjuvants or 
alternative administration routes
- Increase stability and shelf life of vaccines to 
prevent vaccine loss in unfavorable conditions
Limited efficacy in elderly and unprimed 
populations
- Increase vaccine immunogenicity by increasing 
antigen dose, the addition of adjuvants or using 
alternative administration routes
- Increase breadth of immune response by the 
addition of adjuvants, alternative administration 
routes or by inclusion of novel antigens
Lack of cross-reactivity by current vaccines
- Vaccines inducing stalk-reactive antibodies
- M2e-targeted vaccines
- T cell inducing vaccines
- Heterologous prime-boost strategies with 
seasonal and cross-reactive vaccines
Table 1. Limitations of current influenza vaccines and potential solutions.
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The aforementioned limitations of current influenza vaccines may be resolved through the 
implementation of new technologies in the field of influenza production and vaccine formulation. 
Novel antigens often require novel production methods, which carry their own advantages and 
disadvantages. Additionally, these novel antigens often need to be formulated with excipients 
and adjuvants to be sufficiently immunogenic. While important, the development of alternative 
administration methods and devices for influenza vaccines is not within the scope of this current 
review, and has been thoroughly reviewed by Amorij et al previously [7]. In this review, we will 
discuss advances in immunological, formulation and production aspects for current and promising 




The efficacy of current influenza vaccines is determined by the presence of adequate 
hemagglutination inhibition (HI)- or virus neutralization (VN)-titers in vaccinated individuals. 
HI titers indicate antibody responses against HA, which are not cross-reactive, and do not protect 
against mismatching influenza strains. Ideally, an influenza vaccine would protect against all strains, 
uninfluenced by antigenic changes. VN titers indicate antibody responses that are able to neutralize 
influenza virus, and thus can potentially be applied for cross-reactive vaccines. Nonetheless, 
identification of alternative CoPs, such as cross-reactive antibodies or T cell responses would 
significantly aid the development of universal vaccines [8]. 
Induction of immune responses against novel and more conserved epitopes, other than the variable 
epitopes of HA, has come under the attention in recent years (Figure 1). These include vaccines that 
induce antibodies directed against stalk regions of HA and matrix protein 2 ectodomains (M2e), 
and vaccines that induce cellular responses against internal influenza proteins. These vaccine could 
potentially be the basis of a universal influenza vaccine.
HA-specific antibodies
Antibodies against HA can be divided into categories: those reactive against the globular head 
domain, and those reactive to the stalk domain. Current influenza vaccines induce mainly antibodies 
directed against the head domain, which is highly variable due to antigenic drifts. In contrast, the stalk 
domain is more conserved, which makes it an attractive target for the induction of a cross-reactive 
humoral response. Certain stalk-reactive antibodies, such as globular head-reactive antibodies, 
inhibit the virus attachment to cell membranes [9], thereby preventing infection (Figure 1A). Other 
stalk-reactive antibodies disrupt viral membrane fusion (Figure 1B), preventing endosomal escape 
of the virus.  Indeed, several monoclonal antibodies directed against these stalk domains proved 
to be effective, and are currently under development to provide therapeutic treatment of acute 
influenza infections [10].
Several HA stalk-directed vaccines are currently under development, which proved effectiveness 
against both influenza A group 1 and 2 viruses [11], as well as influenza B. However, the potential 
side effects of these antibodies still need to be carefully evaluated. Khurana et al showed that 
HA2 stalk-reactive antibodies promoted viral fusion and respiratory disease symptoms by pH1N1 
influenza in pigs [12], indicating that the induction of stalk-reactive antibodies is not without 
risk. Further clinical studies should determine whether stalk-reactive antibodies are suitable for 
protection against influenza infection.
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Matrix protein 2 ectodomain-specific antibodies
Matrix protein 2 (M2) is a tetrameric transmembrane protein that acts as a proton-selective 
ion channel. It plays a crucial role in the acidification and subsequent destabilization of the viral 
membrane, which facilitates the release of the genetic material of the virus into the host cell. The 
M2 protein is, except in low amounts in whole inactivated virus (WIV) and live attenuated influenza 
virus (LAIV) vaccines, not included in current seasonal vaccines; M2-specific antibodies are generally 
not detected in subjects vaccinated with seasonal influenza vaccines. Nonetheless, it possesses 
a sequence of amino acids that is highly conserved among influenza subtypes, located on the 
N-terminal ectodomain. 
Since M2e is conserved among influenza subtypes, it is a potential target for cross-reactive 
immune responses. M2e is expressed abundantly by influenza-infected host cells [13], and 
M2e-specific antibodies are able to efficiently mark these cells for phagocytosis by natural killer 
cells or macrophages through antibody-dependent cellular cytotoxicity (ADCC) [14]. Furthermore, 
M2e-specific antibodies disrupt the budding process of viral particles, preventing virus release from 
infected host cells (Figure 1C). Thus, M2e vaccines do not prevent viral infection, but efficiently inhibit 
viral replication once inside the host. Several vaccine concepts utilizing M2e-derived antigens are 
currently being evaluated as universal influenza vaccines.
T cell responses
Cellular immune responses appear to play an important role in the cross-protective immune 
response against influenza virus [15]. CD8+ T cells (CTLs) can actively eliminate infected cells through 
perforin-mediated cell lysis (Figure 1D), but also exhibit other effector activities such as Fas ligand- 
and TRAIL (TNF-related apoptosis-inducing ligand)-mediated cytotoxicity and cytokine secretion, 
which all contribute to the protective cellular immune response against influenza infections [16]. 
Recently, several clinical studies correlated cellular responses with a decrease of influenza-related 
illness, indicating that influenza-specific cellular responses might be an alternative CoP for influenza. 
Sridhar et al. showed that individuals which possessed preexisting CD8+ T cells displayed decreased 
morbidity after infection with pH1N1 influenza, underlining the cross-reactivity of CD8+ T cells [17]. 
Wang et al. found that patients infected with H7N9 required prolonged hospitalization in the absence 
of early CD8+ T cell responses, whereas patients with early CD8+ T cell responses recovered quickly 
[18]. Additionally, Wilkinson et al. showed that influenza specific CD4+ T cells decreased viral shedding 
and illness in individuals infected with pH1N1 in the absence of influenza-specific antibodies [19]. 
A novel vaccine concept based on the induction of influenza-specific T cells, MVA-NP+M1, reduced 
symptoms and viral shedding of individuals infected with influenza, demonstrating that such an 
approach has merit [20].
Influenza vaccine formulation and production strategies
21
Most T cell epitopes, which are highly conserved, are located on internal influenza proteins such as 
nucleoprotein (NP), matrix protein 1 (M1) or polymerase subunits (PA, PB1 and PB2). While these 
antigens are not very immunogenic, several formulation strategies have been utilized to successfully 
induce influenza-specific T cell responses. The induction of influenza-specific cellular responses 
might be a great addition to current antibody-inducing influenza vaccines.
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CHAPTER 2
Current seasonal trivalent influenza vaccine (TIV) formulations contain either inactivated influenza 
antigens or live attenuated influenza viruses, derived from two influenza A strains and one influenza 
B strain. Next to TIV formulations, quadrivalent influenza vaccine (QIV) formulations have entered 
the market recently, which adds an additional influenza B strain. Additionally, several pandemic 
vaccines have been developed in the preparation of possible future outbreaks of highly pathogenic 
influenza strains. These vaccines, which are all currently in the market, will be examined below.
Inactivated influenza vaccines
Inactivated influenza vaccines comprise either whole inactivated virus, split, virosomal or subunit 
antigen, all differing in either structural organization or viral components (see Figure 2). WIV 
vaccines were the first to be used in widespread annual influenza vaccination campaigns. However, 
these WIV formulations caused local and systemic adverse effects upon administration [21]. This 
was possibly due to the presence of impurities, such as egg proteins, in the vaccine. WIV vaccines 
were therefore mostly abandoned when split vaccines entered the market, which were considered 
to be less reactogenic. However, the use of current vaccine production technologies results in better 
defined and pure WIV vaccines  than previously, which give rise to very low levels of side effects [22]. 
Nowadays, influenza vaccines usually consist of either split viruses or subunit influenza antigens. 
Split vaccines are influenza virus particles disrupted by diethyl ether or detergent treatment. While 
split vaccine still contains all viral proteins, the original viral particulate organization and viral ssRNA 
are mostly lost, losing some of the inherent immunogenicity of the virus [23]. Split viruses are 
currently widely used in TIV formulations, due to their adequate immunogenicity and relative ease 
of production. Aside from standard intramuscular (i.m.) split vaccines, an intradermal (i.d.) influenza 
split vaccine is currently licensed, which was proven to induce non-inferior immune responses as a 
dose of 9 µg HA compared to the standard 15 µg HA in adults [24]. This dose-sparing effect is likely 
to be mediated by the high density of antigen presenting cells (APCs) in the skin [25]. In contrast, 
elderly still require a normal dose of 15 µg when receiving an i.d. influenza vaccine.
Subunit antigens, that is HA and NA proteins, are also frequently used in TIV formulations. HA and 
NA proteins are separated from the viral nucleocapsid and lipids after diethyl ether or detergent 
splitting. However, the addition of adjuvants to the antigens is sometimes required to reach 
adequate immunogenicity in the elderly [26]. Recently, a recombinant HA (rHA) subunit vaccine has 
entered the market, which contains a high dose (45 µg per strain) of antigen to reach the required 
immunogenicity. The administration of a higher dose of rHA compared to other non-recombinant 
TIV formulations resulted in higher seroconversion rates in healthy adults and the elderly [27], 
but lower efficacy rates in children [28]. Therefore, rHA vaccines need additional formulation with 
adjuvants to optimize immunogenicity in children.
Current influenza vaCCineS
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In addition to split and subunit vaccines, virosomal TIV formulations have been used mainly in EU 
countries since 1997 [29]. Virosomes are reconstituted influenza virus envelopes consisting of HA, 
NA and viral phospholipids. Their particulate structure enables virosomes to retain viral membrane 
fusion and cell-binding capabilities, which could increase their immunogenicity compared to 
subunit and split vaccines. 
Figure 2. Composition of inactivated influenza vaccines. The four different compositions of influenza vaccine 
differ in antigen components and structural organization. These differences also have an impact on the 
immunogenicity of the vaccine.
Viral organization
Fragmented organization
All components Subunit components
WIV Virosomes
Split Subunit
Hemagglutinin Neuraminidase Matrix proteins Viral RNA
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In the literature, there are many studies which state that there are differences in immunogenicity and 
safety between the different inactivated influenza vaccine formulations. However, meta-analyses 
show that they all are similarly immunogenic and safe [30, 31]. Individual studies often compare 
vaccines of a single season, which might give a limited view on these formulations.
Live-attenuated influenza vaccines
Aside from inactivated influenza vaccines, there are also live-attenuated influenza vaccines. 
Intranasal administration of LAIV mimics the natural route of infection of influenza, resulting in a 
localized mucosal immune response at the site of infection [32]. In contrast to inactivated vaccines, 
LAIV induces strong mucosal IgA responses and cell-mediated immune responses, which are 
effective at preventing influenza infection [33]. While proven effective, the use of LAIV raised two 
major concerns. The virus in LAIV can theoretically undergo genetic reversion into a pathogenic, 
transmissible influenza strain. However, this event has yet to be proven, and is unlikely to ever 
happen [34]. The second concern is the use of LAIV in young children, which caused wheezing in 
infants under 2 years. Therefore, LAIV is currently approved for use in children and adults between 
2 and 49 years old.
Quadrivalent influenza vaccines
In recent years, more focus has been laid on including a second influenza B strain in the seasonal 
influenza vaccine. Two distinct influenza B lineages have been circulating since 1985, thereby 
decreasing the efficacy of TIV, which only includes one influenza B strain [35]. Indeed, five strain 
mismatches have occurred between 2001 and 2011, indicating that inclusion of an additional 
influenza B strain, resulting in a quadrivalent influenza vaccine, has become necessary. The first 
QIV (a LAIV formulation) entered the market in 2012, and several other QIV formulations based on 
inactivated vaccine formulations, such as split and subunit formulations, have been licensed since. 
Several manufacturers continue to develop novel QIV formulations, expanding the market share of 
quadrivalent influenza vaccines. 
Pandemic influenza vaccines
In the last decade, the global outbreaks of H5N1 and H1N1 influenza viruses have increased the 
demand for pandemic influenza vaccines. Both WIV and split antigens have been used (with or 
without adjuvants) for the development of pandemic vaccines. While WIV is infrequently used in 
seasonal influenza vaccines, it is used in pandemic vaccines due to its high intrinsic immunogenicity. 
During the H1N1 pandemic of 2009, several adjuvanted and non-adjuvanted pandemic vaccines 
were widely used [36, 37]. In addition to H1N1 vaccines, several pandemic H5N1 mock-up vaccines 
have been currently licensed. Mock-up vaccines are developed to generate a registration dossier, 
which can subsequently be used for the licensing of an actual pandemic vaccine after inclusion of a 
pandemic vaccine strain. This could speed up the regulatory approval process in case of a pandemic.
Influenza vaccine formulation and production strategies
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LAIV formulations are also considered as a pandemic vaccine candidate, since they elicit strong 
local mucosal and cellular immune responses. Chen and Subbarao summarized the preclinical 
development of prepandemic live-attenuated influenza vaccines against H5N1 previously [38]. 
While these pandemic vaccines are effective against their matched strains, they still generally lack 
cross-reactivity against heterosubtypic strains.
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With the advent of novel concepts for immunity against influenza, as described above, novel types 
of antigens such as recombinant proteins, viral vectors, peptides and DNA are under development. 
Many of these antigens are poorly immunogenic, and thus need advanced formulation with 
adjuvants (immunopotentiators and delivery systems) to become sufficiently immunogenic [39]. 
Most of these concepts aim to be universal influenza vaccines, and thus need to induce cross-
protective immune responses. Aside from increasing and steering the immunogenicity, formulation 
of antigens with excipients can increase vaccine stability for unfavorable conditions such as elevated 
temperatures and freezing [40], thereby preventing the loss of vaccines. In the following paragraphs 
we will discuss potential novel antigens and adjuvants for influenza vaccines, as well as formulation 
methods to stabilize them.
Recombinant antigens
The use of recombinant technology enables the production of a wide array of influenza protein 
antigens that can induce different immune responses. These include not only conventional antibody 
responses against HA, but also immune responses against HA stalk regions and M2 ectodomains, 
which are potentially cross-reactive.
Recombinant antigens are the main type of antigen to induce HA stalk-specific antibodies. 
Recombinant headless HA2 protein was expressed on virus-like particles (VLPs) [41], which induced 
cross-reactive antibodies that showed immunogenicity against heterologous influenza strains in 
mice. Recombinant VLPs were also utilized to present the A-helix domain of HA2 [42], which were 
able to induce stalk-reactive antibodies that recognized several influenza group 1 and 2 HA subtypes. 
Next to recombinant VLP antigens, nanoparticles were used to increase the immunogenicity of 
recombinant HA ectodomains. HA ectodomains were fused to ferritin nanoparticles [43], which 
induced high antibody titers in mice to both the globular head and stalk domains of HA.
Recombinant proteins are being widely used to induce M2e-specific immune responses [14]. Purified 
recombinant M2e proteins (in a multimeric state) were also combined with several adjuvants to 
induce M2e-specific antibodies [44]. Vaccines with covalently bound M2e antigen to a carrier 
protein or adjuvant could induce potent cross-protective immune responses in mice. Some studies 
reported a shift to IgG2a as the predominant IgG subtype [45, 46], indicating a skewing towards Th1 
responses, which support the induction of cytotoxic lymphocytes. This additional immune response 
could further broaden the protection of these vaccine concepts.
Viral vectors
Recombinant technology is applied to engineer replication-deficient viral vectors, which produce 
influenza antigens once administered in the host. These vectors are usually immunogenic and can 
display multiple antigens. One of the most studied viral vectors is Modified Vaccinia virus Ankara 
(MVA), which has already been used to express multiple influenza antigens such as HA, M2e, M1 
formulation StrategieS for influenza vaCCineS
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and NP [47]. One of the most promising influenza vector vaccines is MVA-NP+M1, which was able 
to elicit potent T cell responses in both healthy adults and elderly individuals in multiple phase I 
clinical trials [20, 48]. These studies did not find any severe adverse effects associated with the vector 
vaccine, other than an increased reactogenicity profile. MVA-NP+M1 could therefore be a possible 
universal influenza vaccine in the future.
Adenoviruses are other viral vectors used to engineer influenza vaccines. Clinical studies with 
adenoviruses expressing either HA or NP+M1 have been performed successfully [49, 50], indicating 
that adenoviruses are also a suitable vector platform for influenza vaccines.
The possibility of anti-vector immunity remains one of the risks involved with vector-based vaccines, 
since it could induce tolerance to the vaccine. Indeed, both humoral and cellular vector-specific 
immune responses negatively impacted the efficacy of a HIV vaccine based on a adenovirus vector 
in a clinical trial [51], indicating the importance of monitoring for anti-vector immunity in such 
studies.
Peptides
Peptides can be used for the induction of both influenza-specific immune B cell and T cell responses 
against conserved epitopes. Peptide antigens can either be minimal epitopes, which generally 
suffer from poor immunogenicity, or long peptides which are composed of multiple epitopes [52].
Several preclinical studies have used minimal epitope peptides as their main antigen to induce 
influenza-specific cellular responses. Liposomes have proven to be effective adjuvants for these 
peptides in numerous studies. NP366-374 peptide encapsulated in liposomes was able to induce 
potent T cell responses in the presence of anti-CD40 mAbs, and reduced viral lung titers of influenza-
infected mice [53]. HLA-A2.1 and HLA-A24.2 restricted peptides conjugated to liposomes were able 
to minimize morbidity in influenza-infected mice [54, 55]. Remarkably, these peptide-liposome 
conjugates were able to induce CD8+ memory T cells without contribution of CD4+ T cells, which are 
thought to be crucial for the support of effective CTL responses [56]. Conjugation of an influenza 
PA-derived peptide to Pam2Cys, a bacterial lipopeptide and natural PAMP, efficiently induced 
peptide-specific CTL responses, which reduced viral lung titers in influenza-infected mice [57]. 
Ichihashi et al. showed that, surprisingly, influenza peptides conjugated to phosphatidylserine 
were more immunogenic alone than incorporated in a liposomal formulation [58], indicating that 
particulate formulations not always have superior immunogenicity.
Aside from liposomes, virosomes have also been used as delivery systems for short peptide 
antigens. An early study showed that virosomes loaded with the H-2Kd binding influenza NP147–155 
peptide induced CTLs that were able to lyse influenza-infected target cells [59]. The addition of the 
adjuvant CpG ODN 1826 to influenza M158-66 peptide-loaded virosomes increased peptide-specific 
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CD8+ T cell responses even further [60], which resulted in an increased recovery of mice infected 
with heterologous influenza virus.
Long peptide antigens that include multiple epitopes are, compared to short peptides, in an 
advanced stage of development. Recently, FP-01.1 was tested in a phase I clinical trial [61]. FP-01.1 is 
composed of six 35-mer peptides, each consisting of multiple CD4+ and CD8+ epitopes derived from 
influenza A internal proteins, which have been conjugated to a fluorocarbon chain. The vaccine 
formulation was found to be safe and induced cross-reactive immune responses in most subjects. 
Multiple antigenic peptide (MAP) constructs are also effective for enhancing the immunogenicity 
of peptide antigens. The MAP approach has been widely studied with M2e-derived antigens [62]. 
Multimeric-001, which consists of nine linear B cell and T cell epitopes of HA, NP and M1 combined 
in a single 50 kDa polyepitope [63]. Multimeric-001 was able to induce considerable cellular immune 
responses when administered twice in both adults and elderly [64]. Interestingly, Multimeric-001 
was also used in a prime-boost approach with seasonal TIV in the same study. Individuals who were 
primed with Multimeric-001 and subsequently boosted with TIV had significantly higher HI titers 
than individuals who were primed and boosted with TIV. Further formulation with adjuvants might 
increase the immunogenicity of standalone Multimeric-001 vaccine in the future.
Aside from the induction of T cell responses, peptide antigens have also been used to induce HA 
stalk-specific antibodies. Polypeptide HA276-130 (the binding domain of stalk reactive mAb 12D1) was 
conjugated to the carrier protein keyhole limpet hemocyanin, which induced 12D1 antibodies that 
protected mice against influenza H5N1 and H1N1 infections [65].
Peptides are thus promising influenza antigens, especially for the induction of influenza-specific 
T cell responses. While the formulation of these antigens remains challenging, the approaches 
discussed above have shown promising results, specifically in prime-boost regimens with regular 
influenza vaccines. Furthermore, peptide antigens do not require folding or post-translational 
modifications, and might be more stable compared to protein antigens in unfavorable conditions.
DNA and RNA
Unlike protein or peptide-based antigens, DNA vaccines induce antigen production in the host 
itself. In short, a DNA copy is made of the viral RNA segment coding for the antigen of interest 
(i.e. an influenza protein), which is then inserted into an expression plasmid. Bacteria carrying the 
production plasmid are cultured and subsequently the plasmid is purified. The purified plasmid is 
administered, and the plasmid enables antigen production in cells of the host, which results in an 
immune response against the antigen.
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The concept has been evaluated in a phase I efficacy and safety study with an epidermal administered 
influenza DNA vaccine containing an HA gene. The DNA plasmids were coated on gold particles, 
which were subsequently applied epidermally using a gene gun. A trivalent DNA vaccine was able 
to protect individuals from influenza infection, proving that the DNA vaccine concept was viable 
[66].
Aside from the replacement of seasonal influenza vaccines, DNA antigens are also used to induce 
more broadly reactive immune response. In a clinical study, Ledgerwood et al. showed that priming 
with an H5 encoding DNA vaccine in advance of a monovalent H5N1 subunit boost vaccine 
significantly improved antibody responses [67], and induced influenza-specific T cell responses. This 
prime-boost regimen is an example of a novel antigen supplementing existing influenza vaccines. 
The same group showed that vaccination with a H1N1 HA-encoding DNA vaccine and subsequent 
boosting with subunit vaccine induced broadly-protective stalk-directed antibodies in mice and 
ferrets [68, 69]. Both approaches did not require any additional formulation of the DNA vaccine, 
which suggests that DNA plasmids are efficiently taken up by host cells.
An influenza DNA vaccine encoding for H5N1 HA, NP and M2 proteins induced antibody and T cell 
responses in combination with the cationic liposome adjuvant Vaxfectin in a clinical study [70]. The 
vaccine was able to induce HI titers comparable to titers induced by a subunit vaccine, showing that 
adjuvanted DNA vaccines have the potential to be used in humans.
While influenza DNA vaccines are a promising concept, several concerns regarding safety have to 
be considered. Antibodies against the DNA plasmid could render the vaccine ineffective. Also, the 
continued production of influenza antigens in the host might alter the immune system, or induce 
tolerance against influenza antigens. Arguably, the largest issue is the introduction of extraneous 
DNA into the vaccinated subject, which could lead to unwanted genetic changes such as tumor 
growth. Extensive safety and efficacy studies are therefore necessary to overcome these concerns.
RNA-based influenza vaccines are recently in preclinical development. Like DNA, mRNA enables 
influenza antigen production in host cells. A non-amplifying mRNA encoding for HA was able to 
confer protective HI responses in mice and ferrets with a single immunization of 80 µg mRNA [71]. 
Another study incorporated a self-amplifying mRNA encoding for HA and NA in lipid nanoparticles, 
which were able to induce HI titers with a mRNA dose as low as 0.1 µg [72]. This concept vaccine was 
fully synthetic, and is thought to have limited safety concerns compared to DNA-based and protein 
vaccines, which are usually generated in in vitro platforms.
Adjuvants for influenza vaccines
Enhancing the immunogenicity of vaccine antigens by the addition of adjuvants has several 
advantages, such as dose sparing, increased efficacy in the elderly, unprimed individuals and 
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Adjuvant category Adjuvant Antigen(s) Stage of development Ref.
Salts Alum Split, WIV (pandemic) Licensed N/A
Oil-in-water emulsions









AF03 (squalene, Brij 76) Split (pandemic) Licensed N/A
CoVaccine HT (squalene, polysorbate 80, 
sucrose fatty acid sulphate esters) WIV (pandemic) Animal model [73]
Saponins
Iscomatrix WIV (seasonal) Clinical development [74]







CCS/c (cationic liposomes of ceramide 
carbamoyl-spermine/cholesterol)
Subunit 
(seasonal) Animal model [78]
CAF01 (cationic liposomes of DDA/TDB) Split (seasonal) Animal model [79]











CTA1-DD (Cholera toxin subunit A) Peptide (M2e-based) Animal model [81]
LT patch (Escherichia coli enterotoxin) Split (pandemic) Clinical development [82]




IL-12, IL-23 WIV (laboratory strain) Animal model [85]
GM-CSF (Granulocyte-Monocyte Colony 
Stimulating Factor)
DNA (HA-
encoding) Animal model [86]
Type 1 IFN (IFNα) Subunit (seasonal) Animal model [87]
TLR agonists / 
immunomodulators
GLA (glucopyranosyl lipid A) (TLR4) rHA (pandemic) Clinical development [88]
Bacterial flagellins (TLR5) rHA (pandemic)rM2e Clinical development
[83]
[84]






IC31 oligodeoxynucleotide (TLR9) Subunit (seasonal) Animal model [92]












(pandemic) Animal model [96]
Advax (delta inulin) Split (pandemic)rHA (pandemic) Clinical Development
[97]
[98]
Table 2. Adjuvants for influenza vaccines.
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immunocompromised, and broadening of the influenza-specific immune response. Many novel 
antigens such as peptide and DNA antigens require the addition of adjuvants to steer the immune 
response towards a specific response, such as a cellular immune response. The development of 
suitable adjuvants for influenza vaccines is therefore imperative. A comprehensive overview of 
adjuvants currently on the market or in development is shown in Table 2.
There are currently several adjuvants that are approved for use in influenza vaccines. The most 
commonly used vaccine adjuvant, aluminum salt, is currently used in pandemic influenza vaccines. 
However, no beneficial effect of alum with these vaccines was observed during the 2009 H1N1 
pandemic [36].
In contrast to aluminum salts, oil-in–water emulsions have proved to be suitable adjuvants for 
influenza vaccines. MF59 was the first of these adjuvants approved for use with influenza vaccines 
in 1997. MF59 is an oil-in-water emulsion, which consists of 150 nm-sized biodegradable squalene 
oil droplets stabilized by non-ionic surfactants. Several modes of action have been attributed to this 
adjuvant [99], including enhanced regulation of genes  for cytokines and chemokines,  local release 
of ATP as an endogenous danger signal, increased influx of macrophages and monocytes to the 
site of injection, differentiation of monocytes to active dendritic cells, and antigen transportation 
to draining lymph nodes. Numerous reports observed increased immunogenicity and efficacy of 
MF59-adjuvanted subunit vaccine in young children, healthy adults, and elderly individuals [100-
103]. Additionally, MF59 has similar immunostimulatory effects in combination with prepandemic 
vaccine formulations [104]. Overall, MF59 has thus far proven to be a very effective adjuvant for the 
stimulation of humoral responses against both seasonal and prepandemic influenza vaccines.
Similar to MF59, AS03 is also an oil-in-water emulsion based on squalene droplets. However, unlike 
MF59, AS03 is currently only used in pandemic influenza vaccines. AS03 adjuvanted influenza 
vaccines were significantly more immunogenic than their unadjuvanted counterparts both in 
primed and unprimed individuals [105, 106]. Furthermore, AS03-adjuvanted influenza vaccines were 
also able to confer seroprotection in immunocompromised patients infected with HIV-1 [107]. In 
contrast, adjuvanted vaccines failed to increase seroprotection rates in other immunocompromised 
groups, such as transplant recipients or patients with lymphoid malignancies [108, 109].
Saponin-based adjuvants are currently in clinical development for use with influenza vaccines. 
Natural or synthetic saponin QS-21 (a fraction from soluble triterpene glycosides purified from 
Quillaja saponaria) was clinically tested with TIV vaccine, but failed to increase HI titers significantly 
compared to unadjuvanted TIV [110]. These saponins can form complexes with lipids like 
cholesterol resulting in particles, the so-called immune stimulating complexes (ISCOMs). These are 
hollow, cage-like particles of around 40 nm diameter [111]. Clinical studies with ISCOM-adjuvanted 
influenza split vaccines revealed accelerated antibody responses in individuals who received 
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ISCOM-adjuvanted influenza vaccines [74]. Furthermore, this coincided with a notable increase 
of influenza-specific CD8+ T cell responses [112]. A third generation of saponin based adjuvants, 
named Matrix-M, was evaluated in a clinical study in combination with a pandemic virosomal 
influenza vaccine [75]. The addition of Matrix-M resulted in a significant dose sparing of the antigen, 
and increased vaccine-induced T cell responses. Matrix-M was successfully used as an adjuvant for a 
H7N9 VLP vaccine in a phase II clinical trial, in which the adjuvanted VLP vaccine showed significantly 
higher seroconversion rates after vaccination compared to non-adjuvanted VLP vaccine [113].
Bacterial-derived components can also serve as potent adjuvants for influenza vaccines. Flagellin 
was fused genetically to the globular head of a HA1 subdomain, and was able to induce protective 
HI titers in healthy adults with only 2 µg of antigen, and in elderly with 4 µg of antigen [83, 114]. 
Currently advancing to phase III trials, this fusion vaccine shows that bacterial-derived components 
can be very effective adjuvants. Indeed, the co-administration of heat-labile enterotoxin via a patch 
after immunization with an influenza split vaccine boosted HI responses to the vaccine in healthy 
adults [82].
Recently a novel polysaccharide adjuvant, Advax, was used as an adjuvant for pandemic influenza 
vaccines. Made from delta inulin, this adjuvant stimulated both humoral and cellular responses 
induced by split vaccines in ferrets, which protected the animals from a lethal influenza challenge 
[115]. However, an Advax-adjuvanted rHA H1N1 vaccine failed to induce the required EMA/FDA 
seroprotection rates after two immunizations, except with a high antigen dose of 45 µg [98]. While 
the mode of action of Advax might also be partially through the induction of cellular responses, this 
still needs to be assessed in well-designed clinical studies.
Besides increasing the immunogenicity of the antigens, the addition of adjuvants to influenza 
vaccines can induce unwanted immune responses. AS03-adjuvanted influenza vaccines have been 
under close attention since a sudden increase of childhood narcolepsy incidence was observed 
in Scandinavian countries after the pandemic influenza epidemic of 2009-2010 and subsequent 
administration of AS03-adjuvanted Pandemrix influenza vaccines [116]. The 2009 pandemic H1N1 
influenza was associated with the incidence of narcolepsy in patients with a HLA-DQB1*06:02 allele, 
and it is suspected that the pH1N1 vaccine caused an autoimmune response leading to narcolepsy 
in individuals with this genotype [117]. A recent study identified higher amounts of structurally 
altered influenza NP protein in the Pandemrix vaccine than Arepanrix, another AS03-adjuvanted 
influenza vaccine [118]. Strikingly, they found higher levels of NP-specific antibodies in children with 
the HLA-DQB1*06:02 allele, which suggests a link between the antigen content of Pandemrix and 
narcolepsy, rather than a link between narcolepsy and the adjuvant. Another group also suggested 
that differences between vaccine antigens might be related to the higher incidence of narcolepsy 
associated with Pandemrix [119]. Nonetheless, extra care should be given to the safety profile 
when combining powerful adjuvant with complex protein vaccines such as WIV, split, virosomal or 
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subunit influenza vaccines, since the induction of broad antibody responses increases the risk of 
cross-reactivity with self-proteins.
Improving influenza vaccine stability
The shelf life of influenza vaccines is limited to approximately one year if stored refrigerated 
(2 -8°C). The potency of the HA antigen can be negatively affected by either elevated temperatures 
or temperatures below 0°C [40]. Consequently influenza vaccines need to be refrigerated during 
distribution and storage (so-called cold-chain), which is costly and can be difficult to guarantee 
in developing countries. Increasing the stability of influenza vaccines would therefore reduce 
the dependency on the cold chain, and would ensure that antigen retains its potency until 
administration. Additionally, improving the antigen stability can also prolong the vaccine shelf life, 
which would facilitate stockpiling of influenza vaccines in the preparation of a possible pandemic.
Stabilization of liquid antigens is commonly achieved through conversion to dry formulations. The 
solid state provides stability by decreasing the mobility of the protein antigen and the absence 
of water-based degradation pathways. However, drying methods are associated with their own 
stress factors that can affect the stability of the antigen. The addition of excipients such as sugars 
to influenza vaccines can stabilize the antigen during the freeze-drying process and subsequent 
storage [40]. During drying, sugars form a glassy matrix that protects the antigen by providing a 
physical barrier. Furthermore, the glass matrix of some carbohydrates such as inulin or trehalose 
possesses high glass transition temperatures, which increases the heat stability of the formulations 
due to decrease in molecular mobility.
The sugars inulin and trehalose both have been used as stabilizing excipients to facilitate influenza 
vaccine drying (either freeze-, spray- or spray freeze-drying). All four types of inactivated influenza 
antigens have been stabilized successfully by one or more drying methods with various excipients 
[120-123]. This proves that the addition of stabilizing excipients can greatly enhance influenza 




Some of the aforementioned novel formulations are prospective universal influenza vaccines; these 
should be able to protect against all influenza strains regardless of any antigen shifts or drifts. In 
the last few years, many of such universal vaccine concepts have entered clinical trials, as listed 
in Table 3. Vaccines based on HA stalk-reactive antibodies have yet to enter the clinical phase, 
indicating that this concept still has a long way to go.
The most advanced are the M2e- and T cell-based vaccine concepts, with several vaccine concepts 
having completed phase II trials. Most concepts proved to be immunogenic in humans (either 
healthy adults or elderly) and had positive safety profiles. It is expected that some of these vaccines 
will enter phase III trials in the coming years, from which we will finally be able to conclude whether 
these concepts are able to offer increased cross-reactivity against multiple influenza strains. 
Interestingly, prime-boost or simultaneous immunizations combining these novel vaccines with 
seasonal vaccine formulations are gaining popularity [64, 126], indicating that these concepts are 
more prone to supplement rather than to replace existing seasonal vaccines.












































































































































































































































































































































































































































































































































































































































































































































































































































Production of current influenza vaccines
The production of seasonal influenza vaccines is performed each year in a limited window of time 
between influenza strain selection and the release of the final vaccine. The steps involved are 
depicted in Figure 3. Several time determining steps, such as the availability of reagents for the SRID 
assay, are crucial for the advancement of the production process, and thus limit the speed of vaccine 
production each year, regardless of production platform.
Virus propagation on embryonated chicken eggs remains the most frequently used method 
to manufacture influenza vaccines. Furthermore, securing sufficient vaccine-quality eggs to 
manufacture influenza vaccines for the world population is a daunting, probably impossible task. 
Several other risks with egg-based vaccine production also need to be considered. An influenza 
outbreak among poultry is a serious possibility that would decrease the availability of vaccine-
quality eggs [127]. Additionally, influenza wild type (WT) strains need to be optimized for growth 
in eggs, which involves recombination of these WT strains with high-yield laboratory strains such 
as A/PR/8/34. During this step, mutations in the egg-adapted reassortant strain can contribute to a 
mismatch between the vaccine strain and the circulating strain, which occurred recently during the 
ProduCtion StrategieS for influenza vaCCineS
Northern hemisphere
Southern hemisphere
Strain selection by WHO*
Reassortant preparation
SRID reagent preparation





Submission of CMC data
Clinical trials
Approval of clinical data†
Vaccine distribution
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun
Time determining step for both egg- and cell-based influenza vaccine production
* Final strains are selected by goverment agencies
† Clinical data not required in the USA and may soon not be required in the EU
Figure 3. Timeline of seasonal influenza vaccine production. While some novel production methods can grow 
influenza viruses faster, the vaccine production timeline contains several steps that are time determining 
(red lines). This means that while the vaccine can be produced faster, the time from strain selection to vaccine 
release remains similar for all production platforms.
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Production platform Vaccines Status
Fertilized eggs




MDCK cells Seasonal and (pre)pandemic subunit and WIV Licensed in EU and USA
Vero cells (Pre)pandemic WIV and split Licensed in EU and Japan
Baculovirus Seasonal subunit Licensed in US and Japan
Table 4. Influenza vaccine production platforms.
2012-2013 influenza season [128]. Decreasing dependence on egg-based influenza propagation is 
thus a crucial step towards the increase of influenza vaccine production capacity worldwide. Current 
influenza production platforms are listed in Table 4.
One alternative to egg-based production systems is cell culture-based systems. Cell culture-based 
influenza propagation is not dependent on the availability of vaccine-quality eggs. More importantly, 
cell-culture based production platforms are easy to scale up, and theoretically should be able to meet 
the high demand for influenza vaccine in case of a pandemic situation [129]. However, WT influenza 
strains still need to be adapted for growth on cells, and building costs and validation of cell-based 
manufacturing plants are high, which might be unattractive for manufacturing companies [127].
As of yet, only a few cell culture-based seasonal and prepandemic influenza vaccine formulations 
are currently approved. Madin-Darby canine kidney (MDCK) cells were the first to be used for the 
production of seasonal TIV vaccines [130]. Most WT human influenza viruses grow efficiently in MDCK 
cells, and existing egg-adapted reassortant strains can grow to similar titers [131]. These advantages 
make MDCK cells an acceptable substitute for egg-based influenza virus production. Vero cells 
have also been used as a production platform for both seasonal and prepandemic vaccines [132, 
133]. Influenza virus cultivation in laboratory-scale bioreactors was compared between MDCK and 
Vero cells, but production yields between cell lines were not significantly different [134]. However, 
different virus strains showed differences in growth stability depending on culture medium and 
cell line. Searching other cell lines suitable for influenza production is therefore important, since 
influenza viruses might grow more efficiently on cell lines other than the ones that are currently 
used.
One of these novel cell lines is human retina-derived PER.C6, which is able to grow without the 
need of solid support for growth such as microcarriers [135]. The growth of suspension cell cultures 
is limited to the concentration of cells in the medium, rather than surface area in case of adherent 
cell cultures. This might allow easier scale-up of the vaccine production if necessary. A split H7N1 
influenza vaccine grown on PER.C6 cells was successfully tested for safety in a phase I clinical trial 
[136], but failed to induce adequate immune responses. It is believed that, similar to recombinant HA, 
higher doses of antigen are needed to confer protective antibody titers. Other cell-based platforms 
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for influenza production such as Human Embryonic Kidney (HEK)-293 and Amniocyte-derived 
(CAP) cell lines are currently still in preclinical development [137, 138]. These human-derived cell 
lines might be more suitable for the growth of human-adapted influenza strains compared to the 
currently used animal-derived cells. Indeed, there are indications that influenza viruses grow better 
in cell lines derived from their preferred host [139].
While these production methods are definitely an improvement, vaccines produced on cell lines 
have to be thoroughly screened for adventitious viruses and residual cell line DNA and cell line 
proteins, which might cause adverse effects [140]. Nonetheless, cell-based influenza virus production 
remains an improvement over egg-based production methods, due to increased vaccine purity.
Recombinant influenza antigens represent another alternative technology to traditional egg 
production methods. The baculovirus expression vector system (BEVS) efficiently produces 
recombinant HA in insect Sf9 cells, resulting in a recombinant influenza subunit vaccine [141]. 
By producing merely the HA antigen and not the entire influenza virus, several purification and 
inactivation steps can be omitted from the production process. This also results in predictable and 
more robust yields during production. However, the current rHA vaccine on the market requires 
a dose of 45 µg HA per strain to be effective, which is 3 times higher than the standard 15 µg HA 
dose in non-recombinant influenza vaccines. Further formulation of rHA with adjuvants might be 
required for considerable dose sparing.
Aside from technological improvements of the vaccine production process, it is necessary to increase 
the number of influenza vaccine manufacturers worldwide to meet demand. Technology transfer of 
influenza vaccine production methods to new manufacturers is therefore important. Incentives like 
the International Technology Platform for Influenza Vaccines (ITPIV) and other projects provide the 
transfer of influenza vaccine production knowledge to new vaccine manufacturers [142], expanding 
the number of influenza vaccine producers and increasing influenza vaccine production capacity in 
the world.
Production of future influenza vaccines
The advent of novel influenza vaccines antigens also requires production technologies that are 
different from classical egg- or cell-based virus propagation. This could offer several advantages, 
such as faster production times, increased capacity and product consistency, and less risk of 
adventitious agents in the final product.
Recombinant protein technology is bound to play a major role in the production of these novel 
antigens. Already utilized for the production of rHA, it is clear that recombinant technology is a 
viable option for the production of influenza antigens.  The previously discussed peptide-based 
Multimeric-001 vaccine is produced in E. coli, for instance. HA and M2 ectodomain antigens, both in 
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peptide and in protein forms, are regularly produced by recombinant technology in various vectors, 
such as E. coli, tobacco mosaic virus, papaya mosaic virus, bacteriophage T7 and baculovirus. The 
ability to fuse a carrier protein or immunopotentiators to the antigen during production is a great 
advantage of recombinant systems, and negates the need of post-production antigen formulation 
with, for instance, an adjuvant. Similar strategies have also been used with T cell inducing antigens 
such as NP epitopes [143]. With its versatility and the recent approval of rHA vaccine, recombinant 
technology is bound to be used widely for the production of novel influenza antigens.
The production process of DNA vaccines has rapidly evolved since the approval of several veterinary 
DNA vaccines [144]. Nowadays, manufacturing kilogram-scale batches of DNA plasmids is not 
uncommon. However, several problems still exist, such as getting an adequate concentration of 
DNA in a small enough volume for vaccination. These problems are expected to be resolved in the 
coming years, as the realization of influenza DNA vaccines comes closer.
Peptide antigens are fundamentally different from aforementioned protein antigens in terms of 
manufacturing process. Short to medium length peptides that do not require specific folding can 
be chemically synthesized rather than biologically produced. Thus, these antigens can be produced 
without the inherent risks of using biological systems, such as the presence of adventitious agents 
or cellular components in the final product. Technological developments in the field of chemical 
peptide synthesis over the last two decades have enabled the industry to manufacture large 
quantities of peptides at competitive prices, underlining the feasibility of large scale production 
of peptide vaccines [145]. Additionally, chemical synthesis of peptides is relatively fast, which is 
required for the production of influenza vaccines. The aforementioned FP-01.1 influenza peptide 
vaccine shows the potential of peptide-based vaccines [61]. However, most peptide antigens will 
need additional formulation with adjuvants or delivery systems in order to be immunogenic, which 
may add complexity and time to the production process of the final vaccine formulation. Another 
more simple option would be combining universal vaccines with current seasonal vaccines in a 
prime/boost regime, in order to broaden the immune response. 
The aforementioned antigen production methods are all relatively fast and flexible, certainly 
compared to the egg-based influenza vaccine production. While most of the novel influenza 
antigens are still in development, there is great potential for these antigens from a formulation and 
production point of view.
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The field of influenza vaccine development is constantly changing. While improvements on 
formulation and production level are continuously being made for traditional influenza vaccines, 
great steps are being made in the development of universal influenza vaccines. The introduction of 
novel influenza antigens and accompanying novel correlates of protection will be the most crucial 
and revolutionary step that has to be taken. Before a universal influenza vaccine is developed, 
it is likely that novel more conserved antigens will supplement current day influenza vaccine 
formulations in order to broaden the immune response by combining strong humoral and cellular 
responses. Fortunately, the production methods for these novel antigens seem more flexible than 
production methods of current influenza vaccines. While novel production methods can produce 
vaccines faster, the timely availability of reagents for vaccine potency testing remains the main 
time-delaying factor, and should therefore be considered. Furthermore, universal vaccines could 
be produced continuously opposed to the current seasonal vaccines, which would greatly increase 
vaccine production capacity and coverage. The next decade will thus be an exciting time for the 
influenza vaccine field.
ConCluSion
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Influenza CD8+ T cell epitopes are conserved amongst influenza strains and can be recognized by 
influenza-specific cytotoxic T cells (CTLs), which can rapidly clear infected cells. An influenza peptide 
vaccine that elicits these CTLs would therefore be an alternative to current influenza vaccines, 
which are not cross-reactive. However, peptide antigens are poorly immunogenic due to lack of 
delivery to antigen presenting cells, and therefore need additional formulation with a suitable 
delivery system. In this study, the potential of virosomes as a delivery system for an influenza 
T cell peptide was investigated. The conserved human HLA-A2.1 influenza T cell epitope M158-66 
was formulated with virosomes. The immunogenicity and protective effect of the peptide-loaded 
virosomes was assessed in HLA-A2.1 transgenic mice. Delivery properties of the virosomes were 
studied in mice and in in vitro dendritic cell cultures. Immunization of HLA-A2.1 transgenic mice 
with peptide-loaded virosomes in the presence of the adjuvant CpG ODN 1826 increased peptide-
specific CTLs. Vaccination with adjuvanted peptide-loaded virosomes reduced weight loss in mice 
after heterologous influenza infection. Association with fusion-active virosomes was found to be 
crucial for antigen uptake by dendritic cells, and subsequent induction of CTLs in mice. These results 
show that influenza virosomes loaded with conserved influenza epitopes could be the basis of a 




The need for cross-protective influenza A vaccines has increased in recent years after several global 
outbreaks of highly pathogenic influenza A strains, such as avian H5N1 [1], swine H1N1 and avian 
H7N9 [2, 3]. The current, mainly antibody-inducing influenza A vaccines are generally ineffective 
against influenza A strains which underwent antigenic shifts and drifts, which leads to vaccine 
mismatch. Influenza-specific antibodies induced by mismatched vaccines fail to recognize the 
surface proteins hemagglutinin (HA) and neuraminidase (NA). As a result, the composition of the 
current influenza vaccines has to be adjusted frequently to cope with these antigenic changes. 
CD8+ cytotoxic T cells that are specific for conserved epitopes of internal influenza A proteins, 
such as matrix protein and nucleoprotein, may provide cross-protection and are thus unaffected 
by antigenic changes [4]. Influenza-specific CTLs can efficiently clear virus-infected cells, thereby 
reducing viral replication and spread. Influenza-specific CD8+ T cells induced by influenza infection 
were recently correlated with less severe illness in adults infected with pandemic H1N1 virus [5]. 
Inducing influenza-specific CTLs by vaccination could therefore be a promising approach to achieve 
cross-protection against heterologous influenza A strains [6].
The influenza M158-66 peptide is a highly conserved human major histocompatibility complex (MHC)-I 
restricted epitope [7, 8], which can induce influenza specific CTLs. However, before CD8+ T cells can 
be induced, several critical processes have to take place [9]. Delivery of the peptide antigens to 
antigen-presenting cells (APCs), in particular dendritic cells (DCs), is crucial for antigen presentation 
on MHC-I molecules. Therefore, formulation of the peptide antigens with a suitable delivery system, 
such as virosomes, is required. Influenza virosomes were previously shown to be capable of efficient 
delivery of peptide antigens and subsequent CTL induction [10]. However, virosomal formulations 
can only deliver low doses of peptide antigens and lack pathogen-associated molecular patterns 
(PAMPs). The inclusion of immunopotentiators such as Toll-like receptor (TLR) agonists could 
improve the immunogenicity of the vaccine formulation, without the need to increase the peptide 
loading efficiency in virosomes, which requires complicated methods [11]. While adjuvants have 
been used to increase neutralizing antibody levels induced by virosomal vaccines [12], their effect 
on influenza peptide-specific CD8+ T cell responses in combination with virosomes has yet to be 
determined.
In this study, we investigated the immunogenicity of virosomes loaded with the human 
HLA-A2.1-restricted peptide M158-66, derived from influenza matrix protein 1. Influenza-specific CD8
+ 
T cell responses and antibody titers were assessed in HLA-A2.1 transgenic mice after immunization. 
The addition of TLR9 agonist CpG was found to be an effective adjuvant for the peptide in conjunction 
with virosomes. Furthermore, immunization with peptide-loaded virosomes adjuvanted with 
CpG increased the rate of recovery in mice after heterologous influenza infection. Finally, delivery 
properties of virosomes were extensively characterized in human DC models and in mice. Both 
peptide-virosome association and virosomal cell binding and membrane fusion capabilities were 





Virosomes were prepared from β-propiolactone inactivated egg-derived influenza A/PR8/34 H1N1 
virus as described previously [13]. In brief, whole inactivated influenza virus (WIV) was disrupted 
by the addition of 100 mM 1,2-dihexanoyl-sn-phosphatidylcholine (DHPC, Avanti Polar Lipids) in 
HNE (5 mM HEPES, 150 mM NaCl, 1 mM EDTA, pH 7.3) buffer. Nucleocapsid was removed from the 
membrane lipids and surface proteins by ultracentrifugation. Virosomes were reconstituted by 
removal of the detergent by dialysis against HNE buffer. Subsequently, virosomes were purified by 
centrifugation on a discontinuous sucrose gradient (10%/60% w/v in HNE), and sucrose was removed 
by dialysis against HNE buffer. Peptide-loaded virosomes were obtained by adding 125 µg/mL 
M158-66 peptide (GILGFVFTL, kindly provided by the Netherlands Cancer Institute) to the virosomes 
(36:1 peptide:protein w/w ratio) prior to detergent removal to enable peptide encapsulation. As 
negative control, fusion-inactivated virosomes were prepared. Virosomes were fusion-inactivated 
after peptide-loading by lowering the buffer pH to 4.5 with a pretitrated volume of 1 M HCl, and 
subsequently incubated at 37°C for 15 min. Afterwards, pH was restored to pH 7.3 with a pretitrated 
volume of 1 M NaOH.
Characterization of virosome formulations
Protein composition of the peptide-loaded virosomes was determined by SDS-PAGE, by using a 
12% precast polyacrylamide gel (Thermo Scientific) and Coomassie Brilliant Blue (Thermo Scientific) 
staining. Mean particle size distribution and zeta potential were determined by dynamic light 
scattering (DLS) with a Malvern Nano ZS (Malvern Instruments). Samples were diluted six fold in 
MilliQ for zeta potential analysis.
Hemolysis assay
Virosome fusion activity was determined by using a hemolysis assay as described previously [14]. 
Vaccine preparations were mixed with human blood erythrocytes and 0.1M 2-(N-morpholino)
ethanesulfonic acid (MES) buffer with different pH ranging from 4.5 to 5.5, and incubated at 37°C. 
After allowing fusion for 30 min, the released hemoglobin was quantified in the supernatant after 
centrifugation by reading absorbance at 540 nm using a Synergy Mx reader (Biotek). Hemoglobin 
release of erythrocytes mixed with water was set as maximal hemolysis (100%).
Association of peptide to virosomes
The interaction between peptides and virosomes was studied using size-exclusion chromatography 
(SEC). M158-66 peptide was labeled with fluorescein for detection purposes. Peptide-loaded 
virosomes or peptide mixed with empty virosomes were applied on a pre-washed PD-10 column 
(GE Healthcare). Samples were eluted with HNE buffer, and fractions of 1 mL were collected in tubes 
and subsequently analyzed for peptide and protein content by using fluorescence (excitation at 480 




Animal experiments were performed according to the guidelines provided by the Dutch Animal 
Protection Act, and were approved by the Committee of Animal Experimentation (DEC) of the National 
Institute of Public Health and the Environment (RIVM) under registration numbers PO201200156 
and PO201300046. 8-12 week old female transgenic C57BL/6-Tg(HLA-A2.1)1Enge/J mice (Jackson 
Laboratory, maintained in-house) were used in all studies. Mice received subcutaneous injections 
(100 µl/dose) in the left hind flank at day 0 and 21 under isoflurane anesthesia. Immunizations 
consisted of either PBS, peptide mixed with CpG, peptide in 50% Incomplete Freund’s Adjuvant 
(IFA, Sigma-Aldrich) with CpG, peptide-loaded virosomes (mixed with and without CpG), inactivated 
peptide-loaded virosomes mixed with CpG, and free peptide mixed with empty virosomes and CpG. 
Mice received 1 µg of M158-66 peptide per dose and 180 µg of virosomal protein. When mentioned, 
50 µg of CpG ODN 1826 (Invivogen) per dose was used as an adjuvant. As a positive control, one 
group of mice was infected with 1*103 PFU of influenza A/HKx31 H3N2 virus in 50 µl PBS by intranasal 
administration under isoflurane anesthesia. On day 35 animals were sacrificed by bleeding and 
cervical dislocation under isoflurane anesthesia.
Challenge study
For the challenge study, six mice were immunized as described previously. Additionally, one group 
of mice was immunized twice with 180 µg (total protein) of influenza A/PR8 WIV vaccine on the same 
immunization schedule as previous groups. On day 35, mice were infected with a sublethal dose of 
1*105 PFU of influenza A/HKx31 virus in 50 µl PBS by intranasal administration. Subsequently, mice 
were weighed daily until day 14 after challenge, after which mice were sacrificed. 
Intracellular staining
Peptide-specific cytotoxic T cells were quantified by flow cytometry analysis. Single cell 
suspensions of excised spleens were obtained using 70 µm cell strainers (BD Falcon). Subsequently, 
2*106 splenocytes were plated per well in 48-wells culture plates (Greiner) and restimulated 
with 50 ng M158-66 peptide for 18 hrs at 37°C 5% CO2. Next, Golgi-plug (1:1000, BD) was added to 
the cells to inhibit cellular protein and cytokine transport, and cells were incubated for another 
4 hrs. Subsequently, cells were transferred to a 96-wells plate, washed twice with FACS buffer 
(PBS, 0.5% BSA), and stained with anti-mouse CD4-PE (BD Biosciences), anti-mouse CD8-FITC (BD 
Biosciences) and Live/dead-Aqua (Invitrogen). Next, cells were washed twice with FACS buffer, 
and fixed with fixation-permeabilization buffer (BD Biosciences). Subsequently cells were washed 
with permeabilization wash buffer (BD Biosciences), and intracellular staining was performed with 
IFN-γ-APC (Biolegend). Finally, cells were washed with FACS buffer and 1.5 to 2 million cells were 
measured on a FACS Canto II flow cytometer (BD Biosciences). Data was analyzed using FlowJo 
software version 9 (Tree Star) for Mac OSX.
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Enzyme linked immunosorbent spot assay (ELISpot)
Cytokines produced by spleen cells were determined by ELISpot. 96-wells Multiscreen PVDF filter 
plates (Millipore) were activated by adding 25 µL 70% ethanol for 2 min, and subsequently washed 
three times with PBS. Plates were coated overnight with anti-mouse IFN-γ antibodies (U-Cytech) at 
4°C. Next, filter plates were washed three times and blocked with 5% Hyclone fetal calf serum (FCS, 
Thermo Scientific) for 1 hour at 37°C. Subsequently, 4*105 isolated spleen cells in IMDM medium, 
5% FCS were added to each well with or without 50 ng M158-66 peptide, and incubated overnight at 
37°C. After overnight stimulation, filter plates were washed five times and IFN-γ was detected using 
biotinylated anti-mouse antibodies (U-Cytech) and 100 µL BCIP/NBT reagent (Thermo Scientific) per 
well. Spots were allowed to develop for 15 min after which the plates were thoroughly washed 
with tap water. Spots were counted using an A.EL.VIS ELISpot reader (Aelvis). The number of IFN-γ 
producing cells in antigen stimulated spleen cells was obtained after background correction 
(subtracting number of spots produced by splenocytes incubated with medium).
Hemagglutination inhibition assay (HI assay)
Hemagglutination inhibition (HI) titers in mouse sera were determined by a HI assay. Sera were 
treated overnight with diluted receptor-destroying enzyme from Vibrio cholerae (1:5, Sigma-Aldrich) 
at 37°C to remove non-specific inhibitors, and were subsequently inactivated at 56°C for 30 min. 
Finally, PBS was added to the sera to obtain a 1:10 dilution. Diluted sera were serially diluted two-fold 
with PBS. Four hemagglutinating units of inactivated influenza A/PR/8/34 or influenza A/HKx31 
were subsequently added to each well and incubated for 20 min at room temperature after mixing. 
Next, an equal amount of a 0.5% (v/v) turkey erythrocyte suspension was added to the wells and 
incubated for 45 min at room temperature. HI titers are reported as the reciprocal of the highest 
serum dilution capable to completely prevent hemagglutination. 
Enzyme linked immunosorbent assay (ELISA)
Influenza antigen specific antibody titers were determined by ELISA as described previously [15]. 
In short, Microlon 96-wells flatbottom plates (Greiner) were coated overnight with 600 ng (HA) of 
A/PR8/34 subunit per well at 4°C. Serial two-fold dilutions of individual mouse sera in PBS, 0.5% BSA, 
0.1% Tween80 were applied on the plate and incubated for 1 hour at 37°C. Subsequently, plates 
were incubated for 1 hour at 37 °C with horseradish peroxidase-conjugated goat antibodies against 
mouse IgG, IgG1 or IgG2c (1:5000, Southern Biotech). Detection of antibodies was performed with 
TMB substrate buffer (0.4 mM TMB in 0.11 M sodium acetate, 0.006% H2O2, pH 5.5). The reaction 
was stopped by adding 2 M sulfuric acid, after which the optical density (OD) was measured at 
a wavelength of 450 nm by using a Synergy Mx platereader (BioTek). Titers are reported as the 
reciprocal of the serum dilution corresponding to OD450=0.2 after background correction.
Peptide-loaded virosomes
59
Dendritic cell uptake studies
Peptide antigen uptake by DCs was determined as follows. Fresh blood was collected from healthy 
donors and collected in heparin-coated tubes. Peripheral blood mononuclear cells (PBMCs) were 
isolated from whole blood using a Lymphoprep (Axis-Shield) gradient. Subsequently, CD14+ 
monocytes were isolated from the PBMC fraction by labeling with human CD14 MicroBeads 
(Miltenyi Biotec) and subsequent separation with a magnetic LS MACS column (Miltenyi Biotec). 
Finally, monocytes were plated at a concentration of 0.4*106 cells/mL in 48-wells plates in IMDM 
medium (Invitrogen) containing 1% FCS, 500 U/mL GM-CSF (Peprotech) and 800 U/mL IL-4 
(Sanquin). After 6 days, vaccine formulations were incubated for 4, 24 and 48 hours with the 
immature DCs at a concentration of 50 ng/mL M158-66-FITC peptide in IMDM with 500 U/mL GM-CSF. 
Subsequently, cells were transferred to a 96-wells plate, washed twice with FACS buffer, and stained 
with Live/dead-Aqua. Cells were washed twice with FACS buffer and analyzed on a FACS Canto 
II flow cytometer. Data was analyzed by using FlowJo 9 software for Mac OSX. Peptide uptake is 
reported as mean fluorescent intensity (MFI) of the FITC signal.
Statistics
Data were analyzed by using one-way ANOVA with Tukey-Kramer’s method for multiple comparisons. 
Probability (p) values of p ≤ 0.05 were considered statistically significant. Statistics were performed 




Characteristics of peptide-loaded virosomes
To confirm that virosome production was successful, the protein composition of peptide-loaded 
virosomes was analyzed by SDS-PAGE. We observed that peptide-loaded virosomes (P-V) retained 
HA and NA proteins, whereas internal proteins, such as matrix protein 1 (M1), were removed from 
the virosome particles (Figure 1). Additionally, SDS-PAGE analysis of P-V under reducing conditions 
revealed that subunits HA1 and HA2 from HA mono- and dimers were formed, similar to WIV. 
Dynamic light scattering showed a particle size of 140 ± 2 nm (mean ± SD, n=3) for P-V, which was 
comparable to the size of source material WIV (143 ± 1 nm). The polydispersity index (PDI) of P-V 
was 0.121, indicating that the particle distribution was very homogeneous and comparable to the 
PDI of WIV (0.036). The zeta potential of virosomes was -21.2 ± 1.7 mV (mean ± SD, n=3), which was 
similar to that of WIV (-21.5 ± 0.3 mV). Therefore, the peptide-loaded virosomes closely resembled 
WIV particles in terms of particle size and surface charge, but were enriched in HA and NA.
Size-exclusion chromatography confirmed that simple mixing of peptide and virosomes did not 
result in substantial association between the two components (Figure 2A). As expected, both 
peptide and virosomes co-eluted when peptide-loaded virosomes were applied onto the SEC 
column, indicating association. The association efficiency of the peptide with the virosomes was 
typically 4-6% of the total amount of added peptide.
In order to confirm whether P-V still possessed fusion activity, a hemolysis assay was performed. 
Both peptide-loaded virosomes and WIV showed low-pH induced fusion activity in the pH range 
that is representative for the endosome (Figure 2B). Additionally, P-V were shown to be successfully 
fusion-inactivated by short (15 min) exposure to pH 4.5. P-V fused at slightly lower pH compared to 
WIV, which might be caused by small differences in HA confirmation and stability in peptide-loaded 
virosomes.
Figure 1. Protein profile of peptide-loaded virosomes. 
SDS-PAGE analysis of peptide-loaded virosomes (P-V) 
and source material whole inactivated influenza virus 
(WIV) under non-reduced and reduced conditions on 
a 12% precast gel stained with Coomassie Brilliant 
Blue. Protein identities were confirmed by mass 
spectrometry.


















Immunogenicity of peptide-loaded virosomes in HLA-A2.1 transgenic mice
To assess whether the produced peptide-loaded virosomes were able to induce peptide-specific 
T cell responses, HLA-A2.1 transgenic mice were primed and boosted three weeks after priming 
with either peptide-loaded virosomes or P-V adjuvanted with CpG. PBS and peptide mixed with IFA 
and CpG were administered as negative and positive control, respectively. Peptide-specific T cell 
responses in restimulated splenocytes were determined two weeks after booster vaccination. Flow 
cytometry analysis revealed that splenocytes from mice immunized with peptide-loaded virosomes 
contained peptide–specific IFN-γ+ CD8+ T cells after ex vivo stimulation (Figure 3A), as opposed to 
PBS injected mice. P-V were able to induce specific IFN-γ+ CD8+ T cell levels comparable to the levels 
induced by P mixed with IFA and CpG. The addition of CpG to P-V significantly (p < 0.001) increased 
the number of peptide-specific CD8+ T cells, which confirmed the immunopotentiating effect of 
CpG. The increase of IFN-γ+ CD8+ T cells after adding CpG to the P-V formulation was in line with the 
increased frequency of IFN-γ producing cells observed utilizing an ELISpot assay (Figure 3B). Several 
other TLR ligands (poly(I:C), imiquimod and Pam3CSK4) were tested in combination with P-V, but 
none were as effective as CpG (data not shown). 
While virosomes mainly act as an efficient vehicle to deliver the peptide antigen to the APCs, the 
presence of CD4+ T cell epitopes in the sequence of virosomal surface proteins enable virosomes to 
provide helper T cell (Th) responses. Th responses are able to support the induction of CD8+ T cells 
[16], and CD4+ T cell epitopes are thus an important part of the vaccine formulation. To gain further 
insight into the possible T cell help that virosomes and the adjuvant provide, the Th1/Th2 balance 
was assessed by determination of IgG1 and IgG2c isotype titers induced by P-V with or without 
CpG. The results show that IgG1 titers remained unchanged (Figure 3C) after addition of CpG, but 
IgG2c titers were significantly (p < 0.0001) increased after vaccination with CpG adjuvanted P-V 
Figure 2. Characteristics of peptide-loaded virosomes. Peptide association of peptide mixed with virosomes 
(P+V mix) and peptide-loaded virosomes (P-V) analyzed by size exclusion chromatography (A). Black lines show 
the virosome elution pattern (based on protein determination), whereas the red line shows the elution of peptide 
(based on fluorescence of M158-66-FITC). The fusogenic activity of WIV (black), P-V (red) and fusion-inactivated P-V 































































when compared to P-V alone (Figure 3D). This indicates that addition of CpG to P-V skewed influenza 
specific responses towards a Th1 response, which supports the CD8+ T cell response against the 
influenza peptide.
In addition to the T cell epitopes, the P-V formulations contain virosomal B-cell epitopes (mainly on 
surface antigens HA and NA) that induce influenza-specific antibodies. While these antibodies are 
usually not cross-reactive, they do provide protection against homologous influenza strains. Thus, in 
case the circulating virus matches the source influenza strain of the virosomes, additional humoral 
responses can aid in protection. CpG adjuvanted P-V induced significantly (p < 0.01) higher HI titers 
compared to non-adjuvanted P-V (Figure 3E). Total IgG titers showed a similar significant (p < 0.05) 
increase after addition of CpG to the P-V (Figure S1). This underlines that CpG is not only an effective 
adjuvant for T cell induction, but also improves B-cell responses, as observed previously [12]. As 
expected, there were no detectable HI and total IgG titers in sera of control mice receiving PBS or 


























































































Figure 3. Immunogenicity of (non-)adjuvanted peptide-loaded virosomes. HLA-A2.1 transgenic mice were 
immunized twice with 1 µg of M158-66 peptide formulated in either virosomes (P-V), virosomes adjuvanted with 
CpG (P-V + CpG) or Incomplete Freund’s Adjuvant (IFA) with CpG (P + IFA + CpG). Mice were immunized with 
PBS as negative control. Two weeks after the final vaccination, peptide-specific CD8+ T cell responses in ex vivo 
stimulated splenocytes were determined using flow cytometry (A) and ELISpot (B). Antibody isotypes IgG1 (C) 
and IgG2c (D) titers were determined in mice sera. HI titers were also determined (E). Data represent mean ± SD 
(n = 6); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n.d., not detectable.
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peptide mixed with IFA and CpG, due to the lack of influenza surface antigens in these formulations.
Efficacy of peptide-loaded virosomes against heterologous influenza infection in mice
In addition to the assessment of immunological responses, the efficacy of the P-V vaccine against 
heterologous influenza infection was examined. HLA-A2.1 transgenic mice were immunized with 
the vaccine and subsequently infected with a sublethal dose of influenza HKx31 (H3N2) virus. The 
weight of the infected animals was monitored for 14 days (Figure 4). Mice that were previously 
infected with a small dose of live influenza HKx31 did not show any weight loss after challenge. Mice 
that received either PBS, WIV or peptide mixed with IFA and CpG showed a decline in weight until 
day 7, after which the animals recovered slowly. In contrast, mice immunized with CpG adjuvanted 
P-V started to recover already after day 6, and their total weight loss was less severe than that of 
mice immunized with PBS or peptide mixed with IFA and CpG. Moreover, at day 7 and 8, the weight 
of mice immunized with P-V adjuvanted with CpG was not statistically different than the weight 
of protected mice pre-exposed to HKx31, whereas mice immunized with PBS, WIV or peptide with 
IFA and CpG did show a significant (p < 0.0001) difference with protected mice. Furthermore, no 
HKx31-specific HI titers were detected in sera of mice immunized with the PR8-based P-V or WIV 
groups (data not shown). Since WIV contains all influenza antigens and does not show any effect 
against HKx31 infection, it can be assumed that virosomes alone (which only contain HA and NA 
proteins) would not mediate any response against HKx31. Thus, this indicates that the increased 
recovery was not mediated by cross-reactive neutralizing antibodies but by the increase of CD8+ 
T cells. Vaccination with P-V mixed with CpG may therefore contribute to the recovery from influenza 
after heterologous influenza infection.


















Figure 4. Efficacy of vaccine after sublethal 
heterologous influenza infection. HLA-A2.1 
transgenic mice were immunized twice with either 
peptide-loaded virosomes with CpG (red), peptide 
mixed with incomplete Freund’s adjuvant and CpG 
(green), WIV (brown) or PBS (blue). As a positive 
control, mice were challenged with a sublethal dose 
of HKx31 virus. Subsequently, mice were infected 
with heterologous HKx31 (H3N2) influenza virus 
and their weight was monitored for 14 days. Data 
represent mean ± SEM (n = 6); *p < 0.0001 for PBS 
and P + IFA + CpG groups versus HKx31.
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Influence of association between peptide and virosomes on peptide association with 
dendritic cells and CD8+ T cell responses
In order to gain some mechanistic insight into the mode of action of our P-V vaccine, we investigated 
the importance of peptide association with the virosomes for the induction of peptide-specific CTLs. 
The delivery concept of virosomes and the importance of peptide association was first assessed in 
vitro. The uptake of peptide antigens by immature DCs was determined in vitro for P-V and free 
peptide mixed with empty virosomes (P+V, Figure 5A). After 4 hours of incubation, P-V showed a 
significantly (p < 0.01) higher peptide association with DCs compared to P+V or free peptide without 
any carrier. This trend was also observed after 24 and 48 hours of incubation, resulting in even larger 
(p < 0.001) differences between P-V and the other formulations. Incubation of P-V with DCs at a 
temperature of 4°C also showed a significant increase of peptide signal (data not shown), indicating 
that P-V readily associated with the cell membrane of DCs prior to internalization. This indicates that 





























































Figure 5. Influence of peptide-virosome association on in vitro dendritic cell uptake and in vivo T cell responses. 
M158-66-FITC peptide uptake by human immature DCs was determined by flow cytometry (A). Either PBS, 
peptide-loaded virosomes (P-V), peptide mixed with empty virosomes  (P+V mix) or free peptide (P) were 
incubated at 37°C with immature DCs for 4, 24 and 48 hours. Data represents mean ± SD (n = 3) performed with 
DCs obtained from three different donors. HLA-A2.1 transgenic mice were immunized twice with aforementioned 
formulations adjuvanted with CpG. Peptide-specific CD8+ T cell responses were determined in ex vivo stimulated 
splenocytes by flow cytometry (B) and ELISpot (C). Data represent mean ± SD (n = 3) and is representative of 
three individual experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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the virosomes attached themselves to the DC surface most probably by sialic acid binding. Thus, 
association of the peptide with the virosomes positively affects the antigen association with DCs, 
proving that virosomes act as a delivery system for the peptide antigen. 
In addition to the in vitro DC studies, in vivo studies in HLA-A2.1 transgenic mice revealed that 
association of the peptide with the virosomes is crucial for the induction of peptide-specific CTLs. 
CD8+ T cell responses were determined in in vitro stimulated splenocytes two weeks after the boost 
vaccination (Figure 5B). P-V + CpG induced significantly (p < 0.0001) higher CTL numbers in mice 
than the peptide + CpG mixture. When CpG adjuvanted peptide was mixed with empty virosomes, 
the number of peptide-specific CTLs in the spleen was significantly (p < 0.01) lower compared to 
P-V + CpG. The frequency of IFN-γ producing cells showed a similar trend; only P-V + CpG showed 
increased IFN-γ spot-forming units compared to peptide mixed with empty virosomes or free 

























































Figure 6. Impact of loss of fusogenic activity on immunogenicity of peptide-loaded virosomes. M158-66-FITC 
peptide uptake by human immature DCs was quantified for both fusion-active and inactive P-V after 16 hours 
of incubation at 37°C (A). Data represents mean ± SD (n = 3) performed with DCs obtained from three different 
donors. HLA-A2.1 transgenic mice were immunized twice with peptide-loaded virosomes with CpG (Active P-V 
+ CpG) or fusion-inactivated peptide-loaded virosomes with CpG (Inactive P-V + CpG). Peptide-specific CD8+ 
T cells were subsequently quantified in ex vivo stimulated splenocytes by flow cytometry (B) and ELISpot (C). 




is not sufficient to induce peptide-specific T cell responses. Furthermore, association of the peptide 
with virosome was not critical for the humoral responses or the Th1/Th2 balance (Figure S2), 
suggesting that these particular responses are only influenced by the virosome and the presence 
of an adjuvant.
Influence of virosomal cell binding and membrane fusion capabilities on the 
immunogenicity of peptide-loaded virosomes
In addition to the role of peptide association, the role of virosomal cell binding and membrane fusion 
activity in the immunogenicity of peptide-loaded virosomes was studied. Content of virosomes is 
released into the cytosol of APCs through pH-mediated fusion with the endosomal membrane. 
First, peptide association by DCs was quantified by flow cytometry after 16 hours of incubation with 
(inactivated) vaccine formulations (Figure 6A). When P-V were fusion-inactivated, the association of 
peptide decreased significantly (p < 0.0001) compared to fusion-active P-V. This indicates that the 
inherent cell binding and membrane fusion capabilities of virosomes are needed to ensure efficient 
uptake by APCs.
Next, we investigated whether the limited uptake of peptide by DCs had an impact on T cell 
induction after administering inactivated P-V to mice. HLA-A2.1 transgenic mice immunized with 
fusion-inactivated P-V generated significantly (p < 0.001) less peptide-specific CD8+ T cells than mice 
immunized with fusogenic P-V (Figure 6B). The frequency of IFN-γ producing cells also showed a 
decreasing trend after inactivation (Figure 6C), showing that inactivation of the influenza virosomes 
has a significant negative impact on the immunogenicity of M158-66 peptide associated with the 
virosome.
To assess the impact of fusion inactivation on the ability of P-V to induce humoral responses, 
influenza-specific antibody titers were determined in serum. The fusion-inactivated formulation 
induced a significantly (p < 0.0001) lower influenza-specific neutralizing antibody response 
than the fusion-active P-V (Figure S3A). However, the total serum IgG titers were only slightly 
but significantly (p < 0.01) lower for the group receiving fusion-inactivated P-V (Figure S3B). This 
indicates that HA-specific antibodies were unable to inhibit hemagglutination, which could be the 
effect of reduced antibody avidity or the generation of antibodies recognizing different epitopes. 
Furthermore, fusion-inactivation of P-V did not affect IgG1 titers, but did negatively affect IgG2c 




Current research on universal influenza vaccines is directed at targeting conserved parts of 
the influenza virion. Aside from B cell epitopes that can induce broadly-protective neutralizing 
antibodies, a T cell component is considered to be an important component of future influenza 
vaccines [17]. Influenza-specific CTLs can increase viral clearance and limit morbidity across 
multiple influenza strains; moreover, recent studies indicate that cellular responses might be 
a correlate of protection against pandemic influenza strains [5, 18]. Inducing potent immune 
responses against influenza-specific T cell epitopes, however, is challenging due to the nature of 
the antigen. Subunit (peptide) vaccines generally possess poor immunogenicity due to the lack of 
any particulate structure or presence of PAMPs. Virosomes have proven to be an efficient delivery 
system for peptides in previous studies [10, 11, 19, 20], but generally have low peptide association 
or encapsulation rates. This makes proper dosage of the peptide antigen difficult; if encapsulation 
rates are low, a disproportionate amount of virosome material is present in the vaccine. Several 
alternative production methods have been developed that enhanced peptide encapsulation 
efficiencies. These included chimeric virosomes [11], virosome lyophilization and subsequent 
reconstitution [19], or covalent attachment of the peptide [20]. However, these methods complicate 
the production process, and might not be suitable for every virosomal peptide formulation. Thus, 
the addition of an adjuvant to virosomal peptide formulations could be a viable alternative to raise 
the immunogenicity of the peptide, without increasing peptide and virosome dose or altering the 
formulation process. 
The selected M158-66 peptide epitope is restricted to the human HLA-A2.1 serotype. To produce 
a vaccine that is effective in a global population, several peptide epitopes covering all the HLA 
serotypes must be included to ensure acceptable coverage. Since few (animal) models currently exist 
to screen for the various HLA types, we selected a HLA-A2.1 epitope, which is a common serotype in 
the Caucasian population and can be tested in HLA-A2.1 transgenic mice. Thus, in contrast to other 
preclinical peptide-based vaccine concepts, this concept influenza vaccine could be used directly in 
humans without changing the peptide antigen.
We demonstrated that the addition of CpG as an adjuvant significantly increased cellular responses 
in mice immunized with peptide-loaded virosomes. Additionally, CpG skewed antibody responses 
induced by peptide-loaded virosomes towards the IgG2c isotype. The production of IgG2c 
antibodies is stimulated during Th1 type responses [21], which support the induction of CD8+ T cells 
[16], which in turn is associated with influenza virus clearance [22]. Since our current peptide-loaded 
virosome production process was inefficient, we opted to mix CpG with our formulation, rather 
than incorporating it in the virosome, which was previously performed with an avian virosome 
vaccine [12]. Incorporating both CpG and peptide antigen in a virosome potentially could increase 
immunogenicity due to the simultaneous signal delivery of both adjuvant and antigen. This would 
be a logical next step for future research.
68
CHAPTER 3
The interaction between the peptide antigen and the virosome particles was shown to be an 
important factor for the overall efficacy of the peptide-loaded virosome vaccine, which confirmed 
an earlier report [10]. Additionally, antigen uptake studies with DCs revealed that association of the 
antigen with the carrier is important for antigen uptake by APCs. While SEC analysis showed that 
the peptide was indeed associated with the virosomes, the exact localization of the peptide, e.g. 
in the aqueous inner compartment or the lipid membrane, remains unknown. The localization of 
peptide antigens in virosomes could have an impact on presentation on MHC-I molecules by APCs 
[23], which in turn can affect the quality of the immune response, and is therefore a relevant topic 
for future studies.
Hemagglutinin conformational integrity and activity, mediating virosomal cell binding and 
membrane fusion, were shown to be crucial for the induction of CD8+ T cell responses. In addition 
to an earlier report which indicated that fusion activity might affect CTL responses induced by 
NP147-155  peptide-loaded virosomes [10], we demonstrated that virosome fusion inactivation had 
a profound impact on the capacity of virosomes to deliver peptide to DCs, and on the induction of 
peptide-specific T cell responses by peptide-loaded virosomes. The role of fusion activity is not only 
important for binding and cell entry of virosomes, but also for CTL induction by WIV vaccines [24, 
25]. Furthermore, fusion-inactivation impaired the induction of influenza-specific IgG2c antibodies, 
which could affect helper T cell responses. In addition, fusion-inactivation impaired the neutralizing 
ability of influenza-specific antibodies generated after vaccination with peptide-loaded virosomes 
significantly, while total influenza-specific IgG levels only were reduced slightly. Thus, inactivation 
of the fusion capacity not only reduces peptide-specific T cell responses, but also severely impairs 
supporting helper T cell and humoral responses induced by the virosomal vaccine.
To assess the efficacy of the vaccine, mice were immunized with CpG-adjuvanted P-V and 
subsequently challenged with a sublethal heterologous HKx31 influenza infection. The mouse 
weight loss data shown in this study indicate that the elevated numbers of influenza-specific CTLs 
after vaccination contributed to the recovery of the mice after heterologous influenza infection, 
independent of neutralizing antibodies. An increase of circulating CD8+ T cells might however not 
be enough to provide complete protection against influenza infections. A boost in CD8+ T cells may 
help clear the virus and improve the rate of recovery of the mice after infection, but is arguably 
insufficient to prevent the early onset and spread of infection. Slütter et al. recently showed the 
importance of local memory CD8+ T cells in the upper respiratory tract to combat influenza A 
infections in the early stages [26]. This insight implicates that the local induction of respiratory 
CD8+ T cells could be an important goal for further T cell based influenza vaccine development. 
The increased systemic T cell levels reported in clinical studies might be an indication that elevated 
local influenza-specific CD8+ T cells in the lungs can provide accelerated recovery and decreased 
morbidity in influenza-infected patients [5, 27].  
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Aside from CD8+ T cell responses, it has been established that T cell help (in the form of CD4+ T cells) 
and B cell responses should not be overlooked [28], and therefore a vaccine concept that utilizes 
both T cell and B cell responses should be pursued to obtain a universal influenza vaccine [29]. 
Influenza virosomes could be an excellent candidate platform for a cross-protective influenza 
vaccine, as it is an effective peptide delivery system and a natural carrier of CD4+ T cell and B cell 
epitopes. 
In conclusion, we demonstrated that peptide-loaded virosomes are able to induce peptide-specific 
CD8+ T cells. The addition of CpG as an adjuvant further increased the efficacy of peptide-loaded 
virosomes. Aside from a greater number of peptide-specific CD8+ T cells, CpG adjuvanted P-V also 
induced T cell help and influenza-specific antibodies. Peptide-virosome association and virosome 
fusion activity are important factors for the effectiveness of P-V. The synergistic effect of virosome 
particles, fusion activity and CpG make a potent combination to increase the immunogenicity of 
peptide antigens. Thus, peptide-loaded virosomes are a promising approach for the development 
of a cross-protective influenza vaccine.
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Figure S1. Total influenza-specific IgG titers after immunization. Influenza-specific total IgG titers in sera from 












































































Figure S2. Effect of association between peptide and virosomes on humoral responses. Mice sera were analyzed 
for HI (A) and total IgG (B) titers. IgG1 (C) and IgG2c (D) isotypes were also determined from sera. Data represent 
































































Figure S3. Effect of fusogenic activity of virosomes on influenza-specific antibodies. Influenza-specific HI titers 
(A) and total IgG titers (B), and antibody isotypes IgG1 (C) and IgG2c (D) titers in sera from mice. Data represent 
mean ± SD (n = 3) and is representative of three individual experiments. **p < 0.01, ****p < 0.0001.
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Influenza peptide antigens have the potential to induce cross-protective influenza-specific T cells. 
However, short peptide antigens are poorly immunogenic and therefore need to be formulated with 
a potent adjuvant. In this study, it was investigated whether whole inactivated influenza virus (WIV) 
can act as an adjuvant for influenza peptide antigens. The immunogenicity of WIV mixed with the 
HLA-A2.1-restricted influenza peptide GILGFVFTL (GIL) was assessed in HLA-A2.1 transgenic mice 
by quantification of peptide-specific IFN-γ+ CD8+ T cells after vaccination. Subsequently, a design of 
experiments (DoE) approach was utilized to study the synergistic effect between WIV adjuvant and 
peptide antigen at different doses. Moreover, the roles of WIV fusogenicity, peptide-WIV association 
and co-localization on the adjuvanticity of WIV were investigated. To assess whether WIV could also 
act as an adjuvant for other peptides, a peptide pool with three wild type (WT) influenza peptides 
was adjuvanted with WIV. In addition, three chemically enhanced peptide ligands (CPLs) derived 
from the WT peptides, which possessed a higher binding affinity to the MHC molecules, were 
adjuvanted with WIV and screened for their immunogenicity compared to the WT peptides. WIV was 
found to be a potent adjuvant for the GIL peptide. The DoE study revealed that WIV was able to act 
as an adjuvant at even low concentrations. Co-localization of the peptide antigen and WIV adjuvant 
was important for the induction of a peptide-specific immune response, whereas peptide-WIV 
association and WIV fusogenicity were not. WIV was also able to act as an adjuvant for both WT 
and CPL peptide pools. This study shows the potential of WIV as an adjuvant for influenza peptides. 
The simple formulation process and the existing safety track record of WIV make this an attractive 
adjuvant, which could also be used for non-influenza antigens.
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introduCtion
Seasonal influenza vaccines mediate their protective effect mainly through the induction of virus-
specific neutralizing antibodies. These antibodies are directed against the influenza surface proteins 
hemagglutinin (HA) and neuraminidase (NA). However, these proteins can undergo changes due 
to antigenic shifts and drifts. These antigenic changes impair the neutralizing ability of antibodies 
induced by vaccines, rendering these vaccines ineffective. Therefore, additional immune responses 
such as cellular responses against influenza need to be induced to increase vaccine effectiveness [1].
Cellular immune responses represent a potential alternative to antibody-mediated immune 
responses. Recently, Sridhar et al. found that cellular immune responses correlated with reduced 
morbidity in patients infected with pandemic influenza [2]. Similarly, Wang et al. showed that patients 
with early influenza-specific CD8+ T cell responses recovered faster from severe H7N9-induced 
disease [3]. These studies confirmed that cellular responses against influenza can indeed be effective. 
Cellular immune responses such as cytotoxic T cells (CTLs) can effectively clear virus-infected host 
cells, thereby inhibiting viral replication and spread. Unlike most vaccine-induced antibodies, 
these CTLs recognize epitopes located on internal influenza proteins, which are conserved in many 
influenza strains. Owing to the conserved nature of these epitopes, cellular responses directed 
against these epitopes are potentially cross-reactive. Short linear peptides representing these 
epitopes are therefore attractive antigens for the development of cross-reactive influenza vaccines.
Peptide antigens as such however suffer from low immunogenicity, due to inefficient delivery 
to antigen presenting cells (APCs) and the absence of pathogen-associated molecular patterns 
(PAMPs) or adjuvants to activate the APCs.  Delivery of the peptide antigen to the cytoplasm of APCs 
is considered to be crucial for proper processing and subsequent presentation on MHC-I molecules, 
while activation of the APCs is important for licensing of naïve effector and memory CD8+ T cells [4]. 
Formulation of peptide antigens with an appropriate adjuvant (which can be a delivery system 
or an immunopotentiator [5]) is thus crucial to induce a cellular immune response against the 
peptide antigen. Water-in-oil emulsions such as Incomplete Freund’s Adjuvant (IFA) are commonly 
used and effective adjuvants for peptides, but are associated with severe adverse events such as 
lesion formation at the site of injection [6]. Thus, alternative adjuvants for peptide antigens are 
highly sought after. Particulate adjuvant systems such as liposomes or virosomes formulated with 
influenza peptides derived from internal proteins have proven to be effective for the induction of 
peptide-specific CTLs [7, 8], especially in combination with Toll-like receptor (TLR) agonists [9, 10]. 
However, the formulation of peptides into these delivery systems can be complicated and may 
result in low encapsulation rates. Adjuvants that can be directly admixed with peptide antigens 
would therefore be preferable.
Whole inactivated influenza virus (WIV) possesses an innate adjuvant capability in the form of viral 
single-stranded RNA (ssRNA). Previously it was shown that influenza ssRNA is a potent TLR7 agonist 
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[11], that increases antibody responses and promotes cellular immune responses. Furthermore, WIV 
contains, aside from CD8+ epitopes, CD4+ epitopes, which provide invaluable T-help that supports 
the induction of functional CD8+ T cells [12]. We therefore hypothesize that the addition of WIV to 
peptide antigens could promote the induction of peptide-specific T cell responses.
In addition to proper formulation of the peptide antigen, modification of the peptide could also 
improve the immunogenicity of the antigen. Previously, chemically enhanced altered peptide 
ligands (CPLs) derived from HLA-A2.1-restricted epitopes were shown to possess a higher binding 
affinity to HLA-A2.1, and  to induce higher amounts of IFN-γ compared to wild type (WT) epitopes in 
an in vitro system [13].  However, like other peptides, these CPLs are currently adjuvanted with IFA. 
Thus, we investigated whether WIV can act as an adjuvant for these modified peptides.
In the current study, we first investigated the adjuvanticity of WIV for the GILGFVFTL (GIL, M158-66) 
influenza peptide, a HLA-A2.1-restricted CD8+ T cell epitope, in a proof-of-principle study. Next, we 
performed a dose-finding study for the optimal WIV adjuvant and peptide antigen concentration 
to induce peptide-specific T cells by use of a design of experiments (DoE) approach. Furthermore, 
we studied the effect of WIV-peptide co-localization and WIV membrane fusion activity on the 
adjuvanticity of WIV. Finally, we tested the adjuvanticity of WIV with three WT T cell peptides and 
three CPL variants of the WT peptides.
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Formulation of vaccines
Influenza A/PR8/34 virus was propagated on fertilized eggs and inactivated with β-propiolactone 
on a pilot scale as described before [14], which yielded PR8 WIV bulk vaccine. To study the effect of 
fusion activity on the immune response, WIV was fusion-inactivated by lowering the buffer pH to 4.5 
with a pretitrated volume of 1 M HCl, and subsequently incubated at 37°C for 15 min. Afterwards, 
the sample was brought to physiological pH by dialyzing overnight against PBS pH 7.2. Membrane 
fusion capacity was subsequently determined by a hemolysis assay as described previously [10].
The Netherlands Cancer Institute kindly provided the HLA-A2.1-restricted influenza GILGFVFTL 
(GIL, M158-66), FMYSDFHFI (FMY, PA46-54) and NMLSTVLGV (NML, PB1413-421) peptides, and CPLs 
[am-phg]ILGFVFTL (G1), [4-FPHE]MYSDFHF[2-AOC] (F5) and N[NLE]LSTVLGV (N53). Nonproteogenic 
amino acids introduced in the peptide sequences are shown in Figure S1. 
Influenza PR8 WIV and peptide antigens were formulated in PBS pH 7.2 (Life Technologies) at various 
concentrations. When mentioned, 50 µg of CpG ODN 1826 (Invivogen) or 50% (v/v) Incomplete 
Freund’s Adjuvant (Sigma-Aldrich) was added to the formulation.
Animal studies
Animal studies were conducted according to the guidelines provided by the Dutch Animal 
Protection Act, and were approved by the Committee for Animal Experimentation (DEC) of the 
National Institute for Public Health and the Environment (RIVM). Eight- to ten-week-old female 
transgenic C57BL/6-Tg(HLA-A2.1)1Enge/J (Jackson Laboratory, maintained in-house) were used in 
all studies.
In the proof-of-principle study, mice (three per group) received immunizations subcutaneously (s.c.) 
in the flank at days 0 and 21 under isoflurane anesthesia, containing either PBS, 50 µg WIV, 1 µg GIL 
peptide adjuvanted with 50 µg WIV or 100 µg GIL adjuvanted with 50 µg CpG.
For the dose finding study, a DoE approach was used (as described below). The selected formulations 
consisting of various doses of WIV and GIL peptide (shown in Table S1) were administered s.c. in the 
flank of mice (six per group) under isoflurane anesthesia at day 0 and 21.
To study the effect of adjuvant co-localization, mice (six per group) were immunized at days 0 and 21 
either s.c. in one flank with PBS or 100 µg GIL peptide adjuvanted with 25 µg WIV, or s.c. in separate 
flanks with 100 µg GIL peptide in one flank and 25 µg WIV adjuvant in the opposite flank. 
The effect of membrane fusion activity was assessed by immunizing mice (six per group) s.c. in the 




The adjuvant effect of WIV on a mix of multiple peptides was assessed with either a WT peptide pool 
(GIL, FMY and NML; 100 µg each) or a modified peptide pool (G1, F5 and N53; 100 µg each). Mice 
(six per group) received an s.c. immunization in the flank at day 0 and 21 containing either PBS, WT 
peptide pool adjuvanted with 5 µg WIV or IFA, CPL peptide pool adjuvanted with 5 µg WIV or IFA, 
or only 5 µg WIV. In all studies, animals were sacrificed by cervical dislocation and bleeding under 
anesthesia at day 35.
Dose finding by design of experiments
An initial dose-response study was performed by a design of experiments approach in order to 
detect potential interactions and effects between the GIL peptide antigen dose and WIV adjuvant 
dose on the induction of GIL-specific T cell responses in vivo. A full factorial design was created using 
MODDE 10.0.0 (Umetrics AB). Results from both flow cytometry and ELISpot methods were selected 
as response parameters. The limits of the doses ranged from 1-100 µg GIL peptide and 1-25 µg WIV. 
This resulted in a design with seven formulations including three center points. To accommodate 
for the high variability in animal experiments, it was chosen to administer each formulation to six 
mice, resulting in a design as shown in Table S1. The models were fitted using partial least squares 
and subsequently optimized by deleting non-significant terms [15], until the model performance 
parameters goodness of fit (R2), goodness of prediction (Q2), validity and reproducibility were at 
their highest. 
Intracellular staining and flow cytometry
T cell populations were assessed by flow cytometry. In short, single-cell suspensions of spleens 
were plated at a concentration of 2*106 cells in a 48-well plate in RPMI medium (Life Technologies) 
with 10% Hyclone fetal calf serum (FCS, Thermo Scientific), and stimulated overnight with 
either medium, 50 ng peptide or PR8 WIV. Cytokine transport was inhibited by incubating 
with Golgi-plug (BD Biosciences) for 4 hours. Cells were subsequently stained with anti-mouse 
CD8-FITC (BD Biosciences), anti-mouse CD4-PE (BD Biosciences) and Live-dead-Aqua (Invitrogen). 
Next, cells were fixated with fixation/permeabilization buffer (BD Biosciences) and washed 
with permeabilization wash buffer (BD Biosciences). Finally, cells were stained intracellular with 
anti-mouse IFN-γ-APC (BD Biosciences), and IFN-γ+ CD8+ T cells were quantified on a FACS Canto II 
flow cytometer (BD Biosciences). Acquired data was analyzed with FlowJo version 10 for Mac OSX 
(TreeStar Inc.).
Enzyme linked immunosorbent spot assay (ELISpot)
An ELISpot assay was used to determine IFN-γ spot-forming units in restimulated splenocytes. 
96-wells Multiscreen PVDF filter plates (Millipore) were activated by adding 25 µL 70% ethanol for 
2 min, and subsequently washed three times with PBS. Plates were coated overnight with anti-mouse 
IFN-γ antibodies (U-Cytech) at 4°C. Next, filter plates were washed three times and blocked with 5% 
Hyclone fetal calf serum (FCS, Thermo Scientific) for 1 hour at 37°C. Subsequently, 4*105 isolated 
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splenocytes resuspended in IMDM medium, 5% FCS were added to each well with or without 50 ng 
relevant peptide, and incubated overnight at 37°C. After overnight stimulation, filter plates were 
washed five times and IFN-γ was detected using biotinylated anti-mouse antibodies (U-Cytech) and 
100 µL BCIP/NBT reagent (Thermo Scientific) per well. Spots were allowed to develop for 15 min after 
which the plates were thoroughly washed with tap water. Spots were counted using an A.EL.VIS 
ELISpot reader (Aelvis). The number of IFN-γ producing cells in antigen-stimulated splenocytes 
was obtained after background correction (subtracting number of spots produced by splenocytes 
incubated with medium).
Determination of association between peptides and WIV
The association of peptides to WIV particles was studied by quantification of unassociated peptide 
in a mixture of peptides and WIV. Peptides were admixed with WIV in similar concentrations used in 
the animal studies. WIV particles were subsequently spun down by ultracentrifugation for 2 hours 
at 30.000 g. Supernatant was collected and analyzed for peptides by mass spectrometry. Percentage 
of unassociated peptide was calculated by comparing peptide content in supernatants of peptide 
mixed with WIV to peptide content in supernatants collected from solutions without WIV. No traces 
of WIV proteins were detected in supernatants, indicating that WIV was successfully separated from 
the free peptide.
Hemolysis assay
Virosome fusion activity was determined by using a hemolysis assay as described previously 
[15]. Formulations were mixed with human blood erythrocytes and 0.1M 2-(N-morpholino)
ethanesulfonic acid (MES) buffer with pH’s ranging from 4.5 to 5.5, and incubated at 37°C for 30 
min. The released hemoglobin was quantified in the supernatant after centrifugation by reading 
absorbance at 540 nm using a Synergy Mx reader (Biotek). Hemoglobin release from erythrocytes 
mixed with water was set as maximal hemolysis (100%).
Statistics
Results were statistically analyzed with a one-way ANOVA followed by a Tukey-post test for multiple 




Proof-of-principle of WIV as an adjuvant
The adjuvant effect of WIV for GIL peptide was assessed in HLA-A2.1 transgenic mice. They received 
two vaccinations of either peptide adjuvanted with CpG, peptide adjuvanted with WIV or WIV 
alone. Splenocytes restimulated with GIL peptide were analyzed for peptide-specific T cells by flow 
cytometry. The specificity of CD8+ IFN-γ+ T cells was determined by comparing peptide-stimulated 
splenocytes with mock-stimulated splenocytes (Figure 1A). 
As expected, 100 µg GIL peptide adjuvanted solely with 50 µg CpG did not induce any 
peptide-specific CTL response in mice (Figure 1B). This can be attributed to a number of factors, 
such as the absence of CD4+ helper epitopes, and the lack of delivery of antigen and adjuvant, both 
of which are crucial for the immunogenicity of short peptide antigens [6]. In contrast, only 1 µg GIL 
peptide antigen adjuvanted with 50 µg WIV induced peptide-specific responses in mice. Mice that 
received only WIV also showed considerable T cell responses, which was attributed to the high dose 
of WIV as described earlier [17, 18]. The GIL epitope is indeed present in PR8 WIV, which explains the 
induction of GIL-specific T cells by WIV at high concentrations. Furthermore, WIV might still act as an 
adjuvant for peptides at lower doses. Thus, in order to maximize peptide-specific T cell responses 
with minimal use of WIV, a dose-finding study was conducted.
Dose-finding and interaction study between GIL peptide and WIV using design of 
experiments
To investigate which concentrations of both WIV and peptide were still able to induce a 
peptide-specific T cell response a dose-finding study of both WIV and peptide was conducted by using 
a DoE approach. DoE approaches are commonly used for the optimization of (bio)pharmaceutical 
formulations [19]. However, there are currently no reports that utilized a DoE approach to assess 
the effect of formulation parameters on in vivo responses, such as cellular immune responses. A full 
factorial design was implemented by varying the peptide antigen dose from 1-100 µg, and the WIV 
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Figure 1. WIV acts as an adjuvant for peptide antigens. (A) Flow cytometry plot displaying specificity of IFN-γ+ 
CD8+ T cells in splenocytes from mice immunized twice with 1 µg GIL peptide adjuvanted with 50 µg WIV. (B) 
Splenocytes restimulated with GIL peptide were analyzed for IFN-γ+ CD8+ T cells with flow cytometry. Data 
represent mean ± SD (n = 3); **p<0.01, ***p<0.001.
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adjuvant dose from 1-25 µg (Table S1).
The formulations, containing a variety of GIL peptide and WIV doses, were tested for their ability to 
induce GIL-specific T cell responses in HLA-A2.1 transgenic mice (Figure 2A and 2B). A combination 
of 1 µg GIL peptide and 1 µg WIV was unable to induce CTL responses. However, when the GIL dose 
was increased to 100 µg, a significant increase of GIL-specific T cells was observed. This effect was 
also observed when the peptide dose was increased from 1 to 100 µg combined with a dose of 
25 µg WIV. These results indicate that WIV is still able to boost the immune responses towards GIL 
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Figure 2. Dose-finding study of WIV and peptide by DoE. HLA-A2.1 transgenic mice were vaccinated two times 
with different doses of GIL peptide and WIV.  Splenocytes restimulated with GIL peptide were analyzed for 
peptide-specific CD8+ T cells with flow cytometry (A) and ELISpot (B). Prediction contour plots obtained by DoE 
visualize the interaction between peptide antigen and WIV for the flow cytometry (C) and ELISpot (D) responses. 
The predicted responses are displayed in the white boxes. Data represent mean ± SD (n = 6); *p<0.05, **p<0.01.
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Association between the GIL peptide and the WIV particles may be a contributing factor to the 
immunogenicity of peptide antigen. Thus, the association between the peptide and WIV was 
determined (Table 1). Only low amounts of GIL peptide (1 µg) mixed with relatively high amounts of 
WIV (25 or 50 µg) showed some association. At higher peptide concentrations, association with WIV 
was negligible, which can be explained by the high molar abundance of GIL peptide compared to 
WIV or a low affinity between the two. In general, it can be concluded that association of the peptide 
to WIV did not have a significant influence on the immunogenicity, contrarily to other delivery 
systems such as liposomes or virosomes [10, 20].
To assess the synergistic effect between the peptide antigen and the WIV adjuvant, a partial least 
squared (PLS) regression model was fitted for the T cell responses. Valid models were obtained 
for both flow cytometry (R2=0.706, Q2=0.633) and ELISpot (R2=0.712, Q2=0.629) responses, and 
model prediction contour plots were generated (Figure 2C and 2D). The contour plots illustrate 
that addition of WIV is essential for the peptide antigen to become immunogenic. Furthermore, 
the model indicates that theoretically the optimum of T cell responses has not been reached yet; 
however, the dose ranges used in this DoE model for both GIL peptide and WIV are at their maximum 
concerning peptide solubility and feasible WIV dose for human use, respectively.
The use of the DoE approach enabled us to illustrate the synergy between antigen and adjuvant, 
and to predict their effect on the cellular immune responses in vivo. The use of DoE in preclinical 
animal studies is difficult, due to the multiple factors, such as biological variability between animals 
and T cell assay variability, which can cause variability in each animal study. Nonetheless, the use of 
DoE provides valuable insight in the effect of antigen and adjuvant dose on the immune response 
in mice, and could be implemented in future vaccine development.
Involvement of WIV-peptide co-localization on immunogenicity
The viral ssRNA present in WIV is a TLR7 agonist, and likely contributes to the observed 
immunostimulating effect of WIV [11]. For most adjuvants, including TLR ligands, co-localization 
with the antigen is necessary to provide local immunostimulatory signals. In the model contour 
plots, it is predicted that a dose of 25 µg WIV combined with 100 µg GIL peptide is able to induce the 
highest peptide-specific T cell responses. Therefore, 25 µg WIV and 100 µg peptide was selected as 
Peptide (µg) WIV (µg) Unassociated peptide (%)
1 1 112 ± 10
100 1 111 ± 6
50 13 96 ± 5
1 25 77 ± 8
100 25 92 ± 20
1 50 87 ± 9
Table 1. Association between GIL peptide and WIV at different concentrations. The fraction of unassociated 
peptide was determined in the supernatant by mass spectrometry. Data represent mean ± SD (n = 3).
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the formulation to be used in mechanistic studies. To investigate the importance of co-localization, 
we administered 100 µg GIL peptide and 25 µg WIV s.c. at separate flanks, each draining to a different 
lymph node. When the peptide and WIV were administered separately at different sites, a significant 
decrease of peptide-specific T cell response was observed (Figure 3). The observed response after 
separate vaccination is probably caused by the WIV only. It is likely that co-localization of WIV and 
GIL peptide in the endosomal compartment of APCs is required to benefit from the co-stimulatory 
adjuvant signal provided by the viral ssRNA [21]. Moreover, a recent study suggested that particulate 
delivery of a TLR7 agonist can improve its immunostimulatory effect due to efficient delivery to the 
endosomal compartment [22], where TLR7 is located. WIV can deliver its own viral ssRNA in a similar 
manner, which might explain the immunostimulatory potential of WIV.
Involvement of WIV membrane fusion activity on immunogenicity
Aside from co-localization, the role of membrane fusion activity of WIV was investigated. Fusion 
activity was shown to be important for the induction of cross-reactive T cell responses by WIV [23]. 
Furthermore, other nearby molecules, such as the peptide antigen in our WIV-adjuvanted vaccine, 
can escape the endosomal compartment during membrane fusion of WIV with the endosomal 
membrane [24]. Fusion activity might thus play a role in the adjuvanticity of WIV. Surprisingly, 
mice vaccinated with fusion-inactivated WIV mixed with GIL peptide still produced high amounts 
of peptide-specific T cells, comparable to those in mice receiving fusion-active WIV with peptide 
(Figure 4A and 4B). A hemolysis assay confirmed the loss of pH-dependent fusion activity of WIV 
(Figure 4C). The current results indicate that fusion activity of WIV is not important for the induction 
of T cell responses against peptide antigens. The immunogenicity of antigens located inside the WIV 
particle itself might be compromised by fusion inactivation as shown before [23], but in the current 
study the admixed GIL peptide apparently was taken up and processed correctly by APCs regardless 











































Figure 3. Effect of co-localization on WIV adjuvanticity. HLA-A2.1 transgenic mice were vaccinated twice with 
100 µg GIL peptide and 25 µg WIV either in one single flank (mixed) or separate flanks (separate). Splenocytes 
were restimulated with GIL peptide and analyzed with flow cytometry (A) or ELISpot (B). Data represent mean ± 
SD (n = 6); **p<0.01, ***p<0.001.
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Adjuvation of multiple peptides by WIV
To investigate whether WIV also acts as an adjuvant for multiple peptides, a peptide pool of GIL 
and two additional human HLA-A2.1-restricted influenza epitopes, FMY and NML, was studied in 
combination with WIV. In addition, we selected three modified peptides to be combined with WIV, 
being G1, F5 and N53, which are CPLs derived from the three aforementioned WT peptide epitopes. 
Modification of WT peptides with non-proteogenic amino acids has previously shown to increase 
binding affinity with the MHC-I molecules, which might result in increased T cell responses [13]. 
Since the selected epitopes are also present in WIV, a reduced WIV dose (5 µg) was chosen from the 
previously established prediction model. At this concentration, it was predicted that WIV still had 
an immunostimulating effect, while bringing the inherent T cell response generated by WIV itself to 
a minimum. Mice were vaccinated with either WT or modified peptide pools adjuvanted with WIV. 
As a control, peptide pools adjuvanted with IFA were included to compare the adjuvanticity of WIV 
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Figure 4. Effect of membrane fusion activity on WIV adjuvanticity. HLA-A2.1 transgenic mice were vaccinated 
twice with 100 µg GIL peptide and 25 µg fusion-active (active) or fusion-inactive WIV (inactive). Splenocytes 
were restimulated with GIL peptide and analyzed by flow cytometry (A) or ELISpot (B). Fusion activity of active 
and inactive WIV-GIL formulations was determined by hemolysis assay (C). Immunogenicity data is presented as 
mean ± SD n=6; n.s.=not significant. Hemolysis data represent mean ± SD (n = 3).
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The individual peptides in both WT and modified pools did not show significant association with the 
WIV particles, similar to the previous observations with the GIL peptide alone in this study (Table S2). 
Thus, it is unlikely that differences in induced immune responses by the peptide vaccines are caused 
by differences in association between peptide and WIV.
As seen previously in this study, the GIL peptide in the peptide pool was able to induce GIL-specific 
T cell responses after immunostimulation with WIV (Figure 5A). In contrast, IFA adjuvanted GIL 
peptide induced significantly lower T cell responses. The modified G1 peptide however was unable 
to induce potent GIL-specific responses, regardless of adjuvant. The G1 peptide adjuvanted with 
either WIV or IFA did induce a G1-specific T cell response, indicating that while the modified peptide 
was immunogenic in combination with an adjuvant, it failed to induce responses that reacted with 
the WT analog.
The WT FMY peptide was able to induce modest FMY-specific T cell responses in combination with 
either WIV or IFA (Figure 5B). Interestingly, the modified F5 peptide was able to induce significantly 
higher FMY-specific responses compared to the WT FMY peptide when adjuvanted with WIV. F5 
peptide adjuvanted with IFA did not show such an increase, indicating that WIV is a more potent 
adjuvant than IFA for the F5 peptide. This difference was also observed with the F5-specific 
responses; F5 peptide induced significantly higher F5-specific T cell responses when adjuvanted 
with WIV than with IFA.
The subdominant NML peptide and the modified N53 were unable to induce any significant 
T cell responses, regardless of adjuvant (Figure 5C). IFA-adjuvanted peptides showed incidental 
T cell responses in some animals, suggesting that IFA is a slightly better adjuvant than WIV for 
this specific peptide. It is unclear why WIV was not effective with NML and N53 peptides, while 
IFA-adjuvanted NML and N53 managed to induce a response in a few animals. It is possible that 
WIV contains epitopes which are more immunodominant than the NML epitope, decreasing the 
NML-specific T cell responses. However, since responses induced by IFA-adjuvanted NML and N53 
peptides were not consistent in all animals, there was no significant difference between IFA- and 
WIV-adjuvanted groups.
These data indicate that WIV is a potent adjuvant for short peptides, both in WT or modified form. 
Other approaches such as peptide-lipid conjugates [25], liposomes [9], virosomes and nanoparticles 
have been used previously to increase the immunogenicity of short peptides [10, 26], but require 
multiple formulation steps and might not be suitable for every peptide due to differences in 
physicochemical attributes. In contrast, WIV can be readily mixed with peptide antigens, which is a 
simple process to scale up. Furthermore, WIV is already licensed and used for decades as an influenza 
vaccine, and recent studies show an excellent safety profile [27]. With this prior knowledge on safety 

































































































Figure 5. T cell responses against wild-type and modified peptides adjuvanted with WIV. HLA-A2.1 transgenic 
mice were vaccinated twice with peptide pools containing 100 µg of wild type (WT) peptides (GIL, FMY and NML) 
or modified (mod.) peptides (G1, F5 and N53) adjuvanted with 5 µg WIV or 50% (v/v) IFA.  Specific T cell responses 
induced by the peptide pools towards either GIL or G1 (A), FMY or F5 (B), NML or N53 (C) were determined for 
all groups. IFN-γ spot-forming units were determined with ELISpot. Data represent mean ± SD (n = 6); *p<0.05, 
**p<0.01, ***p<0.001.
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ConCluSion
While it is known that WIV possesses an innate adjuvant capacity, so far it has never been used as 
an adjuvant for peptide antigens. We showed that WIV is capable of effectively increasing the T cell 
response against GIL and FMY influenza peptides in HLA-A2.1 transgenic mice. Co-localization of 
antigen and adjuvant were necessary to induce a potent T cell response, but the membrane fusion 
capacity of WIV was not important for the immunogenicity of the formulation. Furthermore, we 
showed that WIV was also able to immunostimulate non-natural, modified peptides effectively. Due 
to the ease of production of WIV and its long time safety track record, it is an excellent candidate 
adjuvant for low-immunogenic antigens that induce cellular responses.
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Figure S1. Nonproteogenic synthetic amino acids used for peptide modification. The four nonproteogenic 
synthetic amino acids were introduced either in GILGFVFTL, FMYSDFHFI or NMLSTVLGV peptides, resulting in 
modified [am-phg]ILGFVFTL, [4-FPHE]MYSDFHF[2-AOC] and N[NLE]LSTVLGV peptides.




















































Figure S2. Gating strategy of CD8+ IFN-γ+ T cells in splenocytes. An example of the gating strategy. The 
lymphocyte population was first gated (upper left). From this population, all live cells were selected (upper right). 
Subsequently, CD8+ cells were gated (lower left), after which a quadrant gate was created to select for CD8+ 
IFN-γ+ cells (lower right).
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Table S1. Worksheet of full factorial design of dose-finding study. All experimental points (initially seven) were 
duplicated and included six times to accommodate biological variation between the animals in the in vivo study.
Peptide Unassociated peptide (%)
GIL 87 ± 18
FMY 81 ± 22
NML 115 ± 21
G1 138 ± 34
F5 96 ± 8
N53 99 ± 12
Table S2. Association of peptides with WIV. Peptides were admixed with WIV (in similar concentrations as used 
in vivo) and subsequently separated by ultracentrifugation. The fraction of unassociated peptide was determined 
in the supernatant by mass spectrometry. Data represent mean ± SD (n = 3).
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Predicting the influence of liposomal 
lipid composition on liposome size, 
zeta potential and liposome-induced 





In this study, the effect of liposomal lipid composition on the physicochemical characteristics 
and adjuvanticity of liposomes was investigated. Using a design of experiments (DoE) approach, 
peptide-containing liposomes containing various lipids (EPC, DOPE, DOTAP and DC-Chol) and 
peptide concentrations were formulated. Liposome size and zeta potential were determined for 
each formulation. Moreover, the adjuvanticity of the liposomes was assessed in an in vitro dendritic 
cell (DC) model, by quantifying the expression of DC maturation markers CD40, CD80, CD83 and 
CD86. The acquired data of these liposome characteristics were successfully fitted with regression 
models, and response contour plots were generated for each response factor. These models were 
applied to predict a lipid composition that resulted in a liposome with a target zeta potential. 
Subsequently, the expression of the DC maturation factors for this lipid composition was predicted 
and tested in vitro; the acquired maturation responses corresponded well with the predicted ones. 
These results show that a DoE approach can be used to screen various lipids and lipid compositions, 
and to predict their impact on liposome size, charge and adjuvanticity. Using such an approach may 
accelerate the formulation development of liposomal vaccine adjuvants.
abStraCt
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introduCtion
Many vaccines are based on purified or synthetic antigens derived from their respective pathogens. 
These include antigens, such as peptides and proteins, which are poorly immunogenic on their own. 
Adjuvants, based on delivery systems and/or immunopotentiators, are used frequently to improve 
the immunogenicity of antigens [1]. Liposomes are important delivery systems for vaccines because 
of their high versatility, which enables them to be suited for many types of antigens [2]. 
Numerous lipid compositions and preparation methods for liposomes can be chosen, which affect 
several liposomal characteristics, such as size, zeta potential, bilayer fluidity and encapsulation or 
association of antigen or adjuvant. In turn, these characteristics can influence the adjuvant effect 
of liposomes [3]. The adjuvanticity of liposomes is attributed to several mechanisms, such as 
antigen depot formation, induction of local inflammation and increased antigen uptake by antigen 
presenting cells.
Antigen presenting cells, with dendritic cells (DCs) in particular, play a pivotal role in the induction 
of adaptive immune responses. DCs recognize, internalize and process antigens, and ultimately 
present them to naïve CD4+ or CD8+ T cells [4]. The uptake of antigens by DCs is affected by several 
antigen characteristics, of which size and surface charge are the most influential. Generally, the 
size of most subunit antigens is too small for the DC to be taken up efficiently. Incorporation of an 
antigen into a particulate delivery system such as a liposome, whose size is comparable to that of 
a virus particle, can therefore significantly increase antigen uptake by DCs through endocytosis [5].
The surface charge density of a liposome influences its zeta potential, and thereby its electrostatic 
interaction with the surface of a DC. Since cellular membranes are anionic, cationic liposomes 
are ideally suited to increase antigen uptake by DCs [6]. It is generally accepted that anionic and 
neutral liposomes are less suited for the induction of immune responses [7]. The cationic liposome 
formulation CAF01 is currently advancing through clinical trials in combination with HIV and 
tuberculosis antigens, indicating the potency of cationic liposomes [8, 9].
For the successful priming of naïve B- or T cells by DCs, more is needed than efficient antigen uptake 
and processing. During antigen presentation by the DCs to naïve lymphocytes, costimulatory 
signals are required. These are provided by the DCs, which can express costimulatory molecules 
such as CD40 (for B cells), CD80 and CD86 (for T cells) after maturation [10]. The maturation of 
DCs is considered to be of vital importance for the overall immunogenicity of a vaccine antigen 
[11]. In vitro DC maturation models can therefore be used as preclinical screening tools for vaccine 
formulations [12]. 
Immunostimulatory signals, which are often provided by pathogen-associated molecular patterns 
(PAMPs), are required for the activation of DCs. Inclusion of PAMPs such as Toll-like receptor (TLR) 
ligands or other molecules in liposomes is therefore a popular strategy to increase liposome 
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adjuvanticity [13, 14]. Cationic lipids also seem to affect DC maturation [15]. Besides the positive 
charge, other physical characteristics, such as lipid bilayer fluidity, may affect DC maturation 
[16]. Chemical differences between cationic lipids indeed have shown to affect DC maturation, 
underlining the significance of the lipid composition of cationic liposomes.
Design of experiments (DoE) is a statistical method to screen, identify and optimize important factors 
in various processes, such as pharmaceutical formulation development [17, 18]. It uses a minimal 
number of experiments to model the effects of each formulation parameter, which significantly 
accelerates the identification of optimal conditions. A DoE approach was recently employed to 
optimize the formulation process of itraconazole-loaded liposomes [19]. The authors were able to 
predict drug loading with a mathematical model obtained with DoE, and identify critical formulation 
parameters affecting drug loading. However, no attempts have been made yet to predict biological 
parameters, such as the adjuvanticity of liposomes, with DoE-like approaches.
In this study, the effects of liposomal lipid composition and peptide incorporation on the 
physicochemical characteristics and the adjuvanticity of liposomes were studied. To gain insight 
into the effects of each component with a minimal number of experiments, a DoE approach was 
used. The physicochemical characteristics of the liposomes were determined as the liposome size 
and zeta potential, while the liposome adjuvanticity was determined as liposome-induced in vitro 
expression of DC maturation factors CD40, CD80, CD83 and CD86. To this end, four lipids, i.e., egg-
phosphatidylcholine (EPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-
3-trimethylammonium-propane (DOTAP) and 3ß-[N-(N’,N’-dimethylaminoethane)-carbamoyl]
cholesterol (DC-Chol), and the HLA-A2.1-restricted influenza peptide GILGFVFTL (M158-66), were used 
to generate peptide-loaded liposomes with different lipid compositions. Liposome size and zeta 
potential were determined for each formulation, and prediction models for these parameters were 
generated by using a DoE approach. Simultaneously, the ability of these liposomes to maturate DCs 
was evaluated by determining the expression of DC maturation markers CD40, CD80, CD83 and 
CD86. With DoE, the most influential lipids were identified, and prediction models were generated 
for each maturation marker. Finally, the prediction models were validated by selecting a liposome 
with a previously untested lipid composition. A complete overview of the study is depicted in 
Figure 1.


















Formulation Run Order 
Peptide 
(µg/mL) DOPE DC-Chol DOTAP EPC 
N1 8 10 1 0 0 0 
N2 13 10 1 0 0 0 
N3 12 10 0 1 0 0 
N4 18 10 0 0 1 0 
N5 11 10 0 0 1 0 
N6 9 10 0 0 0 1 
N7 7 10 0 0.333333 0.333333 0.333333 
N8 16 100 1 0 0 0 
N9 17 100 0 1 0 0 
N10 10 100 0 0 1 0 
N11 6 100 0 0 0 1 
N12 14 100 0.333333 0 0.333333 0.333333 
N13 15 100 0.333333 0.333333 0 0.333333 
N14 3 100 0.333333 0.333333 0.333333 0 
N15 4 55 0.25 0.25 0.25 0.25 
N16 1 55 0.25 0.25 0.25 0.25 
N17 5 55 0.25 0.25 0.25 0.25 
































Figure 1. Overview of the study concept. An experimental design describing liposomes with various lipid 
compositions and peptide concentrations is generated with DoE software. Liposomes are formulated according 
to the design. Then, liposomes characteristics such as size, zeta potential and liposome-induced dendritic cell 
maturation are determined for each liposome formulation.  Models are subsequently fitted to the generated 





The influenza peptide GILGFVFTL (M158-66) was synthesized at the Dutch Cancer Institute (NKI). All 
lipids (EPC, DOPE, DOTAP, DC-Chol) were purchased from Avanti Polar Lipids, bovine serum albumin 
(BSA), ethylenediaminetetraacetic acid (EDTA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) and sodium chloride from Sigma-Aldrich, Iscove’s Modified Dulbecco’s Medium (IMDM) 
from Invitrogen, human granulocyte macrophage colony-stimulating factor (GM-CSF) from 
Peprotech, human IL-4 from Sanquin, anti-human CD40-PE and CD80-FITC from BD Pharmingen, 
anti-human CD83-APC and CD86-Pacific Blue from Biolegend, phosphate-buffered saline (PBS; 
155 mM NaCl, 1.5 mM potassium phosphate monobasic, 2.7 mM sodium phosphate dibasic, pH 7.2) 
and Live/dead-Aqua from Life Technologies, lipopolysaccharide (LPS) E. coli K12 from Invivogen and 
Hyclone fetal calf serum (FCS) from Thermo Scientific.
Experimental design
To investigate the effect of the liposome composition on liposome size, zeta potential and 
liposome-induced DC maturation, a linear mixture model was selected with MODDE 10 (Umetrics) 
software. Boundaries for EPC, DOPE, DOTAP and DC-Chol fractions were set at 0 and 1 (with 1 being 
100% of total lipid content). GILGFVFTL peptide content was set between 10 and 100 µg/mL. A 
D-optimal design was selected, which was composed of 18 runs, including a quadruple center 
point [20]. After the runs were completed, models for liposome zeta potential and DC maturation 
factors CD40, CD80, CD83 and CD86 were created with a partial-least square (PLS) regression. Data 
were log-transformed, if needed, and non-significant factors were removed from the model until R2 
(model fit) and Q2 (model prediction power) were optimal.
Liposome formulation
Lipids were admixed (ratios according to the experimental design) to a total amount of 7.5 µmol in 10 
ml chloroform. The lipid mixture was transferred to a 50 mL round bottom flask, and the chloroform 
was evaporated under reduced pressure at 40°C with a rotary evaporator (Buchi Rotavapor R-3). 
The obtained lipid film was subsequently rehydrated for 2 hours, room temperature at 250 rpm 
with a shaker (Edmund Bühler Swip KS-10) after addition of GILGFVFTL  peptide (concentrations 
according to experimental design) dissolved in 1.5 mL buffer (10 mM HEPES, 100 mM NaCl, pH 
7.4). After rehydration, crude liposomes were extruded five times through a 0.2-µm Nucleopore 
Track-Etch membrane (Whatman) with a 10-mL Lipex extruder (Northern Lipids Inc.). Each liposome 
formulation from the experimental design was made in duplicate.
Characterization of liposomes
Liposome size and polydispersity index (PDI) were determined by dynamic light scattering (DLS) 
using a Nanosizer ZS (Malvern Instruments). The zeta potential of the liposomes was determined 
after a 5 fold dilution in MilliQ water by laser Doppler velocimetry using a Nanosizer ZS with a 
universal dip cell (Malvern Instruments).
materialS and methodS
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Maturation of human dendritic cells
Human CD14+ monocytes were isolated from fresh donor blood as described previously [21]. 
Monocytes were plated at a concentration of 0.4*106 cells/mL in 24-wells plates in IMDM medium 
containing 1% FCS, 500 U/mL GM-CSF and 800 U/mL IL-4. Monocytes were differentiated to 
immature dendritic cells (iDCs) after 6 days. iDCs were subsequently stimulated with either medium, 
LPS or liposomes in duplicate. After 24 hours incubation, cells were transferred to a 96-wells plate 
and washed twice with FACS buffer (PBS, pH 7.2, 0.5% BSA, 0.5 mM EDTA). DCs were stained with 
anti-human CD40, CD80, CD83, CD86 and live/dead staining for 30 minutes, and subsequently 
washed twice with FACS buffer. Samples were measured on a FACS Canto II flow cytometer (BD). 
Data were analyzed by using FlowJo 10 software for Mac OSX (Tree Star Inc.). Surface markers are 




A linear mixture model was selected to screen the effects of the lipids EPC, DOPE, DC-Chol and 
DOTAP on the size distribution and zeta potential of the liposomes and their ability to induce DC 
maturation. A D-optimal design was chosen, which generated a worksheet with 18 formulations 
(Table 1). Physical characteristics of the liposomes, i.e., size, PDI and zeta potential, were determined. 
Formulations N1, N2 and N8, which all contained DOPE as the only lipid, did not yield liposomes 
and were excluded from further experiments. Liposome sizes ranged from 150 to 194 nm, with an 
average of 170 nm (Figure 2A) and a low PDI (< 0.2), indicating that the liposomes were relatively 
monodisperse. As expected, the zeta potential of the liposomes containing a cationic lipid (DOTAP 
and/or DC-Chol) was positive, whereas formulations lacking a cationic lipid (N6, N11) showed a zeta 
potential close to zero (Figure 2B).
Based on the experimental results, PLS regression models were fitted for both liposome size and 
zeta potential data using MODDE software. These regression models allowed the identification 
and qualification of input parameters (being peptide, DOPE, DC-Chol, DOTAP and EPC) which 
significantly contributed to the output parameters (size and zeta potential). The model regression 
coefficients reflect the influence of the particular input parameter on the response of the output 
parameter. Valid models were obtained for both output parameters (Figure 3). Liposome size 
was influenced the most by EPC (Figure 3A), which increased liposome size when present in high 
amounts. Model validity for the zeta potential model was low (a value >0.25 indicates a good model 
fit), which is likely a model artifact caused by the high reproducibility [20]. DOTAP and EPC were 
the most significant model terms, with DOTAP increasing the zeta potential, and EPC decreasing it 
(Figure 3B). The incorporation of the peptide antigen had no influence on both liposome size and 
zeta potential, and was thus removed as a model term. 
Response contour surface plots were generated for both liposome size and zeta potential after the 
fitting of the regression models (Figure 4). These surface plots visualize the predicted value of a 
response factor according to the corresponding lipid composition at that specific position in the 
plot (due to the two-dimensional nature of these plots and the multi-dimensional nature of the 
regression models, one input parameter is kept constant).As expected, both cationic lipids (DOTAP 
and DC-Chol) increased to zeta potential of the liposomes, whereas the zwitterionic lipids (EPC and 
DOPE) decreased it.
reSultS
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Formulation Peptide (µg/mL) DOPE DC-Chol DOTAP EPC
N1 10 1 0 0 0
N2 10 1 0 0 0
N3 10 0 1 0 0
N4 10 0 0 1 0
N5 10 0 0 1 0
N6 10 0 0 0 1
N7 10 0 0.333333 0.333333 0.333333
N8 100 1 0 0 0
N9 100 0 1 0 0
N10 100 0 0 1 0
N11 100 0 0 0 1
N12 100 0.333333 0 0.333333 0.333333
N13 100 0.333333 0.333333 0 0.333333
N14 100 0.333333 0.333333 0.333333 0
N15 55 0.25 0.25 0.25 0.25
N16 55 0.25 0.25 0.25 0.25
N17 55 0.25 0.25 0.25 0.25
N18 55 0.25 0.25 0.25 0.25

















































































Figure 2. Liposome characteristics. (A) Size and polydispersity index (PDI) of liposomes were determined by 
dynamic light scattering. (B) The zeta potential of the liposomes was determined by laser Doppler velocimetry. 
Data represent mean ± upper/lower values (n = 2).
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DC maturation by liposomes
The effect of the liposomal lipid composition on DC maturation was evaluated by measuring four 
DC maturation markers (CD40, CD80, CD83 and CD86) on maturated DCs 24 hours after stimulation 
with the liposome formulations from the experimental design. The formulations were tested in 
duplicate on immature DCs isolated from two different donors (donors 1 and 2). LPS was taken as a 
positive control and reference sample in both experiments. The expression of CD40, CD80, CD83 and 
CD86 by DCs (derived from donor 1) after stimulation with the liposomes is presented in Figure 5. 
Datasets from both experiments were fitted with PLS regression models per individual maturation 
marker, and the resulting models and their coefficients are summarized in Figure 6 (maturation 
experiment on DCs derived from donor 1) and Figure S1 (maturation experiment on DCs derived 
from donor 2). While the resulting models differed between experiments (most likely due to donor 
variability), the models showed similar trends. Since this study concerned a proof-of-principle, 

















































Figure 3. Regression models for liposome size (A) and zeta potential (B). On the left summaries of fit for the 
models are displayed. Model fit (R2, >0.5 indicates a good model fit to the data), prediction power (Q2, > 0.5 
indicates sufficient prediction power), model validity (>0.25 indicates that the model error is smaller than the 
experimental error) and reproducibility (>0.5 indicates a small experimental error) are shown. On the right, 
normalized model regression coefficients are displayed. Coefficients with a 95% confidence interval that does 
not cross zero are significant terms.
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overall fit of the models from donor 1 were better than those of donor 2.
For both CD40 and CD80 responses models were yielded with a high model fit, validity and 
reproducibility. Formulation N14 was statistically found to be an outlier, and was subsequently 
removed from all models. For both CD40 and CD80, the DOTAP lipid was found to be the most 
significant model term, indicating that the presence of DOTAP in the liposomes induces CD40 and 
CD80 expression by DCs. The model for CD83 had a relatively low model validity, which again might 
be a model artifact caused by the high reproducibility. The two cationic lipids, DC-Chol and DOTAP, 
were the most significant model terms for CD83. The model for CD86 was valid, but suffered overall 












































































Figure 4. Response contour plots for liposome size and charge. Lipid amounts are displayed as a fraction of 100% 
total lipid. The fraction of the least influential lipid was set at a constant fraction of 0.25. The values in the boxes 
and associated color regions represent the predicted response (either size (nm) or zeta potential (mV)) for that 
particular lipid composition.


















Figure 5. Dendritic cell maturation marker expression after stimulation with either medium or liposomes. 
Maturation markers are expressed as % mean fluorescent intensity (MFI) relative to that induced by LPS (MFILPS). 
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coefficients, which all have a non-significant contribution to the CD86 response, indicating that 
no single lipid had a great effect.  Similar to the models for liposome size and zeta potential, the 
peptide content was a non-significant model term in all the models for the maturation markers. The 
response contour surface plots of all four maturation markers are displayed in Figure 7. From these 
figures it can be clearly seen that in general, a high fraction of DOTAP and to a lesser extent DC-Chol, 
has a positive effect on the expression of all maturation markers. Furthermore, the inclusion of 
DOPE generally had a negative effect on the maturation. The lipid EPC was non-influential for most 
responses, and is therefore still suited as a helper lipid to produce stable liposomes.
Prediction power of obtained models
As described previously, valid prediction models were obtained for liposomal size, zeta potential 
and all four DC maturation markers. The prediction power of the models was tested by selecting 
a liposomal formulation that was not yet included in the D-optimal design. For proof-of-principle 
purposes, an initial target response factor was set for the liposome formulation. In this case, a target 
liposomal zeta potential was set. Since most formulations in the experimental design showed a 
zeta potential of either above 60 mV or 0 mV, a target zeta potential of 30 mV was chosen. The 
zeta potential prediction model subsequently gave a lipid composition (Table 2) which should 
yield liposomes with a zeta potential of 30 mV. The liposome formulation (N19) was made, and size 
and zeta potential were determined (Table 3), which indeed correlated with the predicted values. 
Subsequently, the selected lipid composition could now be used as an input for the previously 
acquired prediction models for liposomal adjuvanticity.
Next, liposome formulation N19 was added to immature DCs, and DC maturation markers were 
determined. The experimentally acquired data were similar to the predicted means (Table 3), 
indicating that the predictions made by the models were accurate.
Figure 6 (left). Regression models for dendritic cell maturation markers CD40 (A), CD80 (B), CD83 (C) and CD86 
(D). On the left summaries of fit for all models are displayed. Model fit (R2, >0.5 indicates a good model fit to the 
data), prediction power (Q2, > 0.5 indicates sufficient prediction power), model validity (>0.25 indicates that 
the model error is smaller than the experimental error) and reproducibility (>0.5 indicates a small experimental 
error) are shown.  The normalized model regression coefficients are displayed on the right. Coefficients with a 
95% confidence interval that does not cross zero are significant terms.
Formulation Peptide (µg/mL) DOPE DC-Chol DOTAP EPC
N19 13.4 0.03 0.07 0.13 0.77



































































































































































Figure 7. Response contour plots for DC maturation markers induced by liposomes. Lipid amounts are displayed 
as a fraction of 100% total lipid. The fraction of the least influential lipid was set at a constant fraction of 0.25. The 
values in the boxes and associated color regions represent the predicted response (either CD40, CD80, CD83 or 
CD86, all in % of LPS-induced expression) for that particular lipid composition.
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Predicted mean Lower Upper Measured
Size (nm) 188.5 183.3 193.7 181.1 ± 8.7
PDI n.a.a n.a. n.a. 0.12 ± 0.01
Zeta potential (mV) 30.0 17.1 39.5 30.3 ± 6.2
CD40 (%  MFILPS) 52.3 40.1 64.5 46.2 ± 16.8
CD80 (% MFILPS) 32.9 30.9 34.7 31.1 ± 3.9
CD83 (% MFILPS) 13.1 9.6 17.7 13.0 ± 4.0 
CD86 (% MFILPS) 24.8 19.7 29.8 26.1 ± 6.8
Table 3. Assessment of the validity of the prediction models. The liposome size, zeta potential and liposome-
induced maturation markers were predicted by the acquired models for formulation N19. Predictions are 
expressed as mean ± 95% confidence intervals. Measured values are given as mean ± upper/lower values (n = 2).
a Not applicable; no valid prediction model for PDI was generated in this study.
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From a historical perspective, most researchers are inclined to vary one factor at a time (OFAT) when 
systematically screening or optimizing a certain system or formulation. Such OFAT approaches 
however are ineffective, since the number of experiments increases exponentially when a variable 
is added to the design. Another drawback of OFAT is that important interactions between the 
parameters can be missed. Utilizing a DoE approach instead solves some of these OFAT-associated 
constraints, by decreasing the number of experiments needed to screen multiple variables, and 
to visualize interactions with the aid of statistical models. Furthermore, prediction models can be 
generated from the existing data, which can predict inter- or extrapolated variables that have not 
been tested yet.
In the current study, a DoE approach was used to investigate a five-component (one antigen and 
four lipids) liposomal system with respect to physicochemical properties and biological activity: 
size, zeta potential and liposome-induced DC maturation. While DoE approaches are increasingly 
used for the formulation and process development of pharmaceuticals [4], they have been rarely 
used in studies involving liposomes. Two previous studies investigated the role of different liposome 
formulation processes on the encapsulation efficiency of either a poorly soluble drug molecule [19], 
itraconazole, or a small peptide [22]. These studies proved that the DoE approach is applicable for 
the development and optimization of liposomal formulations. In this current study, it was found that 
the liposomal lipid composition affected liposomal characteristics such as size, zeta potential and 
liposome-induced DC maturation. The inclusion of a peptide antigen, however, was not of influence 
on any of these factors.
It is clear from our results that the liposomal lipid composition influenced the expression of DC 
maturation markers. However, not much is yet known on the individual effects of these lipids on 
expression of CD40, CD80, CD83 or CD86. Vangasseri et al. previously demonstrated that liposomes 
containing DOTAP effectively induced CD80 and CD86 expression by DC2.4 cells [16]. When the 
cationic head group of DOTAP was replaced by anionic or neutral head groups, the liposomes lost 
their ability to induce DC maturation. Similarly, replacement of the unsaturated fatty acid chain of 
DOTAP with saturated analogues was detrimental to the maturation response. Addition of counter 
ions to the cationic liposomes also did not affect their ability to induce DC maturation. Another 
study showed similar results with DOTAP:DOPC liposomes; a higher molar ratio of DOTAP correlated 
with increased CD83 and CD86 expression by human monocyte-derived DCs [23]. From these 
results, it was hypothesized that not only the zeta potential of the liposomes, but also the chemical 
composition of the lipids influenced the immunostimulatory properties of liposomes. 
Our results confirm that liposomes containing cationic lipids, particularly DOTAP, were able to induce 
DC maturation. Contrarily to the expression of CD80, CD86 and CD40, the CD86 marker expression 
was more sensitive to DC-Chol than to DOTAP. It has been previously reported that DC-Chol 
liposomes also have an immunostimulatory effect on DCs [15]. The difference in expression of the 
diSCuSSion
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maturation markers with these two cationic lipids might be related to the chemical and structural 
differences between the lipids, as mentioned earlier. Further studies are needed to elucidate the 
underlying mechanisms for these differences, in order to support the rational design of optimal 
cationic liposomes for the induction of DC maturation and subsequent immune responses.
The maturation experiments in the current study were performed on immature DCs derived from 
human blood monocytes isolated from donors. This introduces a donor variety into the DC studies, 
which can have a large effect on the prediction models. Indeed, the obtained prediction models 
from experiments using two differed iDC donor sources showed some differences due to biological 
donor variety. To eliminate this biological variability from the models, future investigations could be 
performed on immortalized DC cell lines. Human-derived DC cell lines such as MUTZ-3 have been 
used to screen vaccine immunogenicity, and showed consistent maturation responses opposed to 
monocyte-derived DCs from fresh blood, which showed a large donor variability [24]. Using such 
cell lines would probably yield prediction models that can be used continually on the same cell line, 
which is a huge advantage for the reproduction of the experiments. When combined, the current 
DoE approach and established DC cell lines could form an effective platform to rapidly screen 
liposomal (and other) vaccine formulations without the use of animal studies [12].
Aside from the liposome-induced DC maturation responses, the effects of lipid composition on 
liposome size and zeta potential were investigated and modeled. While the size of the liposomes is 
mostly dictated by the formulation method (e.g., extrusion and sonication), the lipid composition 
does influence the size to some extent. This may be accredited to differences in lipid tail length, 
molecular shape and membrane fluidity, but also the incorporation of charged lipids. Nonetheless, 
the size variations observed in this study were small, and therefore most likely did not influence 
size-dependent mechanisms, such as uptake by DCs [25].The zeta potential of the liposomes was 
influenced by the lipid composition. The cationic lipids DC-Chol and DOTAP both increased the zeta 
potential of the liposomes, while EPC had a neutralizing effect on the zeta potential. The acquired 
model for zeta potential could accurately predict a suitable lipid composition of a liposome with a 
zeta potential of 30 mV. The ability to predict the zeta potential of a liposome according to its lipid 
composition could be a powerful tool, since the zeta potential of liposomes affects several factors 
[26], such as their colloidal stability (electrostatic repulsion), encapsulation efficiency of a drug or 
antigen (electrostatic attraction) and depot formation at the injection site.
In conclusion, this study shows the usefulness of a DoE approach to investigate the influence of 
the lipid composition and antigen content of liposomes on their physicochemical characteristics 
(size and zeta potential) and biological effect (maturation of DCs). The obtained models were able 
to accurately predict liposome size, zeta potential, and relative levels of liposome-induced DC 
maturation factors CD40, CD80, CD83 and CD86. This approach could be a valuable method for the 
development of liposome-based vaccine adjuvants.
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Figure S1 (right). Regression models for dendritic cell maturation markers CD40 (A), CD80 (B), CD83 (C) and CD86 
(D) of the second maturation experiment. On the left summaries of fit for all models are displayed. Model fit (R2, 
>0.5 indicates a good model fit to the data), prediction power (Q2, > 0.5 indicates sufficient prediction power), 
model validity (>0.25 indicates that the model error is smaller than the experimental error) and reproducibility 
(>0.5 indicates a small experimental error) are shown.  The normalized model regression coefficients are 
displayed on the right. Coefficients with a 95% confidence interval that does not cross zero are significant terms. 
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Development of cross-protective influenza 




Seasonal influenza vaccines provide protection against matching influenza A virus (IAV) strains 
mainly through the induction of neutralizing serum IgG antibodies. However, these antibodies 
fail to confer a protective effect against mismatched IAV. This lack of efficacy against heterologous 
influenza strains has spurred the vaccine development community to look for other influenza 
vaccine concepts, which have the ability to elicit cross-protective immune responses.
One of the concepts that is currently been worked on are influenza vaccines inducing influenza-
specific T cell responses. T cells are able to lyse infected host cells, thereby clearing the virus. More 
interestingly, these T cells can recognize highly conserved epitopes of internal influenza proteins, 
making cellular responses less vulnerable to antigenic variability. T cells are therefore cross-reactive 
against many influenza strains, and thus are a promising concept for future influenza vaccines. 
Despite their potential, there are currently no T cell based IAV vaccines on the market. Selection of 
the proper antigen, appropriate vaccine formulation and evaluation of the efficacy of T cell vaccines 
remains challenging, both in preclinical and clinical settings.
In this review, we will discuss the current developments in influenza T cell vaccines, focusing on 
existing protein-based and novel peptide-based vaccine formulations. Furthermore, we will discuss 
the feasibility of influenza T cell vaccines and their possible use in the future.
abStraCt
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introduCtion
Several million people worldwide are infected with influenza viruses annually, which can result in 
hospitalization and even death from complications in severe cases. Vaccination is the preferred 
method to prevent influenza virus infections. Two types of influenza, influenza A and B, currently 
circulate among the human population. The influenza A virus (IAV) however can be further divided 
in several subtypes and strains. The surface antigens of IAV, hemagglutinin (HA) and neuraminidase 
(NA), frequently alter due to antigenic drift and sometimes alter due to antigenic shifts. Seasonal 
influenza vaccines need to be updated accordingly to match the circulating IAV strains. While 
seasonal influenza vaccines are effective against their matched IAV strains, they are unable to cross-
react with unmatched strains. The lack of cross-reactivity of vaccine-elicited immune responses, 
mainly antibodies, is a major limitation of current influenza vaccines.
Several novel concepts for the development of cross-reactive IAV vaccines have been pursued 
in recent years. One concept is a vaccine that induces mucosal IgA responses, which can induce 
strong cross-protective antibody responses against closely related IAV strains (Figure 1). However, 
the cross-reactivity of these IgA responses with respect to more divergent strains is modest [1]. 
Alternatively, vaccines that induce (IgG) antibody responses against conserved antigens, such as 
HA stalk-reactive- or M2e-specific antibodies, might be promising [2, 3]. Studies however indicate 
that these approaches mostly lead to cross-reactive responses within the same phylogenetic 
group of IAV, such as H5N1 and H1N1 [4], with some exceptions [5, 6]. Finally, vaccines inducing 
influenza-specific T cell responses can offer broad and long-lasting immune responses. Since T cells 
recognize epitopes that are mostly derived from viral proteins located in the nucleocapsid, which are 
conserved between IAV strains, T cell responses can be effective against a broad range of influenza 
strains. This averts the necessity of seasonally changing the influenza vaccine composition, and thus 
could be a significant improvement over the current influenza vaccines. A drawback of a purely 
T cell-inducing vaccine for the prevention of seasonal influenza could be that, unlike IgA antibodies, 
T cell responses cannot prevent infection but prevent (severe) disease. For the application as a 
universal vaccine, currently T cell responses are thought to have the highest potential to induce 
such broad heterosubtypic responses that can react to any IAV subtype.
Natural IAV infections induce, next to antibody responses, T cell responses that are potentially 
cross-reactive. Indeed, it is assumed that memory T cell established by previous IAV infections 
prevent subsequent IAV infection in some instances; most individuals experience severe 
IAV-induced symptoms only a few times in their life. However, there are indications that the CTL 
activity of T cell recall responses wanes over times in humans, suggesting that T cell responses 
established by IAV infections can only protect for a few years [7]. Additionally, the number of 
available influenza-specific memory T cells should be large enough to be able to rapidly respond 
to IAV infection without excess additional expansion of the T cell pool [8]. Furthermore, it is known 
that regulatory T cells suppress T cell responses during IAV infections, which can have a negative 
effect on the subsequent formation of a memory T cell pool [9]. Natural IAV infections therefore 
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do not mount a T cell response potent enough to provide long-lasting protection against all 
heterologous IAV strains. T cell-inducing influenza vaccines might overcome this shortcoming by 
establishing long-lasting, cross-reactive T cell responses. In this review, we will focus on the latest 
developments in T cell-inducing influenza vaccine research. The selection of antigen, formulation 
























Figure 1. Reactogenicity of immune responses against influenza strains. Influenza A strains are displayed in 
their respective phylogenetic groups. HA-specific IgG responses (orange) react only with homologous influenza 
strains. Mucosal IgA responses (red) can provide heterosubtypic reactivity against related influenza strains. Stalk- 
or M2e-specific antibodies (blue) are cross-reactive within either group 1 or group 2 influenza strains. T cells 
react universally against all influenza strains, regardless of subtype or group.
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CD8+ T cells
Primed CD8+ T cells, otherwise known as cytotoxic T cells (CTLs), are able to lyse influenza-infected 
cells. Via the endogenous antigen presentation pathway, infected cells will present influenza-derived 
epitopes on their cell surface, which are recognized by influenza-specific CTLs. The CTLs then induce 
apoptosis of the target cell either through the secretion of perforins and granzymes, or through the 
Fas ligand pathway. Furthermore, CTLs produce proinflammatory cytokines such as TNF-α and IFN-γ 
that exert antiviral activity, which further aids viral clearance [10, 11].
Several recent studies have elucidated the importance of CD8+ T cells during IAV infections in 
humans. Sridhar et al. showed that individuals that possessed a higher frequency of CD8+IFN-γ+IL-2- 
T cells experienced a decreased clinical illness during infection with pandemic 2009 H1N1 IAV [12]. 
CD8+IFN-γ+IL-2- T cells  were correlated with a decreased risk of fever, an absence of viral shedding 
and reduced influenza-like illness (ILI) symptoms. These cells also expressed the lung-homing marker 
CCR5, which might explain their effectivity. CD8+ T cells induced by seasonal IAV strains were shown 
to be cross-reactive with several influenza A strains such as 2009 H1N1, swine-origin H3N2 and the 
recently emerged H7N9 IAV [13-15]. Indeed, when cellular responses were studied in individuals 
infected with pandemic 2009 H1N1 IAV, rapid recall responses of CD8+ T cells were observed, 
which peaked within 1 week after infection [16]. These responses were thought to originate from 
lymphoid memory CD8+ T cells established from prior seasonal IAV infections. Memory T cells 
were demonstrated to last for at least several years in a study which assessed IAV-specific T cell 
responses in PBMC’s of individuals collected from 1999 to 2012 [17]. PBMC’s from several donors 
were stimulated with Resvir-9 (a H3N2 reassortant strain), and IAV-specificity and CTL activity was 
subsequently determined by intracellular staining with several labeled, highly conserved CTL 
peptides and IFN-γ.
Taken together, these studies indicate that CD8+ T cells can play a role in the protection against IAV 
infections, that these T cells are long-lived and are able to cross-react with multiple IAV strains. Thus, 
the induction of these T cells may be the basis of broadly reactive universal influenza vaccines.
CD4+ T cells
CD4+ T cells also play an important role in IAV infections, but contrarily to CD8+ T cells, have not been 
studied extensively yet in humans. In animal models, activated CD4+ T cells can exert different roles 
in relation to IAV infections. CD4+ T cells can act as T helper cells (Th), providing costimulatory signals 
by CD40/CD40L signaling to antigen presenting cells (APCs) during the priming of B cells and CD8+ 
T cells [18, 19]. Interestingly, reactivation of adoptively transferred CD4+ Th (from IAV challenged 
mice) increased the recall capacity of both memory CD4+ and CD8+ T cell responses in receptive 
mice after IAV infection [20]. While CD4+ Th is not necessarily required for the induction of effector 
CTLs, it is crucial for the transition of CD8+ T cells to the memory phase, which is essential for the 
maintenance of long-lived immunity [21, 22]. Surprisingly, CD4+ T cells can also acquire cytotoxic 
role of t CellS in influenza
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activity through the release of perforin in mice, providing direct protection against IAV infection 
[23].
In humans, it was found that preexisting CD4+ T cells were reactive to pandemic 2009 H1N1 
peptides, and were correlated with lower virus shedding and reduced illness during IAV infection 
[24]. Unexpectedly, CD8+ T cell responses were not associated with reduced illness in this study. 
Nonetheless, it can be concluded that preclinical and clinical studies indicate that targeted induction 
of CD4+ T cell responses, next to CD8
+ T cell responses, may be an attractive goal for novel vaccines.
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t Cell-induCing influenza vaCCineS
Immune responses and in particular the antibodies elicited by current seasonal influenza 
vaccinesare limited in their effectiveness against heterologous IAV infections. From the current 
knowledge on T cell responses during IAV infections in preclinical and clinical studies, as described 
above, it is believed that T cell-inducing influenza vaccines have the potential to result in broadly 
reactive, universal influenza A vaccines. While most vaccines are still in preclinical development, a 
few concepts have recently entered the clinical phase. In Table 1 the most recent developments in 
T cell-inducing vaccines are listed.
Recently, the potency of viral vector-based influenza vaccines has been reviewed [47]. In the 
following paragraphs, several other potential T cell-inducing influenza vaccines are highlighted.
Live attenuated influenza vaccines
Live attenuated influenza vaccines (LAIV) are currently on the market as intranasal (i.n.) IAV vaccines. 
LAIV induces next to humoral responses both CD4+ and CD8+ T cells in children [25, 26]. Remarkably, 
no cellular immune responses are detected in adults receiving LAIV; the cause of this discrepancy 
might be related to the naïve status of children. Furthermore, LAIV is more effective than current 
seasonal trivalent inactivated influenza vaccines (TIV) in children but not in adults, suggesting that 
the induction of cellular immune responses increases the efficacy of LAIV [48]. The encapsulation of 
LAIV in a biopolymer of alginate and subsequent subcutaneous (s.c.) administration induced CD8+ 
T cell responses that protected mice from a heterologous IAV challenge [49], indicating that LAIV can 
induce T cell responses via immunization routes other than i.n. by use of formulation strategies. The 
induction of cellular responses by LAIV might be explained by the “live” state of the vaccine antigen; 
it can still infect after vaccination. During the viral replication, many viral proteins containing CD8+ 
and CD4+ epitopes are produced within the infected host cell, leading to efficient antigen processing 
via the endogenous pathway, which leads to MHC-I presentation and subsequent T cell activation.
Whole inactivated influenza virus
Like LAIV, whole inactivated influenza virus (WIV) contains internal proteins such as nucleoprotein 
(NP), matrix proteins 1 and 2 (M1 and M2 respectively), polymerase basic proteins 1 and 2 (PB1 
and PB2 respectively) and polymerase acidic protein (PA), which possess conserved T cell epitopes. 
WIV vaccines were replaced by subunit and split vaccines due to incidence of adverse effects 
associated with WIV [50], but have been given increased attention the past few years in the search 
for cross-reactive vaccines [51]. Improvements on WIV production and purification methods have 
decreased WIV-associated side effects, making this vaccine acceptable for use again, especially for 
the induction of broadly reactive immune responses. At normal clinical dose, which typically does 
not exceed fifteen micrograms of HA protein, WIV induces adequate neutralizing antibody titers, 
but generally fail to induce any cellular responses regardless of administration route [52]. However, 
studies by Budimir et al. showed that multiple high doses of WIV, such as two times 6 micrograms, 
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membrane fusion activity and the presence of viral ssRNA for the induction of CTLs were established 
[54, 55]. Intramuscular (i.m.) administration of WIV proved to be more effective at inducing CTLs than 
i.n. administration [53]. This was confirmed by Takada et al., who found that intranasal vaccination 
with WIV failed to induce T cell responses [56]. In contrast, one study utilizing gamma-irradiated 
WIV showed that the protective effect of WIV was mainly mediated by T cell responses [28]. It is 
suspected that the method of WIV inactivation can have an effect on its immunogenicity. Aside from 
increased dosage, WIV-induced cellular responses can also be boosted by the addition of adjuvants. 
For instance, a dose of 2.5 micrograms WIV adjuvanted with cationic lipid/DNA complex (CLDC) was 
able to induce influenza-specific CD4+ and CD8+ T cell responses in mice, whereas alum adjuvanted 
WIV only induced high antibody responses [57]. Similar to studies with WIV, the addition of alum to 
virosomes proved to be detrimental to cellular responses in mice [58], since it skewed the Th to a 
Th2-type response.
Virosomes
Virosomal vaccines can also induce influenza-specific CTL responses. The addition of adjuvants 
to virosomes is necessary to induce T cell responses, since unadjuvanted virosomes only induce 
humoral responses. The incorporation of LpxL1, a detoxified lipopolysaccharide, in virosomes 
significantly increased IFN-γ secretion in mice [59]. Madhun et al. showed that addition of 
the saponin-based Matrix-M adjuvant to virosomes significantly increased the production of 
Th1-associated cytokines IL-2 and IFN-γ when administered i.m. to mice [60]. Strikingly, a significant 
induction of multifunctional CD4+ T cells was also observed in a murine model after the addition of 
Matrix-M to the virosomal vaccine. In a similar study, Radosevic et al. screened multiple adjuvants (i.e. 
aluminium phosphate, aluminium hydroxide, MF59 and Matrix-M) in combination with virosomes 
in mice [61]. Unlike the study by Madhun et al., virosomes were readily able to induce CD4+ T cells, 
and addition of any adjuvant, including Matrix-M, did not increase these responses. However, only 
MF59 and Matrix-M adjuvanted virosomal vaccines were able to induce IAV-specific CD8+ T cell 
responses. Furthermore, addition of any aluminium salt-based adjuvants proved to be ineffective 
at eliciting any cellular responses, which was probably due to Th2-skewed immune responses by 
aluminium salts.
The ability to induce cellular immune responses by some marketed influenza vaccines is of great 
value in order to offer limited cross-reactivity against non-matched influenza strains. These vaccine 
formulations can play a role as an intermediate solution until the next generation of cross-protective 
influenza vaccines is developed.
Peptide antigens
Peptides are another type of antigen that can be used in T cell-inducing influenza vaccines. However, 
short peptides that consist of a minimal epitope are generally not immunogenic, and thus require 
additional modification or formulation to be able to induce T cell responses [62]. 
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Several preclinical studies have used minimal epitope peptides as their main antigen to induce 
influenza-specific cellular responses. Short influenza peptides conjugated to phosphatidylserine 
were able to induce CD8+ T cell responses in mice [34]. The conjugation of lipids to peptides opens 
up several possibilities; a PA-derived peptide conjugated to Pam2Cys, a lipid and TLR2 ligand, 
efficiently induced peptide-specific CTL responses in mice [63]. Furthermore, peptides conjugated 
to liposomes were able to minimize morbidity in IAV-infected mice through the induction of 
CD8+ T cells [35, 36]. Remarkably, these peptide-liposome conjugates were able to induce CD8+ 
memory T cells without the contribution of CD4+ T cells. Liposomes act as a delivery system for 
the peptides, which are then internalized more efficiently by APCs than unformulated peptides. 
Direct conjugation of the peptide to a lipid or liposome is however not required. NP366-374 peptide 
encapsulated in liposomes was able to induce potent T cell responses when mixed with anti-CD40 
mAbs, and reduced viral lung titers of influenza-infected mice [64]. 
Aside from liposomes, virosomes have also been used as delivery systems for short peptide antigens. 
These virosomes utilize the membrane fusion activity of HA proteins to deliver the loaded peptide to 
the cytosolic compartment of the APC. An early study showed that virosomes loaded with the H-2Kd 
binding influenza NP147–155 peptide induced CTLs that were able to lyse IAV-infected target cells [65]. 
The addition of the adjuvant CpG-ODN 1826 to influenza M158-66 peptide-loaded virosomes was 
shown to increase peptide-specific CD8+ T cell responses even further [37], which resulted in a faster 
recovery of vaccinated mice after heterologous influenza virus infection.
Long peptide vaccines consisting of multiple epitopes are, opposed to short peptide vaccines, 
already in the clinical testing phase. Flu-v consists of an equimolar mixture of four synthetic 
polypeptides derived from M1, M2 and NP IAV proteins, formulated with the adjuvant Montanide 
[39]. Flu-v induced peptide-specific T cells in healthy subjects; unfortunately, reactivity against 
actual IAV strains were not determined. However, vaccination studies in mice showed that CD8+ 
T cell responses induced by Flu-v did reduce mortality after IAV-infection [66].
Similar to Flu-v, FP-01.1 consists of six polypeptides derived from M1, NP, PB1 and PB2, which were 
conjugated to a fluorocarbon moiety. The vaccine was able to induce CD4+ and CD8+ T cells in 
healthy subjects [38]. Moreover, these T cells were cross-reactive with H1N1 and H3N2 IAV-infected 
target cells. This is the first study that shows a peptide vaccine capable of inducing cross-reactive 
T cells in humans, which is very encouraging for the development of cross-reactive T cell-inducing 
vaccines.
The studies described above suggest that peptide-based approaches are very promising in the 
development of T cell-inducing IAV vaccines. However, an important challenge is the genetic 
variability among the human population in relation to epitope recognition and presentation. CD4+ 
and CD8+ T cells recognize IAV epitopes displayed on MHC molecules, which are called human 
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leukocyte antigen (HLA) molecules in humans. Different HLA polymorphisms occur in the human 
genome, resulting in a host of varying HLA molecules in the human population. Each HLA can only 
bind specific viral epitopes, which means that multiple epitopes of the same antigen need to be in 
a peptide-based vaccine to cover the human population [67]. In silico prediction methods can be 
employed to determine the potential T cell immunogenicity of conserved epitopes across multiple 
IAV strains [68]. Furthermore, several transgenic mouse strains have been bred that express HLA 
molecules, which can be used in preclinical development. Nonetheless, there remains a significant 
challenge for peptide-based vaccines to include enough epitopes to cover each HLA type, which 
would be required for a vaccine to be effective in the entire population.
Other T cell influenza vaccine concepts
Aside from the vaccine strategies described above, several other concepts are currently in clinical 
development (Table 1). Multimeric-001 is a synthetic recombinant protein composed of 9 T cell and 
B cell epitopes derived from HA, NP and M1 influenza proteins [30]. The vaccine in combination 
with the adjuvant Montanide ISA 51VG was able to induce cellular responses in healthy subjects. 
The cellular responses showed limited reactivity to multiple IAV strains. In a follow up study, 
the Multimeric-001 vaccine showed an induction of humoral and cellular responses in elderly 
subjects similar to responses observed in healthy adults [31]. While the results of these studies are 
encouraging, the true effectiveness of the induced cellular responses against homologous and 
heterologous IAV infections has yet to be determined.
Another concept which has advanced to the clinical stage of development is the modified vaccinia 
virus Ankara vectored vaccine MVA-NP+M1 [43]. This vaccine consists of a vaccinia virus Ankara 
expressing the influenza proteins NP and M1. Several clinical trials, including a phase II study, were 
conducted with this vectored vaccine. MVA-NP+M1 was able to expand pre-existing memory CD8+ 
T cells in both healthy adults and elderly, and also increased the IAV-specific CD4+ T cell population 
[44, 45].
T cell-based influenza vaccine concepts in the clinical phase
The protein-based influenza vaccines such as LAIV, WIV and virosomes currently have the advantage 
that they are already licensed and have been widely used. Such vaccines might be excellent 
candidates to prime naïve populations for both cellular and humoral responses.
Peptide-based vaccine concepts have the advantage that they can be easily engineered and 
produced synthetically. However, as mentioned above, selection of the right epitopes remains vital. 
These vaccines also require additional formulation with adjuvants to increase their immunogenicity. 
Nonetheless, several peptide-based vaccines have entered the clinical phase.
Vectored T cell-inducing vaccines are a sophisticated concept. They include both antigen and 
130
CHAPTER 6
adjuvant in a single particle. Since they express whole proteins rather than epitopes, vectored 
vaccines might have a higher coverage amongst different populations compared to peptide-based 
vaccines. A recent study also combined a seasonal influenza vaccine with MVA-NP+M1 to increase 
the breadth of the immune response [69]. Such an approach is a major improvement and might 
be an ideal solution to induce both humoral and cellular immunity with a single vaccine. Other 
concepts, such as peptide-based influenza vaccines, are also eligible to be used simultaneously with 
seasonal influenza vaccines, as demonstrated recently [33]. This is a good step towards a universal 
influenza vaccine.
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vaCCine Priming
The IAV-naïve status and age of persons may influence the immunogenicity of T cell-inducing 
IAV vaccines. This was already observed with LAIV vaccines, which effectively induce cellular 
responses in naïve children, but not induce such responses in adults, who already established an 
immunological memory to IAV [25, 26]. A study in mice reported that CD8+ T cells primed by LAIV 
rapidly differentiated to IAV-specific memory T cells after short-interval boosting, and were able 
to protect against heterologous challenge [70]. Several T cell-inducing vaccine concepts consider 
the potency of the prime-boost approach; a DNA-protein prime-boost concept enhanced the T cell 
responses to IAV in mice [71], and in a clinical trial priming with Multimeric-001 before a seasonal 
influenza vaccine boost greatly increased IAV-specific cellular responses in elderly subjects [31]. 
Priming at an early age in naïve mice with IAV resulted in the induction of long-term memory 
CD8+ T cells with the broadest reactivity, while priming at an older age resulted in a CD8+ T cell 
population with a reduced diversity [72]. Thus, T cell priming at an early age, when the subject is 
still naïve, should be considered before immunization with an influenza vaccine that only induces 





Many T cell-inducing vaccine concepts aim for the induction of systemic IAV-specific T cell 
responses. However, local T cell responses at the site of IAV infection are potentially more effective. 
The presence of IAV-specific resident memory T cells (Trm) in the lungs was correlated with clearance 
of heterologous IAV infection in mice [74]. CD4+ T cells mediated the formation of CD8+ Trm cells, 
adding yet another important function for CD4+ Th [75]. Current knowledge on the establishment 
of Trm cells has been reviewed recently [76]. While the process of Trm induction is not completely 
unraveled, some possible mechanisms can be exploited to induce IAV-specific Trm responses with 
vaccines. A recent study specifically targeted an antigen to resident lung DCs using antibodies, 
and were able to generate IAV-specific CD8+ Trm cells in mice that provided protection against a 
lethal influenza challenge [77]. Furthermore, it is known that CXCR3-expressing CD8+ T cells play an 
important role in the establishment of CD8+ Trm cells in the lungs [78]. The near future may learn us 
whether specific targeting of certain T cell populations, e.g. by adjusting the route of administration 
to the lungs [79, 80], may add to the potential of T cell-inducing influenza vaccines.
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PreCliniCal CorrelateS of ProteCtion
There is clear evidence that cellular responses correlate with a reduction of symptoms after IAV 
infection. However, current correlates of protection (CoP) for influenza vaccines are all based 
on the induction of antibodies, such as the presence of hemagglutination inhibition- or virus 
neutralization titers, which are inadequate CoPs for T cell-inducing vaccines. Instead, responses that 
indicate the presence of effector T cells such as IFN-γ and IL-10 cytokines, combined with cytotoxic 
effector molecules like granzyme B may be more suitable as CoP for T cell-inducing vaccines [81]. 
These parameters also need to be further evaluated in epidemiological studies in order to define 
their efficacy. For instance, it is still unclear what quantitative levels of IAV-specific CD8+ or CD4+ 
T cell responses are required for protection against an IAV challenge.  Furthermore, an adequate 
translation from animal models to the human setting has to be made. While there is quite some 
experience with humoral responses against IAV in animal models and their relation to the clinic, 
such experience has not been established yet for cellular responses. Establishing these responses as 
human CoPs, and translating study findings from animal models to humans remain important tasks 
for the development of T cell-inducing IAV vaccines.
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There are some concerns whether IAV-specific T cells can provide the same level of protection 
compared to IAV-specific antibodies. While T cells have a broader reactivity, they can only recognize 
and lyse IAV-infected host cells. Most likely, an IAV infection is already spreading before an efficient 
T cell response is mounted. It can therefore be debated whether T cells responses actually provide 
protection (i.e. sterilizing immunity) or only shorten the length and severity of influenza symptoms 
(i.e. decreased morbidity). The difference between these two can be very hard to distinguish. 
Therefore, elucidation of T cell responses after influenza infection in humans is of critical importance 
to determine the efficacy of T cell-inducing influenza vaccines. Nonetheless, reduction of morbidity 
of IAV infections would already be a great success in situations where seasonal influenza vaccines 
would be ineffective, such as a mismatched influenza epidemic or an influenza pandemic. The 
definition of protection should therefore not only be limited to sterilizing immunity, but also to 
reduction of disease morbidity.
Another concern is the possibility of excessive T cell responses to IAV infections, which could cause 
immunopathology in the lungs [82]. There are indications that excessive T cell responses mediate 
severe lung inflammation and subsequent lung damage after IAV infection in mice. Only one study 
describes the phenomenon in humans; elevated IAV-specific CD8+ and CD4+ T cell responses were 
found in pandemic 2009 H1N1-infected children with severe pneumonia [83]. It was however 
unclear whether these T cell responses were the cause of pneumonia or simply present due to the 
infection. 
It is yet unknown whether T cell-inducing influenza vaccines can mount long-lasting T cell responses 
after a limited number of immunizations. As already discussed above, natural IAV infections are able 
to induce T cell responses, but their effectivity is limited. Studies suggest that local inflammation and 
inflammatory cytokine production caused by IAV infection suppress  CD8+ T cell responses in mice. 
This was partly attributed to an increased expression of PD-L1 on the CD8+ T cells, which cripples 
the functionality of these T cells [84, 85]. T cell-based vaccines however should not experience 
the effects of these immunosuppressive pathways, since inflammation after immunization is 
generally limited. It is thus likely that these vaccines can induce T cell responses which are more 
potent than those elicited by natural IAV infections. Nonetheless, it is important that T cell-inducing 
vaccines elicit balanced T cell responses, and special interest should be given to T cell-mediated 
immunopathology during safety studies of these vaccines.
Aside from the intensity of T cell responses, special attention should be given to the selection of 
target epitopes derived from IAV. A recent study described the existence of tolerizing epitopes in 
certain influenza strains, which are recognized by autologous regulatory T cells and may suppress 
protective T cell responses [86]. Another study found that T cells against certain immunodominant 
epitopes such as M158-66 have a poor functionality, and are unable to clear IAV-infected cells [87]. It 
was hypothesized that these immunodominant epitopes are actually a decoy of IAV to evade T cell-
ConCernS and limitationS of t Cell-induCing iav vaCCineS
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mediated immunity and to prevent the generation of more potent T cells against other epitopes. It is 
therefore important that such epitopes, which could lead to decreased or impotent T cell responses, 
are identified and excluded in any prospective T cell-inducing IAV vaccines.
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Humoral immune responses elicited by current IAV vaccines do not provide sufficient cross-
protection against non-matched IAV infections. IAV-specific T cells recognize conserved epitopes 
of IAV and thus have to potential to be cross protective. Many different T cell-inducing vaccines 
are currently under development, and some have even reached clinical phases. Selecting suitable 
preclinical testing models and clinical CoPs are vital for further development of such vaccines. 
In addition, proper understanding the effectiveness of each T cell response and their possible 
pathological effects is of great importance. The current developments with T cell-inducing IAV 
vaccines, including novel formulations and extended immunological insight, are fast evolving and 
may ultimately result in universal influenza vaccines.
ConCluSion
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The potential of Bioneedles to deliver influenza vaccines was investigated. Four influenza vaccine 
formulations were screened to determine the optimal formulation for use with Bioneedles. The 
stability of the formulations after freeze-drying was checked to predict the stability of the influenza 
vaccines in the Bioneedles. Subunit, split, virosomal and whole inactivated influenza (WIV) vaccine 
were formulated and lyophilized in Bioneedles, and subsequently administered to C57BL/6 mice. 
Humoral and cellular immune responses were assessed after vaccination. The thermostability of 
lyophilized vaccines was determined after one-month storage at elevated temperatures. Bioneedle 
influenza vaccines induced HI titers that are comparable to those induced by intramuscular WIV 
vaccination. Delivery by Bioneedles did not alter the type of immune response induced by the 
influenza vaccines. Stability studies showed that lyophilized influenza vaccines have superior 
thermostability compared to conventional liquid vaccines, and remained stable after one-month 
storage at 60°C. Influenza vaccines delivered by Bioneedles are a viable alternative to conventional 
liquid influenza vaccines. WIV was determined to be the most potent vaccine formulation for 
administration by Bioneedles. Lyophilized influenza vaccines in Bioneedles are independent of a 




The conventional method of influenza vaccine delivery is intramuscular injection of liquid 
formulations using syringes and needles. The use of needles may cause fear and stress in children 
and adults [1]. Needle stick injuries and reuse of needles and syringes are additional risks associated 
with conventional injections. To overcome these problems, extensive research is being carried out 
on alternative delivery methods and delivery routes for influenza vaccines [2]. Multiple delivery 
routes are currently being studied, including nasal, pulmonary, sublingual, oral and dermal routes. 
These routes usually require different delivery methods than needles; these can be sprays, dry 
powders or microneedles. Alternative delivery methods for the intramuscular and subcutaneous 
routes are limited. Examples in development are liquid jet injections and powder jet injections [3, 4].
Recent outbreaks of influenza A strains, such as the highly pathogenic avian influenza A H5N1 
[5], the 2009 pandemic influenza A H1N1 and more recently avian influenza A H7N9 [6, 7], have 
increased the need for more effective vaccines. Novel influenza vaccines are required to be quickly 
available for mass vaccination in case of epidemics. Current influenza vaccines have limited stability, 
and thus require a cold-chain. This makes distribution and storage of these vaccines expensive and 
challenging, specifically in developing countries due to the limited cold-chain infrastructure.
There are four types of marketed non-adjuvanted inactivated influenza vaccines: whole inactivated 
virus, virosomal, split and subunit vaccine. These vaccines differ in terms of viral components 
and particulate organization [8]. Subunit and virosomal vaccines contain only the influenza 
hemagglutinin (HA) and neuraminidase (NA) surface antigens, while WIV and split vaccines also 
contain internal viral components such as internal proteins and, in case of WIV, viral RNA. WIV and 
virosomes maintain a viral particulate organization of approximately 150 nm, whereas subunit and 
split vaccines consist of a less organized mixture of components. These differences in characteristics 
have effects on vaccine immunogenicity and efficacy of the different influenza vaccines, which is 
important for the development of novel influenza vaccine formulations and delivery methods.
Another potential alternative delivery system for influenza vaccines are Bioneedles [9]. Bioneedles 
are small hollow implants made from thermoplastic starch (Figure 1). They are loaded with an antigen 
by filling the inner compartment (volume of 5 µl) with a liquid vaccine formulation followed by 
subsequent lyophilization. Vaccination with antigen-filled Bioneedles is performed by intramuscular 
or subcutaneous implantation under high velocity using compressed air [9]. After implantation, the 
Bioneedle dissolves, resulting in the release of the antigen. A phase I clinical study showed that 
empty Bioneedles are well tolerated by healthy volunteers during and after administration [10]. 
No local toxicity other than tissue damage from Bioneedle injection was observed at the site of 
implantation. Previous studies with tetanus toxoid and hepatitis B vaccines have shown that 
antigens delivered by Bioneedles induce comparable or improved immune responses in mice 
compared to liquid vaccines delivered by conventional injection [11, 12]. Moreover, the lyophilized 
vaccine antigens in these Bioneedles showed improved thermostability. This reduces the need for 
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a cold-chain and allows long-term storage of vaccines. Furthermore, Bioneedles are ideally suited 
for mass vaccinations. Vaccination with Bioneedles is relatively easy, very quick and does not have 
the risk of needle stick injuries. Applicators (currently under development) will be low cost devices 
working on compressed air. Pressurizing the device is done manually, which make it ideal for use 
in developing countries. Furthermore, cost assessments have indicated that Bioneedle applicator 
devices could be supplied free of charge for the use in public health care in developing countries.
In this current study, we compared the immunogenicity of influenza vaccine filled Bioneedles 
with the immunogenicity of conventional liquid influenza vaccines in mice. In order to identify the 
most potent influenza vaccine formulation for inclusion in Bioneedles, we included four types of 
non-adjuvanted influenza vaccine. Furthermore, the thermostability of the lyophilized influenza 
vaccine formulations was evaluated. Finally, vaccine release from Bioneedles was imaged in vivo, in 
order to determine vaccine release kinetics from the Bioneedles at the site of injection.




Preparation of influenza vaccines
Bioneedles (15 mm long and 1 mm wide, internal volume of 5 µl) were obtained from the Bioneedles 
Technologies Group. Influenza A/PR/8/34 whole inactivated virus was produced by Intravacc. The 
process was based on egg virus propagation and  β-propiolactone virus inactivation [13]. Split 
and subunit vaccines were produced by solubilization of WIV with n-octyl-β-D-glucopyranoside 
(Sigma-Aldrich) as described previously [8]. Virosome vaccine was produced as described previously 
[14]. All vaccines were concentrated with Centriprep centrifugal filters (Millipore) with a molecular 
weight cut-off (MWCO) of 10 kDa, and formulated in HBS (20 mM HEPES, 125 mM NaCl, 9 mM CaCl2, 
5 mM MgCl2). Vaccine formulations for Bioneedles contained 2.5% (w/w) D-trehalose dihydrate 
(Sigma-Aldrich) as a stabilizer. Influenza vaccine-containing Bioneedles (subunit, split, virosomal and 
WIV vaccine) were prepared by filling Bioneedles with 5 µL of 1 mg/mL (HA content) liquid vaccines 
from the hollow back of the Bioneedle using specially designed filling apparatus, and frozen on a 
metal plate at minus 50°C [12]. Next, Bioneedles were freeze-dried using a Zirbus Sublimator 3x4x7 
(Zirbus Technology). Lyophilized Bioneedles were stored in glass vials with rubber stoppers under 
ambient air and relative humidity. 
Liquid vaccine characterization
The protein composition and purity of the vaccine formulations was determined by SDS-PAGE. 
Formulations were run under non-reducing conditions on a 12% precast gel (Thermo Scientific), and 
stained with Coomassie Brilliant Blue (Thermo Scientific). Particle size was measured by dynamic 
light scattering (DLS) using a Malvern Nano ZS (Malvern Instruments). The results are given as the 
average particle size diameter and the polydispersity index (PDI). 
Lyophilized vaccine characterization 
Samples for recovery and stability studies were prepared by filling 3 ml glass vials (Müller + Müller) 
with 25 µl vaccine formulated with 2.5% trehalose and subsequently freeze-dried using the 
same drying procedure as the vaccine-filled Bioneedles. Vials were closed with rubber stoppers 
under ambient air and relative humidity. In order to assess the initial recovery, the vaccines were 
reconstituted in 100 µl MilliQ water immediately after lyophilization. In order to determine their 
heat stability, lyophilized and liquid vaccines were stored for 1 month at 4°C, 24°C, 37°C or 60°C; 
lyophilized vaccines were subsequently reconstituted in 100 µl MilliQ water. Recovery data of 
heat-stressed samples were compared to data of unstressed samples acquired immediately after 
lyophilization. Each condition was performed in triplicate, and individual samples were measured 
three times for each method.
Relative moisture content (RMC) was determined by Karl-Fischer titration. In brief, lyophilized 
vaccines were dissolved in Hydronal-Coulomat A solution (Sigma-Aldrich) and titrated using a 




HA structural quantification by RP-HPLC
The HA1 subunit of HA was quantified by RP-HPLC according to the method of Kapteyn et al [15]. In 
short, influenza vaccines were dissolved in 0.15 M Tris-HCl, pH 8.0 and solubilized by incubation with 
1% (w/v) Zwittergent 3-14 (Millipore). Trypsin agarose beads (Sigma-Aldrich) were subsequently 
added in order to cleave HA into HA1 and HA2 subunits. After removal of the beads, samples were 
reduced with 25 mM dithiothreitol (DTT, Sigma-Aldrich) and subsequently alkylated with 50 mM 
iodoacetamide (IAA, Sigma-Aldrich). IAA was neutralized by addition of 25 mM DTT. Prepared 
samples were analyzed on an Agilent 1100C system (Agilent Technologies) using a polystyrene 
POROS R1/10 2.1 mm x 100 mm column (Applied Biosystems) equipped with a 2 µm precolumn 
filter and frit (Upchurch Scientific). The autosampler and column heater were set at 6°C and 60°C 
respectively. Mobile phases used were 0.1% trifluoroacetic acid (TFA), 5% acetonitrile in water 
(solvent A), and 0.1% TFA in acetonitrile (solvent B). The solvent gradient from A to B was 0-32% 
in 2 min, 32-64% in 3.5 min, 64-100% in 1 min and 100% for 1 min, with a flow of 0.8 mL/min. 
HA1 protein was detected by an Agilent 1046A fluorescence detector (Agilent Technologies) with 
excitation and emission wavelengths set at 280 nm and 335 nm respectively. After each sample, the 
system was rinsed with 100 µL of 1% (w/v) Zwittergent 3-14 with a gradient elution of solvent B from 
100% to 0% in 6 min.
HA antigenic quantification by surface plasmon resonance (SPR)
Antigenicity of the influenza formulations was quantified by a SPR method modified from Estmer 
Nilsson et al [16]. Samples were analyzed on a Sensor Chip CM5 with a Biacore T200 biosensor system 
(GE Healthcare). HBS-EP+ (GE Healthcare) was used as analysis buffer. Recombinant HA protein from 
influenza A/PR/8/34 (Protein Sciences) was immobilized to 7000-10000 response units using an 
Amine coupling kit (GE Healthcare) with ~65 µL rHA (10 µg/mL) in 10 mM phosphate buffer, 0.05% 
Surfactant P20 (GE Healthcare), pH 6.0. Dilutions series of the vaccine samples were made, and anti-
influenza A/PR/8/34 sheep serum (1:150, NIBSC) was added to each dilution. The sample-serum 
mixture was subsequently injected during 400 seconds during which sensorgrams were acquired. In 
between each sample the sensor chip surface was regenerated using 50 mM HCl, 0.05% Surfactant 
P20. Acquired sensorgrams were analyzed using Biacore T200 evaluation software (GE Healthcare). 
Antigenicity was calculated relative to a known concentration of rHA A/PR/8/34.
Immunizations
Animal experiments were conducted according to the guidelines provided by the Dutch Animal 
Protection Act, and were approved by the Committee for Animal Experimentation (DEC) of the 
National Institute of Public Health and the Environment (RIVM). For all experiments, 7-week-old 
female C57BL/6 mice (Harlan) were used. Prime and boost immunizations were performed at day 
0 and 21 respectively under isoflurane anesthesia. Animals were sacrificed by bleeding under 
anesthesia at day 28. Mice received 5 µg HA of WIV, split, virosome or subunit influenza in either liquid 
or Bioneedle form; the placebo group received HBS. Liquid formulations (50 µL) were administered 
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subcutaneously (s.c.) in the neck between the ears. Bioneedles were implanted subcutaneously 
in the neck between the ears using a sterilized trocar with mandrin under anesthesia as reported 
previously [12]. To compare the s.c. route with the classical intramuscular (i.m.) route, fluid WIV and 
subunit vaccine were also applied i.m. in the hind-left leg.
Hemagglutination inhibition assay (HI assay)
Hemagglutination-inhibiting titers in mouse sera were determined by an HI assay. Individual 
sera were treated overnight with diluted receptor-destroying enzyme from Vibrio cholerae (1:5, 
Sigma-Aldrich) at 37°C to remove non-specific inhibitors, and were subsequently inactivated at 56°C 
for 30 min. Finally, PBS was added to the sera to obtain a 1:10 dilution. Diluted sera were transferred 
to a 96-wells V-bottom plate (Greiner) and serially diluted two-fold with PBS. Four hemagglutinating 
units of inactivated influenza A/PR/8/34 was subsequently added to each well and incubated for 
20 min at room temperature after mixing. Next, an equal amount of 0.5% (v/v) turkey erythrocyte 
suspension (Harlan) was added to the wells and incubated for 45 min at room temperature. HI titers 
are given as the reciprocal of the highest serum dilution capable of preventing hemagglutination. 
Sera without detectable titers were scored 2, 1/5th of the detection limit.  
Enzyme linked immunosorbent assay (ELISA)
Influenza antigen specific antibody titers were determined by ELISA. Microlon 96-wells flatbottom 
plates (Greiner) were coated overnight with 600 ng of A/PR8/34 subunit HA (as determined by SPR) 
per well at 4°C. After washing twice with 0.05% Tween80, serial two-fold dilutions of individual 
mouse sera in PBS, 0.5% BSA, 0.1% Tween80 were applied on the plate and incubated for 1 hour 
at 37°C. Plates were washed three times and subsequently incubated for 1 hour at 37 °C with 
horseradish peroxidase-conjugated goat antibodies against mouse IgG, IgG1 or IgG2c (1:5000, 
Southern Biotech). Detection of antibodies was performed with 3,3’5,5’-tetramethylbenzine (TMB) 
substrate buffer (0.4 mM TMB in 0.11 M sodium acetate, 0.006% H2O2, pH 5.5) after washing three 
times and incubated for 10 min at room temperature. Enzymatic reaction was stopped by adding 
2 M sulfuric acid, after which the optical density (OD) was measured at a wavelength of 450 nm 
using a Synergy Mx platereader (BioTek). Titers are given as the reciprocal of the serum dilution 
corresponding to OD450=0.1 after background correction.
Enzyme linked immunosorbent spot assay (ELISpot)
Cytokines produced by spleen cells were determined by ELISpot. 96-wells Multiscreen PVDF filter 
plates (Millipore) were activated by incubating with 25 µL 70% ethanol for 2 min, and subsequently 
coated overnight with anti-mouse IFN-γ or IL-4 antibodies (U-Cytech) at 4°C after washing with 
three times PBS. Next, filter plates were washed three times and blocked with 5% Hyclone fetal 
calf serum (FCS, Thermo Scientific) for 1 hour at 37°C. Subsequently, 4*105 isolated spleen cells in 
IMDM, 5% FCS were added to each well with or without 50 ng influenza A/PR/8/34 subunit antigen, 
and incubated overnight at 37°C. After overnight stimulation, filter plates were washed five times 
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and IFN-γ and IL-4 were detected using biotinylated anti-mouse antibodies (U-Cytech) and 100 µL 
BCIP/NBT reagent (Thermo Scientific) per well. Spot were allowed to develop for 15 min after which 
the plates were thoroughly washed with water. Spots were counted using an A.EL.VIS ELISpot reader 
(Aelvis). The number of IFN-γ or IL-4 producing cells in antigen stimulated spleen cells was obtained 
after background correction (subtracting number of spots produced by splenocytes incubated with 
buffer lacking antigen). Subsequently this number was corrected for the number of spots found in 
splenocytes from mice immunized with HBS.
In vivo imaging
WIV vaccine was labeled with infrared dye IRdye 800CW (LI-COR) using the manufacturer’s 
instructions for imaging purposes. Antigenicity of labeled WIV was checked by HA quantification 
by SPR. Hairless, immune-competent 7-week-old female SKH1-Elite mice (Charles Rivers) were 
immunized with IRdye or labeled WIV (5 µg) administered either s.c. or by Bioneedle between the 
ears in the neck. Mice were subsequently scanned several times with an IVIS Spectrum imaging 
system (PerkinElmer) during one week. The excitation wavelength was set at 710 nm and emitted 
light was measured at 760, 780, 800 and 820 nm, after which spectral unmixing was performed 
to distinguish auto-fluorescence from label-specific fluorescence. The fluorescent signal at the site 
of injection was quantified over time. After the experiment, animals were sacrificed by bleeding 
under anesthesia and cervical dislocation. To determine antigenicity of labeled WIV, HI titers were 
determined in sera of sacrificed mice.
Statistics
Statistical comparisons between experimental groups for HI titers were made with a one-way 
ANOVA followed by a Tukey-Kramer test for multiple comparisons. Statistical comparisons between 
experimental groups for IgG titers were made with a one-way or two-way ANOVA test followed 
by Bonferroni correction for multiple comparisons. Probability (p) values ≤ 0.05 were considered 




Liquid influenza vaccine characterization
Non-reducing SDS-PAGE (Figure 2) analysis showed that WIV and split vaccines contained all 
viral proteins including nucleoprotein (NP) and matrix protein 1 (M1). In contrast, virosomal and 
subunit vaccines contained hemagglutinin and, compared to WIV and split, a reduced amount of 
neuraminidase.
The particle sizes of WIV and virosome vaccines were found to be 137 and 131 nm respectively 
and relatively monodisperse (PDI close to 0), as shown in Table 1. Split vaccine had a particle size 
of 520 nm but with a high PDI, indicating a relatively heterodisperse particle size of the antigens. 
Subunit vaccine had a similar high PDI, with a particle size of 103 nm, indicating an organization 
smaller than influenza virus particles.
Lyophilized influenza vaccine characterization
Bioneedles were successfully filled and freeze-dried with influenza vaccines. To establish the 
recovery of the vaccine in terms of HA content after freeze-drying, vaccine formulations lyophilized 
in vials were reconstituted and analyzed for HA1 content by RP-HPLC and for antigenicity by surface 
plasmon resonance (Table 1). HA1 content and antigenicity of liquid vaccines were set as 100% 
recovery and were compared with lyophilized vaccines. The relative standard deviations of these 
methods were in the range of 4-11 % (RP-HPLC) and 1-7 % (SPR), respectively. The recovery of HA1 
content from the lyophilized vaccines ranged from 110% for virosomal vaccine to 137% for WIV 
vaccine. Similarly, antigenic recovery ranged from 95% for split vaccine to 118% for virosomal 
vaccine. These recoveries were not significantly different compared to the starting materials, 
indicating that all vaccine formulations retained their HA1 content and antigenicity after freeze-
drying.
reSultS







Figure 2. Protein composition of the liquid influenza 
vaccines. Formulations were analyzed by non-
reducing SDS-PAGE using a 12% pre-cast gel 
stained with Coomassie Brilliant Blue. From left to 
right: WIV, virosome (VS), split and subunit (SU). 
HA = hemagglutinin (76 kDa); NP = nucleoprotein (60 
kDa); NA = neuraminidase (58 kDa) and M1 = matrix 




Dynamic light scattering showed that the particle size of lyophilized WIV vaccine was 146 nm after 
reconstitution, which is slightly higher compared to the particle size of liquid WIV vaccine. The PDI 
remained low, indicating that the virus particles did not aggregate or disintegrate during or after 
freeze-drying. Virosomal and subunit vaccines both showed an increased particle size and PDI 
compared to the liquid formulations. In contrast, the particle size of split vaccine was decreased 
after lyophilization, while retaining a high PDI, indicating that the vaccine still had a heterodisperse 
particle distribution.
Humoral immune responses 
The immune responses induced by the vaccines delivered with Bioneedles were compared with 
those induced after subcutaneous administration of conventional liquid influenza vaccines. Liquid 
WIV and subunit vaccines were also administered via the intramuscular route in control groups. 
Intramuscular vaccination is the standard route for administration to humans; as a result, the i.m. 
control groups are used as standard for the in vivo evaluation of the influenza Bioneedle vaccine 
concepts.
Serum HI titers were undetectable three weeks after the first immunization (day 21) with virosomal, 
split or subunit vaccine administered either i.m., s.c. or by Bioneedles (data not shown). Only 
influenza WIV vaccine induced low HI titers (2log(HI) = 2 to 7 ) after a single immunization, regardless 
of delivery method.
Vaccine Liquid Lyophilized
Size (nm) PDI Size (nm) PDI HA1 recovery (%) Antigenic recovery (%)
WIV 137 ± 1 0.07 146 ± 3 0.09 137 ± 11 111 ± 1
Virosome 131 ± 2 0.13 151 ± 9 0.24 110 ± 9 118 ± 4
Split 520 ± 14 0.63 150 ± 4 0.43 115 ± 4 95 ± 7
Subunit 103 ± 2 0.41 131 ± 4 0.32 115 ± 11 100 ± 2
Table 1. Characteristics of liquid and lyophilized influenza vaccine formulations. Size and polydispersity index 
(PDI) are shown for liquid formulations and reconstituted lyophilized formulations. Recovery of HA1 and 
antigenicity of lyophilized vaccines are shown as a percentage of vaccines before freeze-drying. Data represent 
mean ± SD (n = 3).



















Figure 3. HI titers one week after the second 
vaccination with liquid or Bioneedle influenza 
vaccines. Data represent geometric mean ± SD (n = 7). 
For groups with mice having an undetectable HI titer, 
the number of responders is indicated above the bars. 
Asterisks indicate titers are significantly (**p < 0.01, 
****p < 0.0001) different from each other.
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Bioneedle-delivered vaccines were directly compared to the s.c. liquid vaccines. The HI titers in sera 
taken one week after the second immunization (day 28) were assessed by an HI assay (Figure 3). The 
HI titers found in mice after vaccination with subunit, split or WIV vaccine delivered by Bioneedles 
did not differ significantly from the HI titers induced by s.c. vaccination with liquid influenza vaccines. 
In contrast, serum HI titers induced by virosomal vaccine delivered by Bioneedles were significantly 
higher than HI titers induced by s.c. administered liquid virosome vaccine. Liquid virosome vaccine 
induced poor HI titers in general, with four out of seven animals being non-responders.
Next, Bioneedle delivered influenza vaccines were compared to intramuscular administered subunit 
vaccine, currently a standard influenza vaccine. Subunit vaccine delivered by Bioneedles induced 
high HI titers compared to HI titers induced by i.m. subunit vaccine. Subunit and virosomal vaccines 
delivered by Bioneedles showed similar HI titers compared to the respective liquid formulations. 
Furthermore, HI titers in mice immunized with split or WIV vaccine delivered by Bioneedles were 
significantly higher compared to those induced by i.m. subunit vaccine. Thus, influenza vaccines 
delivered by Bioneedles elicited equal or superior HI titers after vaccination compared to the 
standard i.m. administered subunit vaccine.
In addition to HI titers, antigen-specific serum IgG titers from one week after the second immunization 
(day 28) were determined (Figure 4). WIV, split and subunit vaccines all elicited equally high IgG titers 
after either i.m. or s.c. immunization, or administration by Bioneedles. In contrast, s.c. administered 
virosomal vaccine induced IgG titers that were significantly lower than those induced by virosomal 
vaccine delivered by Bioneedles, further indicating that Bioneedles have a positive effect on vaccine 
immunogenicity.
Cell-mediated immune responses
In order to investigate whether immunization with the different influenza vaccines induced 
cell-mediated immune responses, the antigen-specific frequencies of both IFN-γ and IL-4 
cytokine-producing splenocytes of immunized mice were assessed (Figure 5).
















Figure 4. Antigen-specific serum IgG titers one 
week after boost vaccinations. Data represent 
mean ± SD (n = 7). Asterisks indicate titers are 
significantly (****p < 0.0001) higher than those of mice 
s.c. immunized with liquid virosome vaccine.
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Overall, both subcutaneous and Bioneedle administration of subunit, split and virosome vaccine 
formulations induced comparable frequencies of IFN-γ producing splenocytes. Bioneedle groups 
however did have less non-responders than subcutaneous groups. In contrast, i.m. liquid WIV and 
WIV vaccine delivered by Bioneedles induced high levels of IFN-γ producing cells compared to the 
other influenza vaccines. The difference between s.c. administered liquid WIV vaccine and Bioneedle 
administered WIV vaccine was not significant. Bioneedle influenza vaccines showed frequencies 
of IL-4 producing splenocytes after vaccination that did not differ significantly from responses 
induced after i.m. administered subunit or WIV vaccines. Subcutaneous delivered liquid subunit, 
split and virosome vaccines however induced frequencies of IL-4 producing cells that did not differ 
significantly compared to their Bioneedle counterparts. Thus, delivery of influenza vaccines by 
Bioneedles did not significantly alter the type of immune response.
To further assess the quality of the cell-mediated immune response, the IgG subtype profile in the 
sera was determined. The ratio between IgG1 and IgG2c, the C57BL/6 analog of IgG2a [17], was 
determined for each individual mouse after immunization (Figure 6). Mice immunized with influenza 
subunit, split or virosomal vaccine all showed a mixed IgG2c/IgG1 ratio regardless of delivery 
method. Thus, in line with the data on the cellular immune response, delivery of influenza vaccines 
by Bioneedles did not alter the type of immune response. Additionally, WIV vaccine, independent 

























































Figure 5. Numbers of IFN-γ (A) and IL-4 (B) cytokine producing splenocytes of immunized mice after ex-vivo 
stimulation with influenza subunit. Data represent mean ± SEM (n = 7). The number of responders, if less than 7, 
is indicated above the bars.


















Figure 6. IgG2c/IgG1 subtype ratios in serum of mice 
one week after boost vaccinations. Data represent 
mean ± SD (n = 7). Asterisk indicate IgG2c/IgG1 ratio 
of WIV groups are significantly (****p < 0.0001) higher 
than ratios of other vaccine formulation groups.
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of delivery method, exhibited an IgG2c/IgG1 ratio that was significantly favoring the IgG2c subtype 
compared to subunit, split or virosomal vaccines.Heat stability of liquid and lyophilized influenza 
vaccines
The heat stability of lyophilized influenza vaccines was determined by storing liquid and lyophilized 
influenza vaccines in glass vials at 4°C, 24°C, 37°C and 60°C for one month. For both liquid and 
lyophilized vaccines, the recovery of HA1 and antigenicity was determined by RP-HPLC and SPR 
respectively (Table 2). Additionally, the residual moisture content was determined for lyophilized 
vaccines and used for calculation of the predicted glass transition temperature (Tg) with the 
Gordon-Taylor equation for a binary water-trehalose system as described in literature [18].
The residual moisture content may affect the mobility of biopharmaceuticals entrapped in glassy 
matrixes such as lyophilized (glassy) trehalose. In general, a higher moisture content indicates a 
lower Tg and consequently may increase molecular movement at lower storage temperatures giving 
risk to destabilization of the entrapped biopharmaceutical. The residual moisture content was found 
to be 2.1% or less for all four lyophilized influenza vaccines. The predicted Tg at a residual moisture 
content of 2.1% was calculated to be approximately 95°C, which is well above normal or elevated 
storage conditions.
Both liquid and lyophilized influenza vaccine formulations were not affected by storage at 4°C and 
24°C for a month. All vaccines showed a recovery of both HA1 and antigenicity that ranged between 
90 to 110% (data not shown). After one-month storage at 37°C, freeze-dried vaccines show HA1 
recoveries of approximately 100%, whereas antigenicity slightly decreased to approximately 80%. 
In contrast, antigenicity of liquid subunit, split and WIV vaccines was lowered below 70% after 
one month at 37°C, while liquid virosomal vaccines retained 81% of their original antigenicity. 
HA1 recoveries for liquid vaccines after one-month storage at 37°C ranged from 84 to 103%. After 
Vaccine Formulation RMC (%) Tg (°C) HA1 recovery (%) Antigenic recovery (%)
37°C 60°C 37°C 60°C
WIV Liquid n.a.a n.a.a 99 ± 5 n.d.b 69 ± 5 n.d.b
  Lyophilized 1.3 ± 0.1 104 96 ± 20 91 ± 12 82 ± 7 83 ± 25
Virosome Liquid n.a. n.a. 103 ± 6 n.d. 81 ± 6 n.d.
  Lyophilized 1.8 ± 0.2 99 104 ± 7 84 ± 6 87 ± 13 93 ± 11
Split Liquid n.a. n.a. 89 ± 3 n.d. 64 ± 16 n.d.
  Lyophilized 1.4 ± 0.2 103 105 ± 8 83 ± 7 85 ± 8 103 ± 9
Subunit Liquid n.a. n.a. 84 ± 1 n.d. 69 ± 3 n.d.
  Lyophilized 2.1 ± 0.4 95 109 ± 5 82 ± 10 74 ± 12 96 ± 3
Table 2. Heat stability of lyophilized influenza vaccine formulations. Residual moisture content (RMC) of 
lyophilized vaccine formulations was determined directly after lyophilization. Glass transition temperatures 
(Tg) were calculated from RMCs. Lyophilized vaccines were stored for one month at 37°C and 60°C. Recovery of 
HA1 and antigenicity was determined after reconstitution and is shown as a percentage of initial recovery after 
lyophilization. Data represent mean ± SD (n = 3).
a Not applicable. b Not detectable; detection limit = ~1 µg/ml (equal to 0.1% recovery).
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one-month storage at 60°C, lyophilized influenza vaccines were minimally affected, with HA1 and 
antigenicity recoveries being higher than 83%. Strikingly, liquid influenza vaccines showed no 
detectable recoveries of either HA1 or antigenicity after one-month storage at 60°C, indicating that 
the liquid vaccines were completely deteriorated.Biodistribution of vaccine-filled Bioneedles
To investigate the vaccine release profile of influenza vaccine-filled Bioneedles, an infrared dye 
was either filled in Bioneedles or bound to influenza WIV vaccine before filling and subsequent 
freeze-drying. Nude mice received either IRdye or IRdye-labeled WIV s.c. or by Bioneedle. The 
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Figure 7. In vivo imaging of vaccine-filled Bioneedles. IRdye and labeled WIV were administered either s.c. or by 
Bioneedles in mice, after which the fluorescence was tracked over time.
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Figure 7. Subcutaneous administered IRdye rapidly disappears from the site of injection (SOI), 
and is completely undetectable after 6 hours at the SOI. In contrast, Bioneedle-delivered IRdye 
remained visible at the SOI up to 24 hours post administration, indicating that the IRdye was 
slowly released from the Bioneedle (Figure 8A). Surprisingly, s.c. administered WIV remained at 
the SOI for a prolonged period of time, similar to Bioneedle-delivered WIV (Figure 8B), although 
Bioneedle-delivered WIV maintained a steady antigen presence at the SOI even after 72 hours. Total 
release of WIV over time did not differ between s.c. and Bioneedle groups (Figure 8C).
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Figure 8. Quantitative fluorescence at the site of injection over time for both IRdye (A) and WIV (B). Area under 
the curve (AUC) was calculated for each mice (C). Data represents mean ± SD (n = 5).
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This study demonstrates that influenza vaccines delivered by Bioneedles elicit equal or improved 
immune responses in C57BL/6 mice compared to conventional liquid vaccines. Furthermore, 
lyophilization of the different influenza vaccine types formulated with trehalose and HBS greatly 
improved the heat stability of the influenza vaccines.
The four influenza vaccine types were selected for their differences in compositions and particulate 
organization. All vaccines were produced from a single virus batch, enabling a fair comparison 
between the vaccines. Comparative immunogenicity studies remain few [8, 19], and studies 
on subcutaneous influenza vaccines are mostly limited to a single vaccine type. This knowledge 
gap makes it difficult to preselect the most suitable influenza vaccine candidate for delivery with 
Bioneedles. Therefore, a head-to-head comparison between these four vaccines was performed 
in this study. Characterization of the produced influenza vaccines confirmed that WIV and split 
vaccines contained all viral components, whereas virosome and subunit vaccines only contained 
the membrane proteins HA and NA. Determination of the particle size and polydispersity of the 
vaccines showed that WIV and virosome vaccines do have a relatively monodisperse particle size. In 
contrast, the produced split and subunit vaccines showed heterodisperse particle sizes, indicating 
that the vaccines contained viral components in a less organized fashion. WIV and virosome 
vaccine retained their particle size after freeze-drying, while split and subunit vaccines displayed 
still a heterodisperse particle size. These differences however did not influence the survival of 
the trehalose/HBS stabilized vaccines after freeze-drying in vials; a complete recovery of HA1 
protein (HPLC) and vaccine antigenicity (SPR) was observed after freeze-drying. This indicates that 
influenza vaccine containing Bioneedles can be produced without the loss of vaccine structure and 
antigenicity.
Immunization of C57BL/6 mice with all influenza vaccine-filled Bioneedles induced strong systemic 
humoral responses. Serum HI titers induced by vaccines delivered by Bioneedles were higher 
than the HI titers induced by intramuscular administered subunit vaccine and comparable to HI 
titers induced by intramuscular administered WIV vaccine. Overall, Bioneedle-delivered influenza 
vaccines induced similar HI titers as their liquid counterparts, indicating that this alternative method 
of administration could be used for influenza vaccines. The HI titers induced after i.m. immunization 
with WIV or subunit vaccine were comparable to those found in the study by Hagenaars et al [8]. 
This might indicate that in terms of HI titers, subcutaneous and intramuscular administered liquid 
influenza vaccines elicit comparable responses.
The current correlate of protection (CoP) for human influenza vaccines is indicated by an HI titer 
higher than 40 in humans after vaccination [20]. However, previous studies have shown that 
cellular immune responses are important as well, especially for pandemic vaccine candidates [21]. 
Additionally, it is believed that cellular responses may play an important role in the elderly, in which 




and IgG subtype profiling revealed that subunit, split and virosomal vaccines induced comparable 
mixed Th1/Th2 responses. In contrast, immunization with WIV vaccines resulted in an IgG subtype 
profile that was significantly skewed towards IgG2c, indicating a cellular response skewed towards 
Th1 [23]. This observation can be explained by the presence of viral ssRNA in the WIV vaccine, which 
is not present in subunit, split and virosomal vaccines [24, 25]. Administration by Bioneedles did not 
alter the cellular or IgG subtype profile significantly, which indicates that the route and method of 
Bioneedle administration have no impact on the quality or type of immune response induced by 
the influenza vaccines.  
From the data it can be concluded that influenza vaccine-filled Bioneedles can induce immune 
responses that are similar to responses induced by subcutaneous and intramuscular influenza 
vaccines. Considering the virosome vaccine, there is an indication that Bioneedles might actually 
improve the immunogenicity of influenza vaccines. This could be explained by several mechanisms. 
A previous study by Hirschberg et al showed a dose sparing effect after immunization with 
tetanus toxoid-filled Bioneedles [11]. Influenza vaccines might benefit from a dose sparing effect 
by Bioneedles. To investigate the dose-sparing potential of influenza Bioneedles, dose-response 
studies are warranted. Furthermore, while trehalose is present as lyoprotectant in the lyophilized 
vaccine formulations, it has shown no adjuvant activity in influenza vaccines before [26, 27].
The Bioneedles may cause a depot effect at the SOI, which might result in an increased 
immunogenicity of the Bioneedle-delivered influenza vaccines. To investigate what happens to the 
Bioneedles at the SOI, a biodistribution study was performed with infrared-labeled WIV. Initially, 
the Bioneedle groups show little infrared signal, most likely due to the solid, freeze-dried state of 
the contents in the Bioneedle. After 1 hour, the infrared signal at the SOI significantly increases, 
indicating that the Bioneedle was dissolved. After this initial delay in vaccine release time, the 
infrared signal of Bioneedle-delivered IRdye is parallel to the signal of s.c. administered liquid 
IRdye. Studies with infrared-labeled WIV showed similar results, with an initial lag time caused by 
the reconstitution process of the Bioneedle. Surprisingly, s.c. administered WIV vaccine showed a 
prolonged presence at the SOI. Similarly, Bioneedle-delivered WIV vaccine also remained visible at 
the SOI after 3 days. These results are similar to data obtained from a study with inactivated polio 
vaccine (IPV), which showed that both liquid and Bioneedle-delivered IPV remained at the SOI for 
several days [28]. Contrarily, a study found that ovalbumin was cleared within 3 days at the SOI [29], 
suggesting that the residence time of antigens may vary. Physicochemical characteristics of the 
antigen such as size and surface charge might influence the residence time at the SOI. Furthermore, 
antigens may interact with the Bioneedle material after Bioneedle reconstitution, which may affect 
antigen residence time. However, the current data does not suggest that the Bioneedle significantly 
increases the residence time of the antigen. Thus, the observed increased immunogenicity of 
Bioneedle-delivered influenza vaccines was not the result of a depot effect at the SOI. Further 
studies thus should be conducted to elucidate this observation.
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The vaccine antigens in the produced influenza Bioneedles were expected to possess increased 
vaccine stability. The stability of the different types of influenza vaccines after lyophilization was 
assessed in vials. In order to retain the vaccine antigenicity after lyophilization and subsequent 
storage, trehalose was chosen as stabilizer. Trehalose is known for its excellent lyoprotective 
capacities in influenza vaccine formulations [26, 30, 31]. Lyophilized vaccines had low residual 
moisture contents, positively affecting the glass transition temperature of the vaccine product 
[18]. Glass transition temperatures calculated were above 95°C, indicating that the glassy matrix 
provided by trehalose was physically stable, and retained its glassy structure with low molecular 
mobility at the storage conditions evaluated in this study. Lyophilization of the influenza vaccines 
resulted in vaccine formulations that were heat stable at 60°C for at least one month. In sharp 
contrast, conventional liquid influenza vaccines showed a decrease in stability after one-month 
storage at 37°C. The liquid vaccines lost all HA1 content and antigenicity after storage at 60°C for one 
month, indicating that conventional liquid vaccines have limited heat stability. It should be noted 
that antigenic recoveries of freeze-dried vaccines dropped slightly after one-month storage at 37°C 
and 60°C, which could have an impact on immunogenicity of the product. However, a previous 
study by Geeraedts et al concluded that storage of liquid WIV vaccine at 40°C for three months 
resulted in a significant loss of immunogenic potency of the vaccine [27], whereas lyophilized WIV 
vaccine remained stable under the same conditions.  These results show a similar trend in vaccine 
degradation compared to this study, and demonstrates that freeze-dried influenza vaccines are still 
immunogenic after storage at elevated temperatures. 
In case of Bioneedles, a previous study with hepatitis B antigen demonstrated that heat-stressed 
Bioneedles induced similar immune responses compared to unstressed Bioneedles [12], which 
underlines the stability of freeze-dried Bioneedles. For the current study, it should be noted that the 
lyophilized vaccine product in the Bioneedles might not behave exactly similar in terms of stability 
as the formulations lyophilized in vials. A previous study by Hirschberg et al compared the heat 
stability of liquid tetanus toxoid with tetanus toxoid that was lyophilized in glass vials or Bioneedles 
[11]. Tetanus toxoid showed high antigenicity recoveries after lyophilization in both glass vials and 
Bioneedles. Tetanus toxoid lyophilized in Bioneedles showed a 60% recovery when incubated for 
3 weeks at 60°C, whereas liquid tetanus toxoid lost all activity after 1 week at 60°C. Whether influenza 
vaccine in Bioneedles follows this same trend can be determined once the influenza vaccine stability 
can directly be measured from vaccine material in Bioneedles. If needed, the lyophilization process 
for influenza Bioneedles can be optimized further to increase vaccine recovery and stability.
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This study demonstrates the potential of Bioneedles as an alternative delivery system for influenza 
vaccines. The immune responses induced by four influenza vaccine formulations were compared 
to determine the optimal influenza vaccine for Bioneedle vaccine development. All influenza 
vaccine formulations delivered by Bioneedles induced immune responses that were non-inferior 
to liquid formulations. WIV was determined as the best influenza vaccine formulation for use in 
Bioneedles, due to its ease of formulation and ability to induce both strong humoral and cellular 
immune responses. The freeze-dried state of the vaccine in the Bioneedle makes it suitable for 
long-term storage outside the cold chain, and enables easy stockpiling. To continue development, 
challenge studies with influenza Bioneedle vaccine should be performed to confirm the induction 
of protective immune responses after vaccination. Finally, the potential of Bioneedles for influenza 
vaccine delivery must be confirmed in non-inferiority and/or superiority studies in human. This 
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The development of cross-reactive influenza vaccines remains a challenging ordeal. Several vaccine 
design approaches to tackle this problem are currently being followed, as described in Chapter 2. 
One of these approaches is the induction of influenza-specific T cell responses that lead to clearance 
of virus-infected cells. T cell peptides covering conserved epitopes of influenza are able to induce 
such T cell responses. However, these peptides are poorly immunogenic and require additional 
formulation with one or more adjuvants (i.e., a delivery system and/or immunopotentiator). 
The aim of this thesis was to develop novel formulations that increase the immunogenicity of 
influenza T cell peptides. Three different types of peptide-based influenza vaccine formulations 
were investigated in this thesis; peptide-loaded virosomes, whole inactivated influenza virus (WIV)-
adjuvanted peptides and peptide-loaded liposomes. Additionally, an alternative vaccine delivery 
system, the Bioneedle, was evaluated in this thesis for use in influenza vaccination.
Chapter 2 provides an extensive overview of formulation and production methods for current and 
future influenza vaccines. Key problems concerning current seasonal influenza vaccines, such as lack 
of cross-reactivity, lack of efficacy in high-risk populations and limited production capacity, were 
identified and possible solutions were suggested. Potentially cross-reactive immune responses and 
their formulation strategies for their respective antigens, which may lead to a new generation of 
influenza vaccines, were described. Finally, several novel influenza vaccine production methods 
were reviewed, and the production feasibility of novel influenza concepts was assessed.
Chapter 3 focused on the development of influenza virosomes as a delivery system for influenza 
peptide antigens. The influenza peptide GILGFVFTL was successfully associated with virosomes, 
without affecting virosome size, surface charge or fusogenicity. The immunogenicity of the 
peptide-loaded virosomes was tested in HLA-A2.1 transgenic mice. Peptide-loaded virosomes were 
able to induce peptide-specific T cells, and addition of Toll-like receptor (TLR) 9 agonist CpG-ODN 
1826 to the virosomes significantly increased the T cell response. This formulation was also able to 
decrease morbidity and increase the recovery rate of mice infected with a heterologous influenza 
strain, which indicates that CpG-adjuvanted peptide-loaded virosomes are a promising vaccine 
formulation for the induction of effective T cells. Association between peptide and virosome as well 
as virosome fusogenicity were found to be necessary for effective uptake by dendritic cells and the 
subsequent induction of T cell responses.
The use of WIV as an adjuvant for peptides was investigated in Chapter 4. A physical mixture of WIV 
and the influenza peptide GILGFVFTL was able to induce high peptide-specific T cell responses in 
HLA-A2.1 transgenic mice. The dose for both WIV and peptides was optimized in a following study, 
and a prediction model could be generated from the dose-finding study. Next, it was found that 
WIV and peptide has to be co-localized at the site of injection to induce a T cell response; when WIV 
and peptide were injected at separate sites, the T cell response decreased significantly. Interestingly, 
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WIV did not have to be fusogenic to retain its adjuvanticity. Finally, WIV was used as an adjuvant for 
peptide pools of three wild-type influenza peptides (GILGFVFTL, FMYSDFHFI and NMLSTVLGV), or 
three chemically enhanced peptide ligands (CPL) derived from the three WT peptides. WIV was able 
to increase the immunogenicity of both WT and CPL GILFGFVFTL and FMYSDFHFI, while incomplete 
Freund’s adjuvant was only effective for the GILGFVFTL peptide and its CPL derivative. The results of 
this study indicate that WIV is an effective adjuvant for influenza peptides and might also be useful 
as an adjuvant with other antigens.
In Chapter 5 the influence of the lipid composition on liposome size, surface charge and liposome-
induced dendritic cell maturation was studied by using a design of experiments (DoE) approach. 
Liposome size and surface charge could be modeled and accurately predicted. The surface charge 
of the liposome was mostly influenced by the inclusion of DOTAP, a cationic lipid, in the lipid 
composition. The other cationic lipid included in the study, DC-Chol, had much less influence on 
the liposomal surface charge. Aside from physicochemical characteristics of the liposome, the 
ability to mature dendritic cells (DCs) by the liposomes was investigated. CD40, CD80, CD83 and 
CD86 maturation responses could be modeled as a function of lipid composition. The DOTAP 
lipid positively affected CD40 and CD80 expression, while the other lipids did not influence the 
expression of these maturation factors. CD83 expression was controlled by the presence of DC-Chol 
and DOTAP, while DOPE negatively affected CD83 expression. None of the lipids had a significant 
impact on the CD86 expression. The prediction models for all four maturation markers were able to 
accurately predict the DC maturation responses induced by a liposome composed of a previously 
untested lipid composition. Liposome size and surface charge as function of lipid composition also 
could be accurately predicted. This method could therefore be a valuable tool to rapidly screen the 
immunogenicity of various liposomal formulations in vitro, using a minimal number of experiments 
with the DoE approach.
The current state of the development of T cell-based influenza vaccines is reviewed in 
Chapter 6. In contrast to antibody responses, influenza-specific T cell responses have the potential 
to be cross-reactive against many epidemic and pandemic influenza strains. Many different concepts 
are currently under development, such as whole virion-based vaccines (live-attenuated and whole 
inactivated influenza vaccines), and small subunit antigens such as short or long influenza peptides. 
However, certain aspects of T cell responses have yet to be elucidated. The priming status of the 
vaccinated individual seems to be of great importance for the induction of T cells; naïve individuals 
generate better cellular responses than individuals who are already primed with antibody-inducing 
influenza vaccines. Moreover, the location of the cellular response is important; local T cell responses 
at the site of infection (i.e., the lungs) are more effective than systemic T cell responses. Furthermore, 
there are some concerns about the induction of cellular responses, because they can lead to severe 
lung inflammation and pneumonia. Therefore, the induction of cellular responses by vaccines 
should be adequate but not excessive. Furthermore, it should be noted that T cell responses do not 
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provide protection against influenza infection, but merely accelerate viral clearance and decrease 
disease morbidity after infection. Thus, T cell-based influenza vaccines have great potential, but 
special attention should be given during their development to the immunological aspects of such 
vaccines.
Chapter 7 describes the development of an alternative delivery method for influenza vaccines, 
the Bioneedle. Bioneedles were successfully filled and freeze-dried with four types of inactivated 
influenza antigens (WIV, virosome, split and subunit), while maintaining vaccine antigenicity. 
The immunogenicity of the influenza antigen-filled Bioneedles was assessed in C57BL/6 mice 
and compared to that of intramuscular and subcutaneous administered influenza vaccines. 
Bioneedle-delivered vaccines induced high HI and IgG titers, comparable to i.m. administered 
vaccines. Bioneedle-delivered virosome vaccine performed even better than s.c. administered 
virosome vaccine, which indicates a beneficial effect of Bioneedle delivery. It was also found that, in 
line with previous literature, WIV was able to induce influenza-specific T cell responses, contrarily to 
the other vaccine formulations. An accelerated stability study showed that vaccine-filled Bioneedles 
remained antigenicity after exposure to 60°C for one month, indicating that Bioneedles are superior 





Peptide antigens are an interesting group of antigens for influenza vaccines. Compared to traditional 
protein antigens, they are relatively small, which comes with an inherent poor immunogenicity. 
However, peptide antigens come with several benefits. They encompass one or several epitopes, 
which can be arranged at will for the most optimal immune response. This gives researchers 
the opportunity to design the ideal peptide antigen, which can induce both humoral or cellular 
immune responses. This is especially useful for T cell-inducing influenza vaccines, since priming 
with antibody-inducing influenza vaccines can even affect the efficacy of subsequent cellular-based 
vaccines, as demonstrated with LAIV in children and adults [1]. Furthermore, peptide antigens 
can be produced synthetically, while most other antigens are produced on biological platforms. 
Synthetic-based vaccines can be changed more easily from a production point of view than vaccine 
produced on biological platforms such as cell lines. This offers more flexibility in terms of altering 
the epitopes to be included in the peptide vaccine.
Selection of the epitope(s) to be included in the peptide is arguably the most crucial for the 
effectiveness of the vaccine, but remains a tricky business. While many epitope discovery strategies 
exist, e.g., in silico prediction, mass spectrometry-based discovery and other methods [2-4], not a 
single immunological parameter, such as epitope immunodominance, is yet correlated to protective 
T cell epitopes [5]. Indeed, this was recently demonstrated by Keskin et al., who concluded that 
the M158-66 influenza peptide, which was the peptide of choice in this current thesis because of 
its immunodominance, induced T cell responses with such a poor avidity that the T cells did not 
recognize influenza infected epithelium [6]. With this knowledge, careful consideration should be 
given to pursue further optimization of epitopes, such as increasing epitope binding properties [7].
Nonetheless, peptide-based influenza vaccines remain promising. Concepts that use long 
peptides comprised of multiple influenza epitopes have recently seen considerable success, with 
Multimeric-001, Flu-v and FP-01.1 passing phase I studies [8-10]. The efficacy of these vaccines 
however has not been evaluated yet in humans, and phase II and III studies with these vaccines are 
thus highly anticipated.
Short peptide antigens still remain in the preclinical phase of development as of yet. Due to their 
poor intrinsic immunogenicity, short peptides need additional formulation with drug delivery 
systems and/or other adjuvants to be effective. In this thesis, three types/categories of formulations 
for short peptide antigens have been studied. In the following sections, the prospects for each of 
these formulation types will be briefly discussed.
Influenza virosomes as peptide carriers
Virosomes were originally developed as an inactivated influenza vaccine [11]. While subunit and 




greatly reduces their cross-reactivity. Virosomes are able to induce both humoral and cellular 
responses, similar to WIV formulations. Virosomes were initially marketed by Berna Biotech as 
a seasonal influenza vaccine in Europe since 1997 [12], but have recently been discontinued for 
reasons yet to be disclosed.
Next to the use as an antigen, influenza virosomes have been also identified as a possible vaccine 
delivery system [13]. Virosomes have been extensively studied as a carrier for malaria peptide 
vaccines [14]. Furthermore, hepatitis C peptides were tested in combination with influenza virosomes 
[15]. Next to a publication of Arkema et al. [16], this thesis contains the only other study utilizing 
influenza virosomes as a delivery system for influenza T cell peptides [17]. The formulation was able 
to decrease disease morbidity and accelerate recovery in mice. However, the low encapsulation 
efficiencies and extensive formulation procedures may make the virosome concept less attractive 
for the delivery of influenza peptide antigens. Especially the inclusion of several peptide antigens, 
which is necessary to ensure proper HLA coverage [18], could prove to be too challenging. Thus, 
while the preclinical performance of peptide-loaded virosomes is promising, it is unlikely that this 
concept will be a vaccine formulation viable for human use.
WIV as a vaccine adjuvant
Whole inactivated influenza vaccine was the first influenza vaccine formulation that entered the 
market in the 1940s [19]. WIV was eventually replaced by split, subunit and virosome vaccines, 
because the use of WIV was associated with a higher incidence of adverse effects. However, 
improvements in the production and purification processes have made WIV equally safe as split 
vaccines [20]. The immunogenicity of WIV is however still superior to that of other inactivated 
influenza vaccines, most likely because it contains the viral ssRNA, which is a natural TLR7 ligand 
[21, 22]. This inherent immunogenicity of WIV was the rationale behind the study using WIV as an 
adjuvant for peptide antigens, as described in this thesis. WIV proved to be an effective adjuvant for 
most of the tested influenza epitopes, both for immunodominant and less dominant epitopes. It is 
likely that WIV can increase the immunogenicity of non-influenza antigens as well, for both humoral 
and cellular responses. WIV should therefore be combined with other vaccine antigens in future 
studies to investigate its effect on non-influenza antigens.
The ease of formulation (simple mixing) of WIV makes it an attractive adjuvant. Formulations such as 
virosomes and liposomes are more sophisticated, but require formulation steps that are sometimes 
difficult to scale up for industrial scale production. Simple mixing of adjuvant and antigen means 
that both components can be produced separately. Furthermore, the components can be mixed 
just moments prior to administration, which is useful when adjuvant and antigen combined are 




Liposomes as peptide carriers
Liposomes have been used extensively as delivery systems for various pharmaceuticals and 
biologics, including vaccine antigens. How liposomes affect the immune system themselves is 
however unclear. Liposome formulations that include PAMPs in the lipid layer, such as CAF01, clearly 
serve as an immunopotentiator. However, studies have shown that cationic liposomes induce DC 
maturation without the inclusion of PAMPs or other immunostimulatory molecules [23, 24]. In this 
thesis, we attempted to evaluate and model the effect of the liposomal lipid composition on the 
expression of DC surface markers. While the mechanism(s) behind this immunostimulatory effect 
of cationic lipids on DCs were not investigated, this study confirmed that cationic liposomes can 
activate DCs on their own, and that the DC maturation responses can be predicted when the lipid 
composition is known. The method described in this thesis could be an excellent tool to extensively 
screen liposomal formulations in vitro with minimal formulation efforts.
Influenza Bioneedles
Many alternative administration methods for influenza vaccines have been developed and studied 
over the years [25]. One of these alternatives are Bioneedles, which are hollow injectable implants 
which can be filled with a vaccine formulation. Bioneedles have been tested with numerous 
antigens, including alum-adjuvanted tetanus toxoid [26], LpxL1-adjuvanted hepatitis B surface 
antigen [27], CAF01-adjuvanted BCG and inactivated polio vaccine [28, 29]. In this thesis, Bioneedles 
were made with four influenza vaccine types [30]. Influenza vaccine-filled Bioneedles proved to be 
remarkably thermostable (minimal loss of antigenicity after expose to 60°C for 1 month). This could 
be especially useful in developing countries, where the logistics for vaccine refrigeration are often 
unreliable, hampering the distribution of vaccines. Furthermore, if an appropriate implantation 
device is developed, Bioneedles can be quickly administered by untrained personnel, which is useful 
in mass vaccination campaigns. Bioneedles are therefore a promising alternative to conventional 
needle-based vaccination, and further development of this system should be pursued.
Universal influenza vaccines
T cell-inducing influenza vaccines are just one of the concepts that are currently in development to 
reach the ultimate goal: a universal influenza vaccine, which protects against all influenza strains with 
a limited number of immunizations. Other concepts involve induction of mucosal IgA at the lungs 
or cross-reactive antibodies directed against HA stalk regions or M2e protein. While all concepts are 
promising, it is unlikely they will result in a truly universal influenza vaccine in the next 5 to 10 years. 
However, existing seasonal vaccines might be supplemented with additional antigens that induce 
cross-reactive T cells or antibodies to expand the breadth of the induced immune response. Indeed, 
already two different T cell-inducing vaccines have been combined with seasonal influenza vaccines 
in preclinical and clinical studies [31-33]. Such combinations of seasonal and T cell vaccines have the 
potential to be the next generation of influenza vaccines.
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Griep
Het influenzavirus (ofwel griepvirus) is een RNA-virus van de Orthomyxoviridae familie, dat de 
luchtwegen kan infecteren. Er bestaan drie types griepvirussen; influenza A, B en C, waarvan 
influenza A en B mensen kunnen infecteren. Naast mensen zijn er verschillende andere gastheren 
voor griepvirussen, waaronder vogels, varkens, honden en paarden. Typische symptomen tijdens 
een griepvirus infectie, zijn hoesten, verstopte neus, hoofdpijn, koorts, spierpijn en vermoeidheid. 
In ernstige gevallen kan een griepinfectie leiden tot een primaire virale longontsteking, secundaire 
bacteriële longontsteking of infectie van de sinussen, welke allen potentieel dodelijk kunnen zijn in 
zwakke individuen.
Het griepvirus verspreid zich gewoonlijk in de vorm van jaarlijkse epidemieën die rond het 
winterseizoen vallen. Schattingen van de Wereldgezondheidsorganisatie (WHO) geven aan dat 
jaarlijks wereldwijd 3 tot 5 miljoen mensen opgenomen moeten worden in het ziekenhuis door 
griep-geassocieerde ziekte, waarvan ongeveer een half miljoen mensen sterft aan directe of indirecte 
gevolgen van een griepinfectie. Naast invloed op de volksgezondheid hebben deze epidemieën 
ook negatieve invloed op de economie, door stijgingen in ziekteverzuim en ziektekosten. Het is dus 
essentieel dat griepepidemieën ingeperkt worden.
Griepvaccins
Een griepvirus heeft meestal een ronde vorm met een grootte van 100 tot 150 nanometer. 
Het virus bestaat uit grofweg twee delen: 1) de virale envelop, bestaande uit fosfolipiden en de 
membraaneiwitten hemagglutinine (HA) en neuraminidase (NA), en 2) het nucleocapside, de kern 
die de interne eiwitten en het RNA bevat (zie Figuur 1 in Hoofdstuk 1). De membraaneiwitten HA 
en NA worden onderverdeeld in verschillende subtypen (18 voor HA, 11 voor NA), die samen het 
subtype van het griepvirus aanduiden (bijv. H1N1 of H3N2). Deze membraaneiwitten fungeren ook 
als antigenen. Het immuunsysteem maakt vervolgens antigeen-specifieke antilichamen aan die 
het virus kunnen neutraliseren. 
Vaccinatie is de enige manier, naast een griepinfectie zelf, om deze antilichamen op te wekken. 
De antigenen van griepvirus ondergaan echter voortdurend veranderingen door antigene drift en 
shift, waardoor de opgewekte antilichamen niet meer aan het virus kunnen binden. Om voor deze 
veranderingen te compenseren, worden de huidige seizoenale griepvaccins elk jaar aangepast, 
aan de hand van epidemiologische voorspellingen van de antigene drift. Hierdoor bevatten de 
griepvaccins HA en NA subtypen die meestal identiek zijn aan de griepvirussen die in de betreffende 
winter circuleren. De veranderingen die veroorzaakt worden door antigene shift zijn echter niet te 
voorspellen. Een antigene shift duidt een kruising aan tussen twee verschillende virussubtypen; 
meestal een combinatie van een humaan griepvirus en een vogel- of varkensgriepvirus. Dit 
nederlandSe Samenvatting
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kan gebeuren wanneer er intensief contact is tussen mens en dier, zoals pluimveebedrijven 
en varkensstallen, waar de virussen de kans krijgen om één dezelfde gastheer te infecteren om 
vervolgens te recombineren tot een nieuw virussubtype. Dit kan leiden tot een pandemische 
griepstam, zoals de varkensgriep (ook wel Mexicaanse griep genoemd) in 2009 (H1N1). Seizoenale 
griepvaccins zijn over het algemeen niet effectief tegen nieuwe griepstammen, omdat de 
vaccin-geïnduceerde antilichamen niet kruisreageren met andere HA en NA subtypen. Er zijn dus 
nieuwe griepvaccins nodig die immuunresponsen opwekken die onafhankelijk van virussubtype 
bescherming bieden.
T cel-activerende griepvaccins
Om nieuwe griepvaccins te ontwikkelen die kruisbeschermende immuunresponsen opwekken, 
is kennis van immunologie noodzakelijk. Centraal hierin staan de antigeen-presenterende cellen 
(APCs), waaronder dendritische cellen (DCs). APCs kunnen (vaccin) antigenen herkennen en 
opnemen, waarna ze vervolgens bepaalde epitopen van het antigeen presenteren aan T cellen via 
MHC moleculen. Tijdens dit proces moeten de DCs ook gematureerd zijn, om de antigeenpresentatie 
en activatie van T cellen goed te laten verlopen. Maturatie van DCs wordt meestal geïnduceerd 
door pathogen-associated molecular patterns (PAMPs), immuunstimulatoren die aanwezig zijn in 
bacteriën of virussen, zoals viraal RNA. T cellen zijn onder te verdelen in twee hoofdtypes: T helper 
cellen (Th) en cytotoxische T cellen (CTLs). T helper cellen hebben verschillende functies, zoals de 
activatie van B cellen (die antilichamen produceren) en de ondersteuning van CTLs. CTLs zijn in 
staat om geïnfecteerde cellen te lyseren (zie Figuur 1D, Hoofdstuk 2), en vormen naast antilichamen 
de belangrijkste tak van specifieke immuniteit.
In dit proefschrift leggen we de focus op het ontwikkelen van een griepvaccin dat CTLs induceert. 
CTLs zijn in staat om griepvirus-geïnfecteerde cellen te herkennen aan delen van het virus die aan 
het celoppervlak geëxposeerd worden. In tegenstelling tot antilichamen, die alleen epitopen aan 
de buitenkant van het virus herkennen, kunnen T cellen ook epitopen van interne virale eiwitten 
herkennen, die minder snel muteren. Dit zorgt ervoor dat T cellen onafhankelijk van het virussubtype 
kunnen reageren op een griepinfectie en daarmee mogelijk kunnen leiden tot kruisbescherming.
T cellen opwekken met een vaccin is echter niet eenvoudig. Antigenen die de epitopen van interne 
virale eiwitten bevatten, zoals peptiden, hebben een zwakke immunogeniciteit. Dit is voornamelijk 
te wijten aan twee factoren: 1) peptiden zijn klein en worden slecht herkend en opgenomen door 
DCs, en 2) door het gebrek aan PAMPs matureren de DCs niet, waardoor T cellen niet geactiveerd 
worden. Deze twee aspecten kunnen verbeterd worden door het gebruik van adjuvantia. 
 De opname van peptiden door DCs kan verbeterd worden door zogenaamde delivery systemen 
als adjuvantia te gebruiken; deeltjes die het peptide antigeen naar de DCs kunnen transporteren en 
ín de DC via de juiste route op MHC moleculen naar het celoppervlak kunnen sturen, zogenaamde 
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kruispresentatie. De maturatie van DCs kan door verschillende soorten immunostimulatoren 
geïnduceerd worden.  Het formuleren van het antigeen met adjuvantia is dus een belangrijk 
aspect van het ontwikkelen van een peptide-gebaseerd griepvaccin. Het hoofddoel van dit 
promotieonderzoek is dan ook het ontwikkelen van nieuwe formuleringen voor influenza peptide 
vaccins.
Virosomen als delivery systeem
In Hoofdstuk 3 werden virosomen gebruikt als delivery systeem voor het influenza peptide 
GILGFVFTL. Virosomen zijn lege virusmantels die bestaan uit de eiwitten en lipiden die in de 
virale envelop zitten (zie Figuur 2, Hoofdstuk 2). GILGFVFTL werden vervolgens geassocieerd met 
de virosomen, wat in peptide-geladen virosomen (P-V) resulteerde. Nadat was bewezen dat de 
associatie met peptiden de eiwitsamenstelling, de deeltjesgrootte en lading van de virosomen 
niet beïnvloedde, werd de immunogeniciteit van P-V getest in HLA-A2.1 transgene muizen. Uit 
de dierstudies bleek dat P-V beter in staat waren om peptide-specifieke T cellen op te wekken 
dan peptide alleen (zonder virosomen) of peptide gemixt met virosomen (dus niet geassocieerd). 
De additie van CpG, een immunostimulator, bleek de immunogeniciteit van P-V zelfs verder 
te verbeteren. Verder bleek dat de fusogeniciteit (de eigenschap van een virus of virosoom om 
met een endosomaal membraan te fuseren en zo zijn inhoud af te geven in het cytoplasma) van 
virosomen belangrijk was om een goede T cel respons op te wekken. Vervolgens werd de effectiviteit 
van de P-V als vaccin getest door muizen eerst te vaccineren met P-V, om ze vervolgens te infecteren 
met een heteroloog griepvirus. Uit deze studie bleek dat muizen gevaccineerd met P-V minder 
gewichtsverlies leden, en uiteindelijk sneller herstelden van de virusinfectie. Virosomen zijn dus een 
effectief delivery systeem voor peptide vaccins, en de P-V met CpG formulering is in staat om griep-
specifieke CTLs op te wekken in muizen, die het herstel van een heterologe virusinfectie versnellen. 
Geïnactiveerd influenza virus als adjuvant
In Hoofdstuk 4 onderzochten we de potentie van geïnactiveerd influenza virus (WIV) als een 
adjuvant. Zoals eerder gezegd, zijn immunostimulatoren meestal afgeleid van bacteriële of virale 
componenten. WIV bevat viraal RNA, wat ook een immunostimulator is. Het influenza peptide 
GILGFVFTL werd geformuleerd met WIV, en vervolgens ingebracht in HLA-A2.1 transgene muizen. 
Dit resulteerde in een verbeterde peptide-specifieke T cel respons vergeleken met peptide of WIV 
alleen. Om het belang van co-localisatie van WIV en het peptide te bestuderen, werden beide 
componenten ook apart op verschillende locaties in de muis ingebracht. Hieruit bleek dat wanneer 
WIV en peptide apart op verschillende locaties in de muis werden ingebracht, het adjuvant effect 
van WIV teniet werd gedaan. Tevens bleek dat de fusogeniciteit van WIV niet belangrijk was voor de 
adjuvanticiteit van WIV in combinatie met GILGFVFTL. Naast het GILGFVFTL peptide, werden ook 
twee andere influenza peptiden, FMYSDFHFI en NMLSTVLGV, geadjuveerd met WIV. Ook werden er 
chemisch gemodificeerde versies van deze drie peptiden geïncludeerd in de studie, die een betere 
bindingsaffiniteit hadden met MHC moleculen. Een verhoogde bindingsaffiniteit zou eventueel 
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kunnen leiden tot een betere immuunrespons. De resultaten van de dierstudie wezen uit dat 
vooral de gemodificeerde versie van FMYSDFHFI beter T cellen induceerde dan ongemodificeerd 
FMYSDFHFI. WIV had een adjuverend effect voor alle peptiden. Uit deze studie konden we dan ook 
concluderen dat WIV veel potentie heeft als een adjuvant voor T cel-inducerende peptide vaccins.
Liposomen als op maat gemaakte delivery systemen
Liposomen zijn vesicles van lipiden die als delivery systeem te gebruiken zijn voor antigenen. Er 
kunnen talloze lipiden gebruikt worden om liposomen te maken, die elk andere eigenschappen 
aan het liposoom kunnen geven. Liposomen kunnen daardoor op maat gemaakt worden voor 
een specifiek doeleinde; de grootte en electrische lading kunnen bijvoorbeeld gevarieerd worden, 
wat  eventueel tot een immuunstimulerend effect kan leiden. In Hoofdstuk 5 bestudeerden wij 
welke lipiden het beste gebruikt konden worden in liposomen om in vitro DCs te laten matureren, 
wat weer een maat is voor adjuvant effect van de liposomen. Om te evalueren welke lipiden 
een invloed hadden op DC maturatie en de andere eigenschappen van het liposoom (zoals 
grootte en lading), gebruikten we design of experiments (DoE). Met behulp van DoE konden 
we statistische predictiemodellen voor elke uitleesparameter (liposoom grootte, lading, en de 
DC maturatiemarkers CD40, CD80, CD83 en CD86) genereren, afhankelijk van de lipiden in het 
liposoom. Deze predictiemodellen werden vervolgens gevalideerd door de uitleesparameters 
voor een nog niet gemaakt liposoom te voorspellen, om vervolgens het liposoom te maken en 
daadwerkelijk alle parameters te meten. Hieruit bleek dat de predictiemodellen zeer accuraat waren; 
alle DC maturatiemarkers waren correct voorspeld. Deze methode kan wellicht gebruikt worden om 
de ontwikkeling van liposoomformuleringen als adjuvantia voor vaccins te versnellen, aangezien 
DoE een relatief klein aantal experimenten benodigd om een predictiemodel te genereren.
Thermostabiele Bionaalden voor toediening van griepvaccins 
Griepvaccins worden normaliter intramusculair (i.m.) toegediend via een injectienaald, of in 
sommige gevallen met een intranasale spray. Aan i.m. toediening kleven echter enkele nadelen, 
zoals de noodzaak van getraind personeel, de kans op prikaccidenten en daarmee op besmettingen 
met bijvoorbeeld hepatits B en naaldafval wat hergebruik niet uitsluit. Deze punten zijn vooral 
problematisch in ontwikkelingslanden. Tevens wordt de vraag naar vervanging van de naald in de 
westerse wereld steeds groter om de acceptatie van vaccinatie te verhogen. Vloeibare vaccins zijn 
tevens afhankelijk van de koude keten; ze zijn gevoelig voor hoge temperaturen. Om deze redenen 
wordt er gezocht naar alternatieve toedieningsvormen voor (influenza) vaccins. In Hoofdstuk 7 
onderzochten wij het gebruik van Bionaalden voor de toediening van verschillende griepvaccins. 
Bionaalden zijn holle implantaten gemaakt van biodegradeerbaar zetmeel, welke gevuld kunnen 
worden met een gevriesdroogd vaccin (zie Figuur 1, Hoofdstuk 7). Na een onderhuidse toediening 
(idealiter onder hoge druk met een injector), lost de Bionaald met vaccin op. In onze studie vulden 
wij Bionaalden met vier verschillende typen griepvaccins (WIV, virosomen, split en subunit; zie 
Figuur 2, Hoofdstuk 1), en vaccineerden vervolgens muizen met deze Bionaalden. Dit resulteerde 
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in het algemeen in goede influenza-specifieke antilichaam responsen voor alle groepen; alleen 
de virosoom en subunit groepen waren iets minder immunogeen. Tevens waren deze Bionaald 
vaccins in staat om influenza-specifieke T cellen op te wekken. Vervolgens werd er ook gekeken 
naar de thermostabiliteit van de Bionaalden. Vloeibare vaccins moeten normaliter constant gekoeld 
worden, maar vaccins in de vaste fase (zoals gevriesdroogd vaccin) zijn in het algemeen stabieler. 
Na een maand blootstelling aan een temperatuur van 60°C waren de griepvaccins in de Bionaalden 
nog steeds intact, terwijl vloeibare griepvaccins binnen enkele dagen hun antigeniciteit verliezen. 
Hieruit kunnen we concluderen dat Bionaalden geschikt zijn als een alternatieve toedieningsvorm 
voor griepvaccins, en ook zeer stabiel zijn buiten de koude keten.
Conclusies en vooruitblik
Er zijn in dit proefschrift verschillende adjuvantiaontwikkeld voor gebruik met influenza peptiden. 
Virosomen waren in combinatie met CpG in staat om de immunogeniciteit van het GILGFVFTL 
peptide significant te verhogen. Dit leidde tot een verhoging van het aantal peptide-specifieke 
CTLs in muizen. De geïnduceerde CTLs waren vervolgens in staat om de ernst van een heterologe 
griepinfectie te verminderen en het herstel na infectie te bevorderen. Tevens werd aangetoond dat 
eigenschappen van het virosoom, zoals peptide associatie en fusogeniciteit, cruciaal waren voor de 
inductie van T cellen. Virosomen hebben dus de potentie om een goed delivery systeem te zijn voor 
peptide vaccins.
WIV bleek een effectief adjuvant te zijn voor verschillende peptiden. Het was in staat om de T cel 
responsen tegen de peptiden significant te verhogen, mits WIV en peptide antigeen op dezlefde 
plek toegediend werden. Verder bleek dat modificatie van de peptiden om de bindingsaffiniteit te 
bevorderen de T cel respons kon verhogen. WIV bleek dus een effectief adjuvant te zijn voor peptide 
vaccins.
De toepassing van de design of experiments methode bleek zeer nuttig te zijn om 
liposoomformuleringen te optimaliseren. Ook bleek dat deze methode in staat was om biologische 
responsen geïnduceerd door liposomen, zoals in vitro DC maturatie, te voorspellen aan de hand 
van de liposoomsamenstelling. Deze methode kan dus in de toekomst gebruikt worden om de 
ontwikkeling van liposoomformuleringen voor vaccins te versnellen.
Uit de studie met Bionaalden bleek dat verscheidene influenza vaccins in Bionaalden te formuleren 
waren. Deze bleken immunogeen en thermostabiel te zijn. Influenza vaccins zijn dus met Bionaalden 
op een alternatieve wijze toe te dienen, zonder het gebruik van conventionele injectienaalden.
Het hoofddoel van het onderzoek in dit proefschrift was de ontwikkeling van een universeel 
griepvaccin. De studies in dit proefschrift zijn bijna allemaal uitgevoerd met één influenza peptide 
antigen, GILGFVFTL. Een vaccin gebaseerd op een enkel peptide is echter voor een humaan vaccin 
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niet genoeg; er komen meerdere HLA varianten voor in de humane populatie die allen andere 
epitopen binden. Er zijn dus meerdere peptiden nodig om een voldoende brede basis te leggen 
voor T cel immuniteit in de gehele humane populatie. Er moeten dus nog flinke stappen gezet 
worden voordat peptide vaccins daadwerkelijk op de markt komen.
Daarentegen zijn er op dit moment wel enkele andere universele griepvaccinconcepten in de klinische 
ontwikkelingsfase. De eerste resultaten zijn enigszins hoopgevend; er kunnen influenza-specifieke 
T cellen worden geïnduceerd. Of deze immuunresponsen daadwerkelijk genoeg zijn om heterologe 
griepinfecties tegen te gaan moet nog blijken. Tevens zouden deze vaccins de huidige seizoenale 
vaccins kunnen aanvullen om bredere immuunresponsen te verkrijgen. De komende jaren zullen 
uitwijzen of een universeel griepvaccin daadwerkelijk haalbaar is.
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Adjuvantia Stoffen die de immunogeniciteit van antigenen versterken. 
Kunnen delivery systemen en/of immuunstimulatoren zijn.
Antigeen Een molecuul dat een immuunreactie kan opwekken.
Antigeen-presenterende cellen (APCs) Cel die antigenen opnemen, om vervolgens epitopen 
daarvan aan T cellen te presenteren via MHC moleculen.
Antigene drift Spontane mutaties in het genoom van influenza virus, die 
de epitopen van voornamelijk HA en NA veranderen.
Antigene shift Kruising tussen twee afzonderlijke virusstammen, 
waardoor een nieuw griepvirus ontstaat.
Antigeniciteit De mate waarin een antigeen zijn correcte structuur, welke 
antistoffen herkennen, behoudt.
Antilichaam Eiwit dat aan lichaamsvreemde stoffen kan binden, om ze 
onschadelijk te maken.
Co-localisatie Toediening van antigeen en adjuvant op dezelfde locatie.
CpG Een herhalend DNA patroon wat voorkomt in verschillende 
pathogenen, zoals virussen en bacteriën. Is een 
immuunstimulator.
Cytoplasma Ruimte van een cel die het cytosol en de organellen bevat. 
Antigenen die in het cytoplasma terecht komen kunnen 
via MHC-I moleculen gepresenteerd worden.
Cytotoxische T cel (CTL) T cel die geïnfecteerde cellen (of tumorcellen) kan lyseren.
DC maturatie Een gematureerde DC heeft karakteristieke dendrieten, 
en brengt verschillende costimulatoire moleculen tot 
expressie die nodig zijn voor een succesvolle activatie van 
T cellen. 
Delivery systeem Deeltjes die het antigeen kunnen vervoeren en op de juiste 
plek (meestal APCs) afleveren.
Dendritische cel (DC) Een van de meest voorkomende antigeen-presenterende 
cellen.
Design of experiments (DoE) Methode om systematisch de invloeden van bepaalde 
factoren te screenen. Kan ook gebruikt worden om 
predictiemodellen te genereren.
Endosomaal membraan Membraan van het endosoom. Lichaamsvreemde stoffen 
kunnen door DCs geïnternaliseerd worden in endosomen, 
losse blaasjes (vesikels) bestaande uit het celmembraan.
Epitoop Een deel van een antigeen dat herkend kan worden door 
antilichamen, B cellen of T cellen.
Formulering De samenstelling van hulpstoffen die in een vaccin zitten, 
waaronder stabilisatoren en adjuvantia.
verklarende woordenlijSt
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Fusogeniciteit De eigenschap van een virus of virosoom om met een 
endosomaal membraan te fuseren en zo zijn inhoud af te 
geven in het cytoplasma.
GILGFVFTL Peptide antigeen (en epitoop) afgeleid van influenza Matrix 
eiwit 1. Kan alleen gepresenteerd worden via humane 
HLA-A2.1 moleculen.
Heterologe virusinfectie Een infectie met een griepstam die niet hetzelfde is als de 
griepstam in het vaccin.
HLA-A2.1 transgene muizen Muizen met een humaan MHC (HLA-A2.1) molecuul.
Immunogeniciteit Het vermogen van een antigeen om een immuunrespons 
op te wekken.
Immuunstimulator Stoffen die het immuunsysteem activeren.
In vitro Een test buiten een levend organisme; vaak op cellijnen.
Koude keten Voorzieningen, zoals gekoelde transport en opslag, nodig 
om (vloeibare) vaccins tussen de 2°C en 8°C te houden, 
omwille van de vaccinstabiliteit.
Kruisbescherming Zie kruisreageren.
Kruispresentatie Normaliter worden door de DC alle opgenomen antigenen 
via MHC-II moleculen gepresenteerd. Voor de activatie 
van CTLs moeten antigenen echter via MHC-I moleculen 
gepresenteerd worden. Door kruispresentatie kunnen 
peptide antigenen via MHC-I moleculen gepresenteerd 
worden.
Kruisreageren Een immuunrespons die tegen meerdere 
griepvirusstammen kan reageren, ongeacht virussubtype.
Lyseren Het doden van een cel door het breken van het 
celmembraan.
Maturatiemarkers Moleculen die door gematureerde DCs tot expressie 
worden gebracht. Deze zijn cruciaal voor een goede T cel 
activatie.
MHC moleculen Major histocompability complex; eiwitten aan het 
oppervlak van (immuun)cellen die epitopen presenteren 




Moleculen afkomstig van pathogenen, die als 
immuunstimulatoren kunnen fungeren.
Peptide Keten van een klein aantal aminozuren; in dit geval rond de 
10. Kan vaak ook een epitoop bevatten.
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